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ABSTRACT 
Breast cancer is the most diagnosed cancer type in women and its resultant 
mortality is second only to lung cancer worldwide. While breast cancer is known to have 
many risk factors, inflammation remains an unquantifiable risk, and it can arise from 
obesity, depression, poor health, autoimmune diseases, and other conditions that cause 
systemic chronic inflammation. Chronic inflammation is gaining recognition for its role 
in cancer development, the potentiation of a metastatic phenotype in cancer cells, and 
decreased survival in breast cancer patients. In particular, inflammatory cytokines in the 
interleukin-6 (IL-6) family have been shown to promote an epithelial-mesenchymal 
transition (EMT), tumor cell detachment, invasion, and metastasis. However, therapies to 
inhibit IL-6 have not been successful in treating solid tumors. This is most likely due to 
redundancy, as there are other inflammatory cytokines such as oncostatin M (OSM) and 
interleukin-1 beta (IL-1β) that demonstrate overlapping effects in cancer progression. In 
these studies, the interactions between OSM, IL-6 and IL-1were addressed. First, OSM 
and IL-6 were shown to induce vascular endothelial growth factor (VEGF) in a breast 
cancer subtype-specific manner. Next, OSM was assessed for its capacity to increase 
circulating tumor cell numbers in mouse models of human breast cancer. Lastly, OSM, 
IL-6, and IL-1β expression levels were shown to correlate with each other in breast 
cancer, and high co-expression of these cytokines was shown to lead to decreased patient 
survival. Furthermore, OSM was assessed for its synergistic relationship with IL-1β in 
inducing IL-6 secretion from breast cancer cells. Together, these results suggest that 
vii 
inflammatory cytokines promote metastatic disease in a breast cancer subtype-dependent 
manner. Importantly, these studies both provide a rationale for the development of breast 
cancer therapeutic regimens that target multiple cytokines as well as help explain why 
single anti-cytokine therapies have failed in clinical trials. 
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CHAPTER ONE: INTRODUCTION 
 
A Brief Overview of Cancer 
Cancer describes a large group of diseases that commonly involve abnormal cell 
growth and invasion and the potential for metastasis to target organs. For the most part, it 
has been thought that cells become cancerous through a multi-step process that is 
typically due to DNA mutations. Mutations in genes that regulate cellular growth, cell-
cycle regulation genes, DNA repair genes, and a multitude of other genes related to cell 
transformation and migration are affected. However, by the turn of the century it became 
clear that changes in DNA sequences alone could not explain the extremely 
heterogeneous nature of malignancies seen by clinicians. Epigenetics, the process of 
shutting down or turning on genes through histone and DNA methylation or histone 
acetylation, gained a lot of attention by the end of the 1990’s and was postulated as one 
of the main drivers of malignancy (1). Broadly speaking, epigenetic inhibition or 
stimulation of various genes that regulate the cell cycle and growth have been well 
documented. This role for epigenetics in cancer progression was a major blow to the 
Knudson’s two-hit hypothesis, where mutations or damage to DNA were considered the 
main drivers for the transformation of normal cells into highly aggressive metastatic 
cancer cells. However, since methylation and acetylation can be targeted with various 
inhibitors, therapies that target oncogenic epigenetic events are possible (2). By 2010, a 
multitude of histone deacetylase (HDAC) inhibitors have been investigated for their 
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potential role as therapeutics in certain malignancies (3). For example, HDAC inhibitors 
have been effective against hematological malignancies, but it is still unclear as to 
whether they will have positive clinical effect against solid tumors like breast cancer. 
Also, recent studies on ovarian cancer indicate that there may be some positive clinical 
potential for HDAC inhibitors in combination with chemotherapeutics (4). 
While epigenetic aberrations are now known to be a major factor in the 
development of various malignancies, the etiological origins of these alterations in the 
development of cancer are not well defined. An interesting hypothesis has been 
developing over the past decade that postulates that inflammation can drive epigenetic 
alterations. In a study on cardiovascular disease, it was shown that inflammation 
promotes DNA hypermethylation and is a strong risk factor for the development of 
cardiovascular disease (5). Additional studies have shown a link between inflammation 
and epigenetics in a variety of other diseases ranging from macular degeneration, 
depression, and systemic sclerosis to cancer (6-9). It is also well known that localized 
inflammation and systematic inflammation have a strong dietary component and that 
pathological dietary habits have been shown to be a risk factor in many types of 
malignancies. Interestingly, diet, inflammation, and gut flora have been recently linked to 
epigenetic effects in colorectal cancer (10-12). 
Inflammation is now a well-recognized driver of many aspects of malignancy 
from aberrant epigenetics to DNA damage, immune evasion, and cancer stem cell 
development (overview shown in Figure 1) (13, 14). Inflammation has become a 
potential target in cancer therapy through the use of specific inhibitors (14). This 
dissertation is a set of studies of specific inflammatory mediators and cytokines that 
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promote the production of breast cancer growth factors, invasion, and metastasis, as well 
as decreased survival. Specifically, we show that proinflammatory factors such as 
oncostatin M (OSM) drive expression of other inflammatory cytokines, increase tumor 
angiogenesis, and the number of circulating tumor cells (CTCs) in breast cancer. 
Collectively, this body of research also provides a rationale for the development of anti-
OSM therapeutics for the treatment of metastatic breast cancer. 
Breast Cancer 
Global statistics indicate that breast cancer is the leading cause of cancer deaths 
among women worldwide (15). However, when just taking into consideration developed 
countries, breast cancer is the second leading cause of cancer deaths. This is due to the 
availability of better treatments, while the less treatable lung cancer remains the deadliest 
overall. In the United States, it is estimated that over 230,000 women will be diagnosed 
with breast cancer and over 40,000 breast cancer-related deaths are expected to occur in 
2017 (16, 17). Of all of the types of breast cancer, invasive ductal carcinoma (IDC) is the 
most common and arises from the milk duct tissues in the breast (18). Breast cancer can 
also arise from other tissues in the breast, such as from the glandular lobes that results in 
lobular carcinoma, which make up 10-15% of all breast cancer, and from periductal 
stroma that results in phyllodes tumors, which are comparatively rare (19). Inflammatory 
breast cancer (IBC) is a very aggressive form of breast cancer, which accounts for less 
than 3% of all breast cancer cases (20). IBC typically start out as IDC where the cells 
shed and block lymphatic vessels, resulting in marked swelling and inflammation of the 
breast. 
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During tumor progression, IDC starts as ductal hyperplasia, progresses to atypical 
hyperplasia with dysplasia, and then to ductal carcinoma in situ (DCIS), where the tumor 
cells start growing abnormally in the ductal tissue, but are not yet invasive (21) (Figure 
2). Finally, when the tumor cells become malignant and acquire a more aggressive 
phenotype, they can penetrate through the basement membrane and into the local tumor 
microenvironment (TME). At this point, the tumor is designated invasive ductal 
carcinoma (IDC) and can potentially metastasize to distant organs through the lymphatic 
or the circulatory systems. 
 Significant morbidity and mortality associated with breast cancer comes from its 
metastasis to vital organs. The primary tumor itself is not typically lethal, as the breast is 
not considered essential for survival. Breast cancer most commonly metastasizes to lung, 
brain, liver, spine, and bone, all of which can lead to functional and structural disruptions 
in the target organs (22-25). Mechanisms that promote breast cancer metastasis are still 
not well understood, but it is thought that metastasis occurs by tumor cell dissemination 
through the lymphatic or the blood circulatory system. In most cases, cancer cells have to 
go through a phenotypic change called an epithelial-mesenchymal transition (EMT). This 
process causes the cells to change from an adherent, non-motile cell into a non-adherent, 
invasive, and highly mobile cell. Recent research indicates that the higher the tumor 
expression level of EMT markers, the more aggressive the breast cancer cells become and 
the worse the overall prognosis the patient experiences (26, 27). 
Breast Cancer Metastasis 
Once breast cancer cells become invasive they have the propensity to become 
metastatic and migrate to distant organs. For cancer to metastasize, it must undergo a 
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multi-step process called the metastatic cascade, which involves the tumor cell’s 
migration from the local TME through adjacent tissue into the circulatory system. For 
tumor cells to be able to move through local tissue barriers, the cells must first undergo 
an EMT (28, 29). In the process of EMT, epithelial cells that are not motile and maintain 
cell-cell and cell-matrix contact become mesenchymal, motile, and lose cell-to-cell 
contact. These mesenchymally-transitioned cells then enter the lymphatic or blood 
circulatory system in a process called intravasation (29, 30). Once the cells enter the 
circulation, they are designated as circulating tumor cells (CTCs) and can extravasate, or 
exit, into a target organ. CTCs that enter the circulation typically do not survive to form 
metastases, and in fact only 0.1% of all CTCs survive in the circulation (31), as most 
CTCs undergo apoptosis or are destroyed by the immune system. The few cells that do 
survive, extravasate into a target organ, undergo the reverse of EMT called a 
mesenchymal-epithelial transition (MET), and may either lay dormant (32) or develop 
into a secondary metastatic tumor (33). 
Metastasis does not occur to just any organ but to sites where there is some level 
of microenvironment compatibility with the primary tumor cells such that the cells can 
implant and grow at the secondary site. Typically for breast cancer, some of the primary 
targets of metastases involve areas that are rich in capillaries and/or growth factors and 
include lung, brain, bone, and liver (15, 34-36). Once the cells have metastasized, target 
organ function is disrupted as the metastatic lesion grows and replaces healthy tissue. 
Bone metastases are particularly insidious as they cause marked morbidity and lead to 
rapid loss in quality of life, mobility loss, and intense pain that is refractory to opioid 
medication (37, 38). 
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 A common belief is that for cancer to metastasize, the tumor has to grow to a 
certain size before it is able to intravasate into the circulatory system. This is true for 
many types of cancer; however, recent studies show that for breast cancer, cells can 
metastasize as early as the DCIS stage when the cells are technically not supposed to be 
invasive (39, 40). This may necessitate a change in the clinical paradigm for the treatment 
of breast cancer, where new detection modalities need to be investigated. In addition, 
there may be other risk factors that affect early dissemination of breast cancer cells. For 
example, during systemic inflammation, inflammatory factors increase the propensity of 
the tumor cells to become invasive (41-43). 
Inflammation in Breast Cancer 
Many risky behavioral factors such as smoking, high alcohol consumption, 
sedentary lifestyle, depression, and high body mass index can promote chronic 
inflammation (44-46). Furthermore, poor dietary choices in adolescence with refined 
sugars and grains, processed meat, and low intake of vegetables have been linked to 
increased serum concentrations of inflammatory proteins such as C-reactive protein and 
interleukin-6 (IL-6) (46). Chronic breast inflammation arises from a multitude of factors 
including obesity, chronic infection, and poorly designed breast implants (47-49). 
Inflammation appears to drive breast cancer progression due to long-term insults 
associated with increased reactive oxygen species, DNA damage, mutation rate, and cell 
proliferation (49-54). Inflammatory cytokines such as IL-6 and others in the gp130 
family are known for their role in both acute and chronic inflammation and in promoting 
cancer progression (42, 55-57). In particular, increased breast cancer recurrence after 
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remission has been associated with poor health in connection to systemic inflammation 
(50). 
Some of the downstream mediators of inflammation are cyclooxygenase-2 (COX-
2) and prostaglandin E2 (PGE2), which are both correlated with a poor breast cancer 
prognosis (58). Aromatase activity, which increases serum estrogen levels and promotes 
breast cancer cell growth, can be induced by PGE2 and other inflammatory mediators 
(52, 53, 59). Interestingly, the use of non-steroidal anti-inflammatory drugs (NSAIDs) to 
suppress COX-2 has been associated with decreased risk of breast cancer (60). 
Inflammation caused by various inflammatory mediators and cytokines in the gp130 
family increase tumor angiogenesis, survival, immune evasion, and metrics associated 
with metastasis (42, 61, 62). Interestingly, no matter what the etiological origin of IBC is, 
it is typically considered invariably fatal (20, 63). Together, these studies suggest that 
there is an intrinsic link between inflammation and breast cancer aggressiveness and 
possibly to breast cancer subtypes. 
Breast Cancer Subtypes 
Breast cancer is a highly heterogeneous disease where a multitude of genetic 
defects can lead to tumorigenesis and metastasis. Breast cancer aggressiveness roughly 
correlates with the tumor cells’ expression of estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67, a marker for 
proliferation (64). Importantly, these markers are used as prognostic and therapeutic 
markers in the clinic. ER and PR are intracellular steroid receptors, and the cells 
expressing them tend to be dependent on estrogen and progesterone signaling for 
proliferation and survival (65, 66). When breast cancer cells lose their expression of ER 
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and PR, they become estrogen- and progesterone-independent (also called ER- and PR-) 
and are unresponsive to therapies that ablate these hormones (67). When assessing ER 
and PR expression in tissue, a binary relationship exits at the cellular level, where each 
breast cancer cell either expresses or does not express ER and/or PR. On the other hand, 
HER2 expression is measured on a scale from low to high above the basal level of HER2 
expression by normal breast epithelial cells. High HER2 expression (HER2HIGH), 
generally caused by gene amplification (68), constitutively activates various signaling 
pathways such as the PI3K/AKT and mitogen-activated protein kinase (MAPK) pathways 
and leads to the promotion of tumor cell proliferation, survival, and invasion (69) (65). 
Furthermore, this receptor can also gain a mutation where it becomes ligand-independent 
and is able to self-activate. When HER2 self-activates, the overall expression level of 
HER2 may still be low but the effects of HER2 are dramatically increased. 
While ER and HER2 are therapeutically targetable markers, Ki-67 is primarily 
used as a marker for cell proliferation where high levels of Ki-67 staining (Ki67HIGH) in 
the nucleus correlate to high levels of cellular mitosis (70). Unlike with ER, PR, and 
HER2 markers, Ki-67 is strictly used as a prognostic marker as it is not a very viable 
target for therapy due to the fact that nuclear proteins are very difficult to target with 
small molecule inhibitors. Currently there are no known therapies or clinical trials in 
progress for inhibition of Ki-67. 
Using these clinically relevant breast cancer markers, ER, PR, HER2, and Ki67, 
breast cancer can be subdivided into four subtypes. The breast cancer subtypes include 
Luminal A, Luminal B, Triple Negative/basal-like, and Her2-type (71) (Figure 3). 
Luminal A (ER/PR+ HER2LOW Ki67LOW) is the most frequent subtype in invasive 
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cancers and is also the least aggressive with a good patient prognosis (72, 73). Luminal B 
(ER/PR+, HER2HIGH Ki67HIGH) subtype is abundantly seen in ductal carcinoma in situ 
(DCIS) and is also not very aggressive. Patients with luminal B breast cancer also have a 
good prognosis. The most invasive breast cancer subtypes are triple negative breast 
cancer (TNBC) (ER/PR- HER2LOWKi67HIGH) and Her2-type (ER/PR- HER2HIGH 
Ki67HIGH), which both have a poor overall prognosis (73). Contributing to the poor 
prognosis for patients with TNBC is the lack of targetability by therapeutic interventions, 
as the current anti-ER and anti-HER2 compounds are ineffective against cells lacking 
these targets. 
Breast Cancer Treatment 
Currently available breast cancer treatment modalities include the standard suite 
of chemotherapeutics and radiation treatment along with a handful of FDA-approved 
targeted therapies. ER and HER2 are the most targetable markers. When ER or HER2 
levels are suppressed in the cancer cells that express them, a marked reduction in tumor 
cell growth results. Currently, ER expression is targeted by drugs such as tamoxifen and 
fulvestrant, while HER2 is inhibited by trastuzumab and lapatinib (74, 75). In addition, 
aromatase inhibitors such as letrozole are used to reduce the overall level of estrogen in 
the body to inhibit breast cancer cell growth. With these treatment modalities, both 
luminal A and B breast cancer can be effectively treated. As the disease progresses and 
becomes metastatic, it is more likely that the cancer will develop resistance to these 
therapies as they lose their therapeutically targetable markers and progress into TNBC. 
Since TNBC do not express any of these targetable markers, the existing drugs are 
ineffective in suppressing breast cancer progression. In essence, patients with TNBC 
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have to rely on chemotherapy and radiation alone, and if they are fortunate, in 
combination with new, untested drugs in clinical trials (Figure 3) (76). 
Other therapies such as gefitinib, erlotinib, and cetuximab, which all target the 
epithelial growth factor receptor (EGFR), have been used for TNBC patients in clinical 
trials (77). However, these therapies were not able to statistically improve patient 
outcomes when compared to standard treatment alone (77). Unlike with many other types 
of cancer, it is possible that TNBC is not dependent on EGFR signaling for tumor 
growth, survival, and invasive capacity. The lack of treatments for distant metastases 
makes metastatic TNBC the least survivable subtype with a 5-year survival rate of only 
26% (17). This provides a rationale for the development of better anti-cancer therapeutics 
that are effective against metastatic breast cancer. 
Intracellular Pathways That Promote Breast Cancer Progression 
Inflammation-driven breast cancer is associated with various signaling pathways 
that are activated by inflammatory cytokines (78, 79). While there are a multitude of 
intracellular signaling pathways that affect gene regulation, only a handful are well 
known for promoting cancer progression. In breast cancer, pathways that are involved 
include the signal transducer and activator of transcription 3 (STAT3), 
phosphatidylinositol-3-kinase (PI3K), mitogen activated protein kinase (MAPK) 
pathways, and nuclear factor kappa B (NFκB) (79-85). Specifically, STAT3 signaling has 
been shown to increase breast cancer invasive potential by upregulating matrix 
metalloproteinases such as MMP2/9 (83) and has been associated with drug resistance to 
trastuzumab and doxorubicin (80, 82). The increase in MMPs by STAT3 signaling has 
also been shown to increase EMT, cancer cell detachment, and migration (86). 
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Furthermore, PI3K is associated with increased AKT activation and promotes breast 
cancer cell survival against chemotherapeutics (81, 87). In addition, MAPK signaling 
promotes similar events as STAT3 and PI3K, including cell survival (69), drug resistance 
(88-90), and invasion (91), as well as promoting cell proliferation. NFκB signaling, on 
the other hand, has been shown to be associated with the development of breast cancer 
stem cells, which can repopulate metastases after tumor ablation by chemotherapeutics 
(92). Specifically, NFκB pathway activation been shown to increase breast cancer cell 
proliferation and invasion by increasing cluster of differentiation 44 (CD44) expression, 
which promotes cell migration, survival, and increased stem cell-like characteristics (85). 
Based on these studies it is quite evident that there is a lot of overlap in function between 
the STAT3, AKT, MAPK and NFκB signaling pathways in the context of breast cancer, 
suggesting that there could be synergistic effects when multiple pathways are activated 
(Figure 4). Indeed, other studies show that these pathways can be activated at the same 
time, which can promote a synergistic effect that drives complex breast cancer 
progression (79, 81). In summary, inflammation and inflammatory pathways related to 
the gp130 family of cytokines appear to be able to drive the simultaneous activation of 
these signaling pathways (78, 79). 
Oncostatin M and Breast Cancer 
Oncostatin M (OSM), a gp130 family cytokine, acquired its name due to its 
cytostatic effect on breast cancer cells and was originally thought to be a possible 
therapeutic (93, 94). While this idea was popular between 1990-2000, it was later 
rebuked as new research demonstrated that OSM actually inhibits the expression of tumor 
suppressors (95, 96), induces EMT (97-100), recruits cancer-promoting neutrophils 
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(101), and promotes metastasis (34). Furthermore, OSM signaling is associated with a 
poor breast cancer patient prognosis (97). OSM is secreted by a variety of cells in the 
tumor microenvironment such as tumor-associated neutrophils (TANs) and macrophages 
(TAMs), as well as adipocytes (101, 102). Interestingly, since OSM can be produced by 
adipose tissue, it expression levels may be increased in patients with obesity and type 2 
diabetes, both of which are thought to be drivers in systemic inflammation-mediated 
breast cancer progression (14, 62, 100, 103). Furthermore, OSM appears to accumulate in 
the acidic breast cancer microenvironment, where it binds to ECM proteins and stays 
active (98, 104, 105). Once OSM is secreted, it can act on target cells through the OSM 
receptor complex (OSMR), which consists of the gp130 protein dimerized with OSMRβ 
(106) (Figure 5). Once OSM binds to its receptor, it can activate a multitude of intracellular 
signaling cascades. 
OSM is known to stimulate the activation of three signaling pathways including 
the STAT3 (107), PI3K/AKT (78), and MAPK pathways (78, 107) (Figure 5). 
Additionally, OSM rarely induces a single pathway in isolation, and multiple pathways 
become active at the same time (78). This leads to the multitude of OSM-induced cancer-
promoting effects, which include increased vascular endothelial growth factor (VEGF) 
expression, EMT, tumor cell detachment, invasive capacity, and production of other 
proinflammatory factors such as S100A7 (34, 78, 97-99, 108, 109). Two other interesting 
effects associated with OSM are that it may push less aggressive breast cancer cells 
toward a more aggressive phenotype by suppressing ER expression and it may increase a 
cancer stem cell-like phenotype (99, 110, 111). Therefore, it is thought that inflammation 
stimulated by cytokines such as OSM both promotes hormone-resistance as well as drives 
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cancer cells towards a TNBC phenotype (111). Together, these studies strongly suggest 
that OSM is a proinflammatory factor with a multitude of effects that exacerbate breast 
cancer progression and metastasis. However, there are other related cytokines such as 
interleukin-1 beta (IL-1β) and the parental gp130 family member IL-6, which can have 
synergistic and overlapping functions with OSM (112). 
Interleukin-6, And Interleukin-1 Beta in Breast Cancer 
IL-6 is a cytokine in the gp130 family and is known to bind to a receptor 
composed of a dimer of IL-6Rα and a dimer of gp130 to form a tetramer receptor 
complex (113). The entire signaling complex is composed of a hexameric assembly with 
two IL-6 cytokines, two IL-6Rα subunits, and two gp130 subunits (113). IL-6 has been 
shown to activate multiple pathways including STAT3, JNK, and MAPK (114-116), 
which increase tumor cell growth, invasion, and metastasis (42, 114, 117, 118). These 
effects motivated the development of therapeutic agents to inhibit IL-6 signaling 
including chimeric or humanized antibodies against IL-6 and the IL-6Rα (42, 62, 119). 
Anti-IL-6 therapeutic agents, such as tocilizumab that inhibits IL-6 and siltuximab that 
targets IL-6Rα, have been effective against Castleman’s disease, which is characterized 
by high levels of IL-6 and abnormal proliferation of B and T immune cells (120, 121). 
However, despite siltuximab’s effectiveness in limiting IL-6 signaling in patients, and 
despite IL-6’s known effects in cancer progression, siltuximab has been ineffective in 
limiting the lethal effects of solid tumors (122, 123). This suggests that there may be 
additional inflammatory cytokines related to IL-6 that contribute to cancer invasion, 
metastasis, and mortality such as IL-1β, which specifically induces IL-6 in breast cancer 
cells (124). 
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IL-1β is a proinflammatory cytokine in the IL-1 family, and it binds to a receptor 
complex composed of IL1-R1 and IL-1RAcP (125, 126). Once the receptor complex is 
activated, IL-1β induces the NFB and MAPK pathways (127-129). IL-1β signaling is 
able to increase tumor cell growth, invasiveness, and metastasis in vivo by the stimulated 
secretion of proteases that degrade the ECM (125, 130-133). Anti-IL-1β therapeutics 
have been developed (134); however, much like with the anti-IL-6 biologics, IL-1β 
inhibition has not yielded positive results in patients when compared to standard 
chemotherapeutics (135). These studies suggest that for breast cancer patients, inhibition 
of a singular cytokine may not be enough due to the overlapping functions of these 
cytokines. Common anti-inflammatory medications such as NSAIDs inhibit 
cyclooxygenase 2 (COX2) expression, resulting in a decrease in prostaglandin production 
and in the reduced serum levels of a wide range of inflammatory cytokines and growth 
factors such as tumor necrosis factor alpha (TNF), IL-6, IL-1β, and VEGF (136-138). 
Additionally, studies have shown that there may be a benefit in using NSAIDS for the 
reduction of breast cancer risk (60). In conclusion, multiple cytokines may need to be 
suppressed simultaneously to obtain a positive clinical effect with reduction in metastases 
and increased patient survival. 
Cancer Angiogenesis and Hypoxia Factors 
Angiogenesis is one of the hallmarks of cancer progression, as the development of 
new blood vessels is needed to oxygenate and feed the often highly metabolically active 
tumor. Angiogenesis starts when tumors reach >1 mm in size, as this is the maximum 
distance for efficient diffusion of oxygen and nutrients from adjacent capillaries. 
Inflammation in the context of cancer has been associated with the production of the 
15 
 
 
proangiogenic vascular endothelial growth factor (VEGF) (139-142) (Figure 6). 
Furthermore, proangiogenic transcription factors such as hypoxia-inducible factor 1 
(HIF1) have also been linked to inflammation, cancer stem cells, and cancer progression 
(143, 144). HIF1 consists of a dimer of HIF1 and HIF1. Typically, HIF1α is regulated 
by rapid degradation while under normoxic conditions or in the absence of any inducing 
cytokines (145). Once HIF1α has been stabilized by hypoxia or by HIF1-inducing 
cytokines, it can translocate to the nucleus after dimerizing with the constitutively 
expressed HIF1β and activate gene expression of VEGF and other proangiogenic proteins 
such as basic fibroblast growth factor (bFGF) (146, 147). In particular, OSM has been 
shown to increase HIF1α levels through STAT3 activation that leads to an increase in the 
production of VEGF (148-150). IL-6 has also been shown to increase VEGF secretion 
through the induction of STAT3 phosphorylation (116). Despite the mountain of 
evidence showing that VEGF promotes breast cancer progression, anti-VEGF therapies 
have had limited success clinically (151). Much like with the story of the failed therapies 
with anti-IL-6 and anti-IL-1β, it is likely that other proangiogenic factors play a role in 
promoting tumor angiogenesis. One of the consequences of tumor angiogenesis is that the 
tumor cells intravasate into the newly formed vessels and become circulating tumor cells. 
Circulating Tumor Cells and Their Detection 
Circulating tumor cells (CTCs) are an important element in cancer progression as 
they are thought to be the primary means by which tumors promote metastasis to distant 
organs (152). Specifically, high levels of CTCs in the blood of breast cancer patients have 
been correlated with poor prognosis and metastatic involvement in bone, lung, and other 
sites (153, 154). Current CTC detection methodologies involve the qPCR amplification 
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of epithelial markers such as epithelial cell adhesion molecule (EpCAM), cytokeratin 19 
(CK19), and human mammoglobin (hMAM) (155). Detection methods that are reliant on 
the presence of epithelial makers such as EpCAM and CK19 have run into a few major 
problems. For example, CTCs tend to lose their epithelial markers (such as EpCAM and 
CK19) when they undergo EMT and intravasate into the circulation (156, 157). 
Furthermore, detection methods using only epithelial markers have difficulty in 
determining if the CTC is a normal circulating epithelial cell or a tumor cell (158). 
Alternative methods include the use of a colony forming assay which exploits the 
immortalized nature of most tumor cells (159). With the colony forming assay, blood is 
collected from an individual, the red-blood cells are lysed with a hypotonic solution, and 
the resultant collection of cells, which include white blood cells and possible CTCs, are 
plated in tissue culture. Overtime, colonies of adherent tumor cells will grow, and each 
clonal colony is counted as one CTC. However, this method also has problems including 
the lengthy time involved in forming colonies and the fact that some tumor cell types fail 
to form colonies below a certain concentration of cells, which can lead to false negatives. 
Another alternative method for detecting CTCs includes the qPCR-based detection of 
human Alu repeat transposon sequences in human cancer cells. However, this method 
only works in in vivo xenograft mouse models where mouse cells have Alu repeat 
sequences that are different from the human tumor cell Alu repeats (160). Effective 
detection of CTCs remains problematic and controversial as the only FDA approved 
method for detection of CTCs uses the CELLSEARCH® technology, which depends on 
the detection of epithelial markers (153, 154, 161). This necessitates further research into 
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the nature of CTCs with a search for additional useful cancer cell markers that can be 
used in the detection of CTCs. 
Mouse Models for Breast Cancer 
The most common animal model for the study of tumorigenesis, metastasis, and 
drug development is the common mouse, mus musculus. The short life span and high 
metabolism of the mouse allows researchers to study the course of cancer progression in 
a compressed time-scale. Typical animal experiments using mus musculus for the study 
of cancer commonly last between 1-3 months, whereas in humans, studies take 1 to 5+ 
years. Broadly speaking, there are three types of mouse cancer models: the transgenic 
tumor-forming mouse model, the human xenograft mouse model, and the syngeneic 
cancer mouse model (162-164). In the transgenic animal model, the animals are 
genetically modified to overexpress oncogenes such as c-Myc or have loss-of-function 
mutations in tumor suppressor genes such as p53 (164). These animals spontaneously 
develop tumors and are a useful model for studying neo-tumorigenesis where normal 
cells transform into metastatic tumor cells in a step-wise fashion. 
On the other hand, xenograft and syngeneic mouse models require an injection of 
tumor cells into a target organ. Typically, cells from established breast cancer cell lines 
are injected orthotopically into the 4th mammary fat pad of mice. With xenograft models, 
human breast cancer cells are used in immunodeficient mice such as in athymic nude 
mice, which do not have any functional T-cells (160). This prevents the immunodeficient 
animals from rejecting the human breast cancer cells and allows the study of human 
breast cancer in a living system. Alternatively, with a syngeneic mouse model, mouse 
mammary tumor cells derived from clonal mouse populations are injected into mice with 
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the same genetic background. This allows the study of tumor growth and metastatic 
disease in a immunocompetent model (162). An example of such a model utilizes the 4T1 
mammary tumor cell line that was derived from a spontaneous mammary tumor in a 
BALB/c albino mouse. The 4T1.2 cell line was developed by selecting a clonal 
population of 4T1 cells and possesses a metastatic capacity that roughly matches what is 
seen in human breast cancer (165). An advantage of the syngeneic model is that the 
immune system is not compromised and inflammation and immunity, so important for 
metastasis, can be studied (41). 
These animal models collectively give researchers powerful tools by which to 
study breast cancer progression, yet they are not without their faults. Many therapies that 
appear promising in in vivo animal models of breast cancer, fail miserably in the clinic. 
This underlies the need for better animal models that recapitulates human breast cancer 
(166). Although it is unlikely that a single animal model could ever perfectly model 
human breast cancer, utilization of multiple animal models may help confirm positive 
results. In addition, results from animal studies should be corroborated with available 
human data to increase the likelihood of the data being clinically relevant for human 
breast cancer. 
Human Data Analysis 
To assess the relevance of data derived from in vitro and in vivo experiments to 
human breast cancer, it is often important to corroborate this data with human patient 
samples and/or to data that is publicly available in various databases or repositories. An 
example of such a repository is Oncomine™, which includes over 18,000 cancer gene 
expression microarrays assessed from a wide variety of human cancers (167). Data can be 
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downloaded from Oncomine™, and various types of gene expression and correlation 
analyses can be performed. Other sources of online databases include the catalog of 
somatic mutations in cancer (COSMIC), the human protein atlas, the cBioPortal cancer 
genomics database, and others (168-170). Combined with a few bioinformatics tools and 
some rudimentary PERL programming, these online databases can be a powerful source 
of data for researchers to associate in vitro or in vivo data with actual human cancer gene 
expression data. 
Other sources of human patient data can be obtained from serum or tissues 
obtained from breast cancer patients. Serum and tissue samples can generally be acquired 
either from commercial sources and/or from hospitals/institutes that have a repository of 
stored human tissue and serum samples from patients. Alternatively, a new institutional 
review board protocol can be drafted to recruit patients for serum or tissue biopsy 
collection for cancer research, if the already available samples are insufficient or 
inappropriate for the study design. Additionally, serum samples can also be obtained 
from the National Cancer Institute’s serum bank for various research studies (171). The 
collected samples can then be assessed by numerous assays ranging from 
immunohistochemistry, immunoblot analysis, and enzyme-linked immunosorbent assays 
(ELISAs), to laser capture microdissection and qPCR. Overall, these sources of samples 
and data provide researchers a diverse tool set and help move data from tissue culture and 
animal models closer to clinical relevance. 
Summary 
The work presented in the following studies primarily investigates the gp130 
family of cytokines, including OSM and IL-6, in the context of cancer angiogenesis, 
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metastasis, survival, and their synergistic relationship with other proinflammatory 
cytokines. In Chapter 2, co-expression of VEGF and gp130 family cytokines in relation 
to patient survival is assessed. These studies found that high expression levels of these 
proteins correlate with decreased breast cancer patient survival and that the level of 
VEGF production in response to OSM or IL-6 is breast cancer subtype-dependent. In 
Chapter 3, the role of OSM in the promotion of CTCs and lung metastases was 
investigated in multiple in vivo mouse models of breast cancer. Specifically, high levels 
of OSM, through injection of recombinant OSM or induction of OSM expression in 
mammary tumor-bearing mice, resulted in an increase in both CTC numbers and lung 
metastases, as well as in decreased survival. However, OSM had no effect on the survival 
of mice when the earlier steps of the metastatic cascade were bypassed by injecting tumor 
cells directly into circulation. This finding suggests that OSM is important early in the 
metastatic cascade. In Chapter 4, OSM induction of IL-6 was assessed in breast cancer. It 
was determined that OSM-induced IL-6 production is predicated on breast cancer cells 
lacking ER. Specifically, ER+ T47D and MCF7 did not produce any IL-6 in response to 
OSM, while ER+ TNBC MDA-MD-231 cells did. Furthermore, the synergistic 
relationship between OSM and IL1β was evaluated, and these studies demonstrate that 
OSM and IL1β activate separate signaling pathways to promote IL-6 production. 
Interestingly, increased breast tumor expression of OSM, IL-6, and IL1β were all 
correlated with reduced breast cancer patient survival, and all three cytokine expression 
patterns were correlated with each other. Overall, these studies attempt to elucidate the 
complex interplay of inflammatory cytokines in relation to breast cancer angiogenesis, 
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metastasis, and survival and suggest that effective treatment of breast cancer may 
necessitate the suppression of multiple cytokines. 
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Figures 
 
Figure 1.1 Chronic inflammation leads to genomic and epigenetic instability and 
promotes tumor formation. 
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Figure 1.1 Chronic inflammation leads to genomic and epigenetic instability and 
promotes tumor formation  
A, Chronic inflammation promotes the development of downstream pro-
cancerous effects seen in B. B, Inflammation increases genomic instability resulting from 
DNA damage and changes the epigenetic profile of various genes. C, Genomic changes 
in precancerous cells can promote the secretion of inflammatory cytokines and 
chemokines in the tumor microenvironment and induce the development of reactive 
oxygen species. D, The cancer cells are then able to evade the immune system, increase 
cell proliferation, and invade into circulation. Once in circulation, the CTCs can then 
extravasate at distant organs and form a metastatic lesion. Adapted from QIAGEN© 
(172).
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Figure 1.2. Multi-step development of invasive ductal carcinoma (IDC) 
 
Figure 1.2. Multi-step development of invasive ductal carcinoma (IDC).  
First, an epithelial cell lining the normal milk duct becomes hyperplastic and 
proliferates to induce a state called ductal hyperplasia. During atypical hyperplasia, cell 
organization is lost and cells lose their original shape (dysplasia). Next, it progresses into 
DCIS, where the normal ductal structure is lost, and a wide variety of cell sizes and 
nuclear morphologies present. Lastly, in IDC, the cells invade through the ductal 
basement membrane and may potentially metastasize to distant organs. Adapted from 
RnCeus.com© (173). 
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Figure 1.3. Treatment strategies for breast cancer subtypes. 
Figure 1.3. Treatment strategies for breast cancer subtypes.  
Luminal A and Luminal B are the most common types of breast cancer and are 
the most treatable; treatments include anti-hormone and/or anti-HER2 therapies along 
with traditional chemotherapy. HER2-positive, also known as HER2-type, breast cancer 
responds well to anti-HER2 therapeutics. TNBC on the other hand is the least treatable 
subtype of breast cancer, as it lacks the molecular targets that the current targeted 
therapies inhibit. TNBC patients must rely on chemotherapy and radiation alone and/or 
use novel therapies with unknown therapeutic potential. Adapted from Catalanotti V, et 
al. (76). 
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Figure 1.4. Multiple signaling pathway activation in breast cancer cells. 
Figure 1.4. Multiple signaling pathway activation in breast cancer cells.  
Some of the most common intracellular pathways that are active in breast cancer 
are the STAT3, PI3K/AKT, MAPK (MEK/ERK), and the NFB (p65/p50) pathways. 
These pathways are activated in a variety of ways including the stimulation of receptor 
tyrosine kinases (RTK) by ligands such as growth factors and cytokines. Once these 
pathways are activated, usually through phosphorylation of target amino acids on the 
pathway proteins, they can lead to downstream effects such as tumor cell proliferation 
and survival, EMT, migration, invasion, and metastasis.  
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Figure 1.5.  OSM induces the STAT3, PI3K, and MAPK pathways. 
 
Figure 1.5. OSM induces the STAT3, PI3K, and MAPK pathways.  
OSM is known to activate multiple signaling pathways including STAT3, AKT, 
and MAPK. Once these pathways are activated by phosphorylation of target signaling 
proteins, they can induce the translocation of transcription factors into the nucleus. Then 
transcription of downstream target genes such as VEGF, MMPs and other proteases, 
S100A7, and genes associated with osteolytic bone metastasis, all of which promote 
cancer progression. 
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Figure 1.6.  Tumor cells promote the development of angiogenesis. 
Figure 1.6. Tumor cells promote the development of angiogenesis.  
A, Once tumor cells reach a size greater than 1 mm in diameter, they may become 
hypoxic and release VEGF. B, VEGF stimulates angiogenesis whereby adjacent blood 
vessels proliferate, migrate, and form tubes sending new blood vessels into the tumor. 
This helps with tumor cell oxygenation, nutrient uptake, and overall growth. These new 
blood vessels tend to be leaky and it is thought that the porous nature of these immature 
blood vessels facilitate intravasation (174). C, As the tumor grows larger, the requirement 
for more blood supply is increased. Adapted from Lungevity© (175). 
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Abstract 
Background: Breast cancer cell-response to inflammatory cytokines such as 
interleukin-6 (IL-6) and oncostatin M (OSM) may affect the course of clinical disease in 
a cancer subtype-dependent manner. Furthermore, vascular endothelial growth factor A 
(VEGF) secretion induced by IL-6 and OSM may also be subtype-dependent. Here we 
investigate the relationship between cytokine signaling, patient survival, and VEGF-A in 
invasive ductal carcinoma (IDC). 
Methods: The association between expression of cytokines, their receptors, and 
VEGF was assessed with patient survival in a breast cancer subtype-specific manner 
using datasets from OncomineTM. To assess specific signaling factors involved in 
cytokine-induced VEGF secretion, siRNAs for hypoxia inducible factor 1 α (HIF1α) and 
signal transducer and activator of transcription 3 (STAT3) were used. The levels of 
VEGF secretion were then analyzed by ELISA. 
Results: In IDC patients, high VEGF expression in tumors together with high 
cytokine or cytokine receptor expression correlates with decreased survival. Specifically, 
patient survival is significantly lower in HER2-, but not in HER2+, disease when tumor 
co-expression of VEGF and OSM, OSMRβ, IL-6, or IL-6Rα is high. Furthermore, 
assessment of HER2- breast cancer cells in vitro identified unique signaling differences 
regulating cytokine-induced VEGF secretion. In particular, OSM signals through STAT3 
and not HIF1α to induce VEGF secretion in ER- MDA-MB-231 human breast cancer 
cells, while the in ER+ T47D cells, OSM signals through both STAT3 and HIF1α. 
Additionally, ER- MDA-MB-231 cells only respond to OSM and not IL-6, while T47D 
cells respond to both OSM and IL-6, though to a lesser extent.  
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Conclusions: These results highlight that both the survival of breast cancer 
patients with high co-expression of VEGF and IL-6 family cytokines, as well as IL-6 
family cytokine-mediated VEGF secretion is dependent on specific breast cancer 
subtype. Thus, the heterogeneity of human breast cancer in relation to IL-6 family 
cytokines and VEGF may have important implications in clinical treatment options, 
disease progression, and ultimately patient prognosis. 
Introduction 
In the United States, breast cancer is the most frequently diagnosed cancer among 
women (1). With 252,710 new cases of invasive breast cancer (IBC) expected for 2017, 
breast cancer remains a leading public health concern, both in the United States and 
globally. One of the main concerns is the complex relationship between IBC subtypes, 
clinical treatment, and long-term survival (1, 2). The current known IBC subtypes are not 
able to fully capture the heterogeneous nature of breast cancer, and our current 
understanding is lacking in terms of patient treatment versus survival (3). In particular, 
anti-angiogenic therapies for breast cancer have had variable clinical success at best, and 
at worst, show no improvement in disease free survival (4, 5). The high level of clinical 
variability with anti-angiogenic therapies may be due to the highly heterogeneous nature 
of breast cancer and their subsequent biomarkers (6). This underlies the need to improve 
our understanding of clinical outcomes in conjunction with existing breast cancer subtype 
biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2).  
Current breast cancer subtype classifications depend on the evaluation of ER, PR, 
and HER2 (3). Luminal A (ER+ PR+ HER2-; low Ki67) and luminal B (ER+ PR+ 
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HER2-; high Ki67 or HER2+) breast cancer subtypes are typically less aggressive and 
display a more favorable prognosis relative to other subtypes (7-9). In contrast, cancers 
classified as basal-like triple negative breast cancer (TNBC; ER- PR- HER2-) have high 
frequencies of relapse and display less favorable prognoses, in large part due to the lack 
of targeted therapies available to treat this subtype (3, 7). Similarly, HER2-enriched 
cancers (ER- PR- HER2+) also have unfavorable prognoses (10). While superficial 
differences between the subtypes are relatively well known, the specific molecular 
mechanisms that drive these differences remain elusive. Specifically, increased 
inflammatory markers in the serum of breast cancer patients appear to be associated with 
poor prognosis (11). 
Chronic inflammation promotes a maladaptive pathological state, in which 
inflammatory cytokines actually promote tumorigenesis, invasion, and metastasis (12). 
Cytokines of the interleukin-6 (IL-6) family, including IL-6 and oncostatin M (OSM), 
have been implicated in the migration and invasiveness of human breast cancer cells (13-
15), while leukemia inhibitory factor (LIF) has been shown to act as a tumor/metastasis 
suppressor (16-19). Moreover, both IL-6 and OSM have been shown to be capable of 
directly and indirectly driving angiogenesis (20-22). Receptor complexes of the IL-6 
family all consist of at least one molecule of glycoprotein 130 (gp130), as well as 
subunit(s) specific to their respective receptor (23, 24). Following IL-6 or OSM ligand 
binding, the gp130 receptor complexes activates the JAK/STAT, MAPK, PI3K/AKT, and 
JNK pathways, thereby mediating transcription of target genes (25-30). Although IL-6 
and LIF bind specifically to their individual receptors (IL-6R and LIFR, respectively), 
OSM is capable of binding to both the LIFR and the OSM receptor (OSMR) (25, 31-33). 
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The resultant cytokine signaling plays various roles in the development of breast cancer, 
through activation of target genes involved in differentiation, survival, apoptosis, and 
angiogenesis (29, 32, 34). 
Angiogenesis is controlled by a balance of pro- and anti-angiogenic factors that 
maintain a normal rate of blood vessel growth (35). During tumor angiogenesis, both 
tumor cells and tumor-associated stromal/immune cells secrete proangiogenic factors (30, 
36). The most potent proangiogenic factor, vascular endothelial growth factor A (VEGF-
A), promotes the survival, proliferation, and motility of endothelial cells and enhances 
vascular permeability (37, 38). Other VEGF subtypes include the weakly angiogenic 
VEGF-B, and the lymphangiogenic and vasculogenic VEGF-C and VEGF-D (39, 40). As 
a proangiogenic factor, VEGF-A (also referred to as VEGF) regulation typically depends 
on hypoxia-driven signaling through the dimeric transcription factor hypoxia-inducible 
factor 1 (HIF1). As a dimer, HIF1 consists of the inducible HIF1α subunit, which when 
partnered with the constitutively expressed HIF1β, binds the hypoxia response element 
(HRE) (41). However, transcription factor binding sites in the VEGF promoter other than 
the HRE, such as those for signal transducer and activator of transcription-3 (STAT3) and 
activator protein 1 (AP1), allow transcription to be activated by numerous pathways 
under both hypoxic and non-hypoxic conditions (42-45). Under non-hypoxic conditions, 
IL-6 family cytokines have been shown to promote VEGF expression via activation of 
transcription factors HIF1α and STAT3 (22, 30, 46, 47). 
In this paper, we study the differential effects of the inflammatory interleukin-6 
(IL-6)-family cytokines on breast cancer patient outcomes, as well as the induction of 
vascular endothelial growth factor A (VEGF) in a breast cancer subtype-specific manner. 
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Using Oncomine data, we systemically explored the co-expression of VEGF with 
inflammatory cytokine components among invasive ductal carcinoma (IDC) patients 
subdivided by HER2- or HER2+ status. Specifically, we found that HER2- patient 
survival significantly decreases when breast tumors co-express high levels of VEGF and 
high levels of OSM, OSMRβ, IL-6, or IL-6Rα. Conversely, in patients with HER2+ 
disease, co-expression of VEGF and these inflammatory proteins had little to no effect on 
survival. Furthermore, through treatment of HER2- breast cancer cell lines with these 
cytokines, we elucidate some of the specific signaling factors involved in the mediation 
of VEGF secretion. Interestingly, regulation of IL-6-family cytokine-induced VEGF in 
HER2- cells differed between ER+ T47D (ER+ PR+ HER2-) and ER- MDA-MB-231 
(ER- PR- HER2-) cells. In T47D cells, HIF1α played a traditional role in transcriptionally 
activating VEGF secretion, while in MDA-MB-231 cells, VEGF secretion was 
independent of HIF1α and dependent on STAT3 signaling. These results highlight the 
breast cancer subtype-specific differences in cytokine signaling that lead to VEGF 
secretion, and importantly, the potential for therapeutic suppression of IL-6 family 
cytokines in HER2- breast cancer. 
Materials and Methods 
Oncomine analysis 
To explore correlations between IL-6 family cytokines, cytokine receptors, VEGF 
expression, breast cancer receptor status, and patient survival, we attained the Curtis 
Breast human mRNA microarray dataset from Oncomine™ (Compendia Bioscience, Ann 
Arbor, MI). The constraints used to define the dataset used were “Invasive Ductal 
Carcinoma” and a detailed survival status of either “Alive” or “Dead of Disease.” The 
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resultant dataset was used to calculate quartiles. From these, the upper quartile (>75th 
percentile) and lower quartile (<25th percentile) were selected for comparison in order to 
clearly depict survival trends that may have been otherwise muddled by use of all quartile 
combinations. For co-expression analysis, we calculated survival curves using patients in 
the upper quartile of both VEGF and each particular IL-6 family gene (“high/high”) and 
the lower quartile of both (“low/low”). Statistical analyses between survival of two 
groups was calculated using a log-rank test in GraphPad Prism 5 software *p<0.05, 
**p<0.01, ***p<0.001. 
Tissue culture 
MDA-MB-231 and T47D human breast cancer cells (ATCC) were grown in 
RPMI medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin 
streptomycin, and 1% sodium pyruvate and incubated at 37°C at 5% CO2. Cytokine 
treatments were prepared in low serum media (1% FBS) at 25 ng/mL recombinant human 
OSM (Cat#300-10T, Peprotech), IL-6 (Cat #200-06, Peprotech), and LIF (Cat# 300-05, 
Peprotech) for the indicated time points. Human umbilical vein endothelial cells 
(HUVECs, GlycoTech, Gaithersburg, MD) were grown in M199 medium supplemented 
with 15% FBS, 50µg/mL endothelial cell growth supplement (BD Biosciences, Bedford, 
MA) and 10 units/mL porcine heparin (Sigma-Aldrich, St. Louis, MO) at 37°C in 
humidified 5% CO2. 
For cytokine treatment, MDA-MB-231 cells were grown to 50% confluency in 
RPMI 1640 with 10% FBS, 1% Penicillin/Streptomycin and 1% Sodium Pyruvate. Cells 
were then starved overnight in serum-free media. Cells were treated with recombinant 
human OSM (rhOSM, Peprotech Inc., Rocky Hill, NJ) in serum-free RPMI for 72 hours. 
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Conditioned media (CM) was collected, cellular debris was removed following 
centrifugation, and CM was stored at -80°C. 
siRNA transfection 
To determine the mechanism by which VEGF is induced, siRNAs pools targeting 
HIF1α, STAT3, JNK1 and JNK2 were obtained from Dharmacon. In brief, 300,000 
cells/well were plated in a 6-well plate and siRNAs were transfected according to the 
Fast-Forward protocol as outlined by the manufacturer of Hyperfect siRNA Transfection 
Reagent (Cat# 301705, Qiagen). STAT3 siRNAs were used at 25 nM and transfection 
was incubated for 72 hours, serum starved, and then treated with OSM for up to 48 hours. 
JNK1 and JNK2 siRNA was used at concentrations of 20 nM and transfected for 24 
hours prior to OSM treatment. Knockdown was assessed via immunoblot analysis (see 
below). 
Immunoblot analysis  
Cells were grown to 50-80% confluency before being treated with respective 
cytokines and/or siHIF1α. Cells were lysed on ice with 1x RIPA buffer containing 1x 
protease inhibitor cocktail (Cat# P8340, Sigma Aldrich). Lysates were run on an SDS-
PAGE gel, transferred onto a nitrocellulose membrane, and blocked overnight in 5% non-
fat dry milk in PBS containing 0.05% Tween 20 (5% NFDM-PBST). Membranes were 
incubated overnight in 0.6 µg/mL anti-HIF1α primary antibody (Dilution: 1:1000 Cat# 
AF1935, R&D Systems) in 5% NFDM-PBST. Membranes were washed with PBST and 
incubated with HRP secondary antibody (Cat# 705-035-003 Jackson ImmunoResearch) 
in 5% NFDM-PBST for 45 minutes, developed with ECL, and imaged on X-ray film on a 
Kodak 4000R Image Station. 
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Signaling blots were performed as detailed above with the following antibodies: 
STAT3 (Cat# 9132), p-STAT3 (Cat# 9145), JNK1 (Cat# 3708), p-JNK1 (Cat# 4668), β-
Actin (Cat# 3700) ((1:1000, Cell Signaling Technologies). 
VEGF ELISA 
Analysis of VEGF secretion by MDA-MB-231 and T47D cells was assessed via 
VEGF ELISA according to the manufacturer’s protocol (Cat# Dy293B, R&D Systems, 
Bethesda, MD). Cells were plated at a confluency of 50,000 or 100,000 cells in a 24-well 
plate and allowed to adhere overnight. The following day, cells were serum-starved in 
serum free media for 6 hours and treated with cytokines for the indicated time. 
Conditioned media was collected and assessed by ELISA. The absorbance was recorded 
using a microplate reader (Bio-Rad) at 450 nm and background was subtracted (570 nm). 
RT-PCR 
Total RNA was collected from MDA-MB-231 and T47D cells using RNA STAT-
60 and isolated per the manufacturer’s protocol (Tel-Test; Friendswood, TX). cDNA was 
synthesized according to the manufacturer’s protocol (High Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems, In/Life Technologies). RT-PCR primers used 
were as follows: OSMRβ (510 bp): forward, 5’-TTAAAGGCCAGAGGCTATGG-3’; 
and reverse, 5’-TTGACAGAAGAATTGTGGAA-3’. LIFR (420 bp): forward, 5’-
ATACAGATGGTGGAGTGG-3’; and reverse, 5’-TGATGGGTGGACAATAGG-3’. IL-
6R (618 bp): forward, 5’-GTGAGGAAGTTTCAGAACAGTCCG-3’; and reverse, 5’-
TGGGAGGCTTGTCGCATTTG-3’; gp130 (326 bp): forward, 5’-
CATGCTTTGGGTGGAATGGAC-3’; and reverse, 5’-
CATCAACAGGAAGTTGGTCCC-3’; and GAPDH (483 bp): forward, 5’-
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GTCAACGGATTTGGCCGTATT-3’; and reverse, 5’- 
AAAGTTGTCATGGATGACCTT-3’. 
pSTAT3 ELISA 
Intracellular pSTAT3 levels were assessed by ELISA in accordance with the 
manufacturer’s protocol (Cat#7146, Cell Signaling). 50,000 cells were adhered to 24 well 
plates overnight in serum free media. Cells were then treated with OSM or IL6 (25 
ng/mL) for the indicated times, and cell lysates were collected using 1x Cell Lysis Buffer 
(Cat# 9803, Cell Signaling). The lysates were diluted 1:3 with blocking buffer (PBS-
0.05% Tween 20, 1% IgG-free BSA) and assessed by ELISA. Absorbance was assessed 
with a microplate reader at 450 nm with background correction at 570 nm. 
Statistical analysis  
All statistical analyses were performed using GraphPad Prism 5 software. To 
compare multiple groups, one- or two-way analysis of variance were run with Tukey’s 
and Bonferroni’s post-test, respectively where appropriate on ELISA data. Survival data 
was depicted as Kaplan-Meier graphs and significance assessed by the Log-rank test. 
Experiments were considered statistically significant if p values were less than 0.05. 
Error bars represent mean ± S.E. Experiments were performed at least three times to 
determine statistical significance. 
Results 
Inflammatory cytokine and VEGF co-expression is correlated with decreased survival of 
IDC patients  
To address the importance of IL-6 family cytokines in invasive ductal carcinoma 
(IDC), we correlated patient survival relative to expression levels of VEGF with OSM, 
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IL-6, LIF, or their specific receptor subunits. Using the Curtis Breast dataset obtained 
from OncomineTM (48), co-expression in IDC patients was compared to survival and 
quantified by individual quartiles, as demonstrated for OSM and VEGF (Fig. S1A) and 
OSMRβ and VEGF (Fig. S1B). Utilizing just the upper and lower quartiles, we observed 
a significant correlation between high co-expression of OSM and VEGF and decreased 
survival, relative to low expression of both OSM and VEGF (p=0.0190, Fig. 1A). 
Similarly, decreased survival was observed in patients who had high expression levels of 
OSMRβ and VEGF (p=0.0012, Fig. 1B), IL-6 and VEGF (p=0.0005, Fig. 1C), or IL-
6Rα and VEGF (p=0.0016, Fig. 1D) relative to those with low co-expression of each 
respective gene pair. Patient survival was not statistically affected by co-expression levels 
of LIF and VEGF (p=0.0578, Fig. 1E) or LIFRβ and VEGF (p=0.1020, Fig. 1F). 
Together, these results highlight the importance of tumor cell co-expression of VEGF 
with OSM, OSMRβ, IL-6, or IL-6Rα on the poor survival of individuals with IDC.  
HER2- status dictates poor survival in IDC patients with high co-expression of OSM, IL-
6, OSMRβ or IL-6Rα and VEGF  
As published studies have demonstrated the importance of receptor status in 
breast cancer recurrence and treatment (49-51), we next analyzed HER2 status on the 
survival of IDC patients according to VEGF and IL-6 family molecule co-expression. 
Interestingly, high co-expression of VEGF with OSM, OSMRβ, IL-6, or IL-6Rα 
correlated with the poor survival of HER2- patients but not HER2+ patients (Fig. 2). 
Specifically, statistically significant decrease in survival was only observed in HER2- 
patients with high OSM and VEGF expression (p=0.0016) and not in HER2+ patients 
(p=0.5963, Fig. 2A). Decreased survival was also seen in HER2- individuals with high 
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OSMRβ and VEGF co-expression (p=0.0001, Fig. 2B), high IL-6 and VEGF co-
expression (p=0.0005, Fig. S2A), and high IL-6Rα and VEGF co-expression (p=0.0112; 
Fig. S2B). No statistically significant change in survival was detected with the respective 
HER2+ individuals (High OSMRβ/VEGF, p=0.9317, Fig.2B) (High IL-6/VEGF, 
p=0.6106, Fig. s2A) (High IL-6Rα/VEGF, p=0.0671, Fig S2B). Counter intuitive to its 
role as a metastasis suppressor, high expression of LIF with high expression of VEGF 
also was correlated with poor survival in HER2- (p<0.0001, Fig. S2C) but not HER2+ 
IDC patients (p=0.2806 Fig S2C). However, no association between HER2 status and 
survival was observed in IDC patients expressing high levels of LIFRβ and VEGF 
(p=0.1247 and p=0.534, respectively, Fig. S2D). 
Among HER2- individuals, published results suggest that ER+ patients have the 
lowest rates of relapse and a considerably more favorable prognosis than individuals 
expressing other receptor subtypes (49). Therefore, we examined the co-expression of 
OSM and VEGF with HER2 status in individuals that did or did not express ER. 
Surprisingly, in HER2- patients, ER+ status was associated with poor survival in IDC 
patients with high co-expression of OSM and VEGF (p=0.0008), while ER- status had no 
effect on survival (p=0.6998, Fig. S3A, B). ER status played a less significant role in 
patient survival when HER2 status was associated high OSMRβ and VEGF co-
expression (Fig. S3C, D). These data suggest that while ER+ HER2- patients typically 
have fair prognoses (49), high tumor co-expression of OSM and VEGF greatly impacts 
survival in these individuals.  
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OSM mediates VEGF induction independent of HIF1α signaling in TNBC cells 
Stark differences are evident when analyzing the effects of cytokine-driven 
angiogenesis on patient survival, thus underling the heterogeneity of cancer subtypes. As 
our data suggested, high OSM co-expression with the proangiogenic factor VEGF 
resulted in poor HER2- patient survival. To uncover mechanistic differences among 
breast tumor lines with differing ER status, we used two distinct HER2- cell lines, the 
ER-negative MDA-MB-231 (ER- PR- HER2-) TNBC cell line and the ER-positive T47D 
(ER+ PR+ HER2-) cell line, to study VEGF induction by IL-6 family cytokines. 
Inflammatory cytokines have been shown to promote hypoxia-like effects thereby 
inducing transcriptional activity of HIF1α, an important transcription factor for hypoxia-
related proteins such as VEGF. Treatment with OSM, IL-6, or LIF (25 ng/mL) induced 
HIF1α expression by Western blot analysis in both MDA-MB-231 cells at 24 hours and 
in T47D cells at 72 hours, relative to non-treated cells (Fig. 3A, B). These time points 
selected as they were determined to have maximal HIF1α-induction in each cell line (data 
not shown). The addition of an siRNA targeting HIF1α (siHIF1α) inhibited the induction 
of HIF1α following treatment with inflammatory cytokines. Interestingly, despite the 
induction of HIF1α by each of the inflammatory cytokines assessed, an increase in VEGF 
secretion was observed only in cells treated with OSM. OSM treatment accounted for a 
3-fold increase in VEGF secretion in MDA-MB-231 cells at 24 hours (p<0.05) and an 
almost 4-fold increase in T47D cells at 72 hours (p<0.001) compared to non-treated cells, 
as assessed by ELISA (Fig. 3C, D). Treatment with IL-6 or LIF did not produce a 
significant change in the level of VEGF secreted. To determine if VEGF induction was 
mediated through cytokine-induced HIF1α, VEGF secretion was assessed in the presence 
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of cytokine and siHIF1α together. Relative VEGF secretion was not altered in 
MDA-MB-231 cells treated with siHIF1α and OSM (p<0.01, Fig. 3C) relative to 
untreated control, while this same treatment reduced VEGF secretion by nearly 50% in 
T47D cells (p<0.001 Fig. 3D). These results demonstrate that OSM-mediated induction 
of VEGF is at least partially dependent on HIF1α signaling in T47D cells, yet is 
independent of HIF1α signaling in MDA-MB-231 cells. Together, this data suggests that 
OSM-induced VEGF induction is likely mediated through different pathways in ER+ 
versus ER- cells. 
To confirm a functional effect for OSM-induced VEGF production, we performed 
in vitro and in vivo angiogenesis assays. Conditioned media (CM) from MDA-MB-231 
cells treated with OSM induced endothelial cell tube and branch point formation, which 
was suppressed by the addition of a VEGF neutralizing antibody (Fig. S4A, B). A similar 
effect was observed in vivo using a Matrigel plug assay. CM from OSM-treated MDA-
MB-231 cells was mixed with Matrigel and injected subcutaneously in athymic female 
mice resulting in a 12-fold increase in angiogenesis, as compared to CM from untreated 
MDA-MB-231 cells (p<0.001, Fig. S5A, B). Together, these results suggest that OSM, 
but not IL-6 or LIF, promote the secretion of a functional VEGF from breast cancer cells.  
OSM strongly induces STAT3 activation in ER+ and ER- HER2- breast cancer cells 
OSM is capable of binding to and activating both the OSMR and the LIFR, while 
LIF binds to only the LIFR and IL-6 binds to the IL-6 receptor. Stimulation of these 
receptors prompts activation of various signaling pathways including the STAT3 and 
JNK pathways (23, 52-54). To confirm that these receptors were present in our cell lines, 
mRNA from MDA-MB-231 and T47D cells was assessed by RT-PCR and shown to 
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express OSMRβ, LIFRβ, IL-6Rα, and gp130 (Fig. 4A). Next, we sought to determine the 
mechanism by which OSM induces the expression of VEGF by investigating the 
activation of the transcription factors STAT3 and JNK, found downstream of OSMR. 
Treatment with OSM (25 ng/mL) strongly induced phosphorylation of STAT3 (pSTAT3) 
in MDA-MB-231 TNBC cells at both 15 and 30 minutes, as assessed by immunoblot. In 
contrast, addition of OSM only slightly induced phosphorylation of JNK1 (pJNK1) in 
these cells (Fig. 4B). Neither the addition of IL-6 nor LIF led to STAT3 or JNK1 
phosphorylation in ER- MDA-MB-231 cells. In T47D cells, stimulation with both OSM 
and IL-6 promoted phosphorylation of STAT3 at 15 and 30 minutes (Fig. 4C). 
Phosphorylation of STAT3 was not induced in ER+ T47D cells treated with LIF. A slight 
induction of JNK1 phosphorylation was observed following treatment with OSM in 
T47D cells, whereas IL-6 and LIF did not produce an effect. 
In both cell lines, levels of OSM-induced STAT3 phosphorylation were transient 
yet sustained over time up to 72 hours, with preferential activation around 0.5 hours, 
relative to treatment with IL-6 (p<0.001, Fig. 4D, E). Interestingly, treatment with IL-6 
has no observed effect on pSTAT3 levels in MDA-MB-231 cells and only induced 
moderate STAT3 phosphorylation in T47D cells. This highlights an important difference 
between cytokine responsiveness in these cells. 
Activation of STAT3 signaling is required for VEGF secretion by MDA-MB-231 TNBC 
cells 
As our data suggests, OSM-induced VEGF is independent of HIF1α in MDA-
MB-231 TNBC cells. To determine whether OSM promotes VEGF secretion via the 
STAT3 pathway, we used an siRNA targeting STAT3 (siSTAT3). In MDA-MB-231 
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cells, treatment with OSM and siSTAT3 suppressed VEGF secretion to near-baseline 
levels (Fig. 5A). However, this complete suppression was not observed in T47D cells, 
likely due to the role of HIF1α in the secretion of VEGF in this cell line (Fig. 5B). While 
initial studies using a chemical inhibitor of JNK suggested that JNK signaling was in part 
necessary for OSM-mediated induction of VEGF (Fig. S6A), further investigations 
revealed that these effects might have resulted from the off-target suppression of STAT3 
phosphorylation (Fig. S6B). However, siRNAs targeting both JNK1 and JNK2 (siJNK1 
and siJNK2, respectively) had no effect on the levels of VEGF secretion in MDA-MB-
231 or T47D cells treated with OSM (Fig. 5C, D). Together, these results demonstrate 
that OSM mediated induction of VEGF is dependent on STAT3 in MDA-MB-231 cells, 
while T47D cells utilize both STAT3 and HIF1α to promote VEGF production in 
response to OSM. 
Discussion 
The different molecular characteristics of human breast cancer have important 
implications for clinical treatment options, disease progression, and ultimately patient 
prognosis. Therefore, it is important to understand how molecular mechanisms are 
impacted by breast cancer subtypes in order to provide patients with comprehensive 
therapies targeted against their specific disease. In this study, we show the clinical 
importance of tumor cell co-expression of VEGF with OSM, OSMRβ IL-6, or IL-6Rα on 
the survival of individuals with HER2- invasive ductal carcinoma. Using this human 
relevance to drive in vitro studies, we demonstrate that mechanistically, ER+ HER2- and 
ER- HER2- breast cancer cells respond differently to IL-6 cytokines in their induction of 
VEGF. 
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High tumor expression of the inflammatory cytokine IL-6 has been associated 
with poor survival in breast as well as cervical cancer patients (55, 56). Upregulated 
OSM, IL-6, and their receptors have been associated with increased metastatic capacity 
(15, 57), including increased invasion and migration (23, 27, 28, 58, 59) and the 
promotion of angiogenesis (29, 30, 32, 34). Moreover, OSM has been shown to bind to 
extracellular matrix proteins such as collagens, laminins, and fibronectins in an active 
conformation, thereby accumulating in a breast tumor microenvironment to further 
promote these effects (60). In the studies presented here, we show that high co-expression 
of VEGF with OSM, IL-6, or their receptors, correlates with poor survival of IDC 
patients, suggesting their potential value as negative prognostic markers and therapeutic 
targets. This association was not observed among patients with high co-expression of 
VEGF and LIF or LIFRβ, most likely due to the recently described role of LIF as a 
metastasis suppressor (16-18). 
When IDC patients were subdivided by HER2 status, our results demonstrated 
that overall survival was significantly lower in HER2- patients with high OSM or 
OSMRβ and VEGF co-expression than in HER2+ patients. HER2- patients also fared 
much worse when their tumors had high co-expression of IL-6 or IL-6Rα and VEGF. 
Considering OSM alone, high expression of OSM in HER2- individuals was by itself 
associated with poor survival, while expression of OSMRβ was not (data not shown). 
Taking into consideration VEGF alone, one previous study showed that high VEGF 
expression was correlated with the presence of axillary nodal metastasis and lower 
overall survival (OS) rates in non-luminal A breast cancer subtypes, which include 
HER2- TNBC as well as luminal B and HER2 subtypes (61). Work has also been 
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published describing the relationship between expression of the lymphangiogenic factor, 
VEGF-C, its receptors, VEGFR2 and VEGFR3, along with the canonical VEGF receptor 
VEGFR1 with disease-free (DFS) and OS (62-65). Although VEGF-C expression had a 
strong impact on DFS or OS in HER2+ tumors, HER2- patients with high VEGF-C and 
VEGFR1 expression had a worse prognosis overall, thus indicating a clinical relevance 
between VEGF-C expression and HER2 status (62). 
With respect to ER status, we observed a significant negative effect on survival in 
ER+/HER2- individuals with high co-expression of VEGF and OSM or OSMRβ. This is 
interesting in light of the fact that OSM has also been shown to negatively regulate 
expression of the estrogen receptor itself (66). Such regulation can indicate a key element 
in OSM-driven malignancy, with the possibility that ER+ tumor cells lose ER status over 
time and evolve to become less susceptible to hormone therapies and more difficult to 
treat (66). Furthermore, several in vitro studies have demonstrated that OSM has a greater 
effect inducing epithelial-mesenchymal transition (EMT), and tumor cell detachment 
effects in ER+ PR+ HER2- breast cancer cell lines such as T47D and MCF7 than on ER- 
TNBCs like MDA-MB-231 or MDA-MB-468 (15, 30), and data not shown). Though our 
analysis for this work included 1,245 IDC patients, the assessment of HER2 and ER 
status yielded low population sizes suggesting that further examination may be needed. In 
particular, it is difficult to draw concrete conclusions between HER2+ status in relation to 
VEGF and inflammatory cytokines because of the low population sizes, even though 
clear statistical significance was shown with HER2- data. Overall, these results indicate 
that the inflammatory cytokines OSM and IL-6 contribute to the aggressive phenotype 
seen with HER2- disease. 
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Standing alone, these results suggest important differences between breast cancer 
subtypes in relation to VEGF and IL6 family inflammatory cytokines. Based on our 
patient data demonstrating that high levels of IL-6 family cytokines and VEGF co-
expression lead to poor survival in HER2- breast cancer, we investigated cytokine-
induced VEGF secretion from two HER2- breast cancer cell lines, MDA-MB-231 and 
T47D. Typically, VEGF expression is regulated under both hypoxic and non-hypoxic 
conditions, as the promoter region contains several response elements that allow for 
VEGF regulation downstream of various signaling pathways (Fig. 6A, (42-45)). Our 
studies showed that OSM, IL-6, and LIF each increased expression of HIF1α, an 
important transcription factor for VEGF. However, OSM-induced VEGF was 
independent of HIF1α in ER- MDA-MB-231 cells, whereas HIF1α signaling was in part 
necessary for OSM-mediated VEGF induction in ER+ T47D cells. HIF1α may have other 
alternate downstream effects in MDA-MB-231 cells such as the induction of 
angiopoietin-like-4, which has been shown to promote an aggressive phenotype (67). 
Furthermore, knockdown of STAT3 signaling ablated VEGF secretion in MDA-MB-231 
cells while having less effect on VEGF secretion in T47D cells. This difference 
demonstrates that TNBC MDA-MB-231 cells depend on activation of STAT3 for 
induction of VEGF secretion and suggests that inhibition of cytokine stimulation may 
attenuate angiogenesis in TNBC disease. To summarize, OSM-induced VEGF secretion 
is dependent on the activation of STAT3 in MDA-MB-231 cells, while activation of both 
STAT3 and HIF1α appear necessary for VEGF induction in T47D cells (Fig. 6B). These 
results may indicate unique properties pertaining to angiogenic signaling in ER- TNBC 
versus ER+ PR+ HER2- tumors. 
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Though it might be expected that IL-6 should also induce VEGF secretion from 
breast cancer cells, we found that in ER- MDA-MB-231 cells, IL-6 did not activate the 
STAT3 pathway and therefore did not promote VEGF secretion. Previous studies have 
shown that IL-6 has no effect on MDA-MB-231 E-cadherin levels (known to be signaled 
through the JAK/STAT3 pathway) and on various other markers of invasion (68), which 
suggests that while ER- MDA-MB-231 cells express the IL-6 receptor, STAT3 signaling 
is not regulated by IL-6 in these cells. While we showed that IL-6 weakly activated the 
STAT3 pathway in ER+ T47D cells, this induction was only seen through the first hour 
of treatment and did not extend to 48 hours as did OSM-induced pSTAT3. Interestingly, 
under innate immunological stress such as mycoplasma contamination, overall STAT3 
activation was enhanced in T47D cells and pSTAT3 induction by IL-6 mirrored that of 
OSM (data not shown). Mycoplasma-induced pSTAT3 has been previously seen in 
airway epithelial lung cells and is thought to be part of the cause for inflammation during 
mycoplasma infections (69). Overall, the activation of STAT3 signaling by OSM is 
significantly greater than with IL-6 and highlights a difference in signaling magnitude 
and possibly function between these two cytokines in a breast cancer subtype specific 
manner. 
Conclusions 
Taken together, our studies demonstrate that co-expression of VEGF and IL-6 
family cytokine molecules emerge as a potential negative prognostic marker, particularly 
for HER2- IDC disease. Furthermore, we demonstrate that there is distinct differential 
cytokine-induced signaling of STAT3 and HIF1α, which lead to varied levels of VEGF 
secretion among various TNBC and ER+ PR+ HER2- breast tumor cells. Collectively, 
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these results suggest that IL-6 family cytokine inhibition may have a beneficial effect on 
VEGF suppression and long-term patient survival in HER2- disease. 
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CHAPTER TWO: FIGURES 
 
Figure 2.1. Increased co-expression of OSM or OSMRβ and VEGF correlates 
with decreased survival of IDC patients 
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Figure 2.1. Inflammatory cytokine and VEGF co-expression are correlated with 
decreased survival of invasive ductal carcinoma patient.  
These Kaplan-Meier curves in Figure 1A and B are a subset of the data presented 
in Supplemental Figure S1. A) Kaplan-Meier survival curves of invasive ductal breast 
carcinoma patients with high OSM and VEGF expression (upper quartiles, respectively) 
present diminished survival when compared to individuals with low OSM and VEGF 
expression (lower quartiles, respectively). Comparable trends appear upon examination 
of the upper and lower quartiles of patients with B) OSMRβ and VEGF expression, C) 
IL-6 and VEGF expression, and D) IL-6Rα and VEGF expression, indicating significant 
differences between upper and lower quartile survival for each group. Survival of patients 
with invasive ductal breast carcinoma by E) LIF and VEGF expression and F) LIFRβ and 
VEGF expression are not significantly different. Analysis obtained from Oncomine™ 
dataset entitled Curtis Breast. Log-rank test *p<0.05, **p<0.01, ***p<0.001. 
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Figure 2.2. Co-expression of VEGF with OSM or OSMRβ appears to affect 
survival in HER2- but not HER2+ subtypes 
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Figure 2.2 Co-expression of VEGF with OSM or OSMRβ appears to affect survival in 
HER2- but not HER2+ subtypes. 
A) Kaplan-Meier survival curves of invasive ductal breast carcinoma for HER2- 
patients and HER2+ patients by OSM and VEGF expression. In HER2- patients, high 
OSM and high VEGF expression (upper quartiles, respectively) is strongly correlated 
with decreased survival when compared to patients with low OSM and low VEGF 
expression (lower quartiles, respectively). However, this trend is not evident in HER2+ 
individuals, as no significant difference is observed between survival of patients with 
OSM and VEGF expression in upper and lower quartiles, respectively. Similar trends are 
observed in Kaplan-Meier survival curves for B) HER2- and HER2+ by OSMRβ and 
VEGF expression. Analysis obtained from Oncomine™ dataset entitled Curtis Breast. 
Log-rank test *p<0.05, **p<0.01, ***p<0.001. 
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Figure 2.3. IL-6 family cytokine OSM induces VEGF secretion independent of 
HIF1α signaling in MDA-MB-231 cells 
Figure 2.3. IL-6 family cytokine OSM induces VEGF secretion independent of HIF1α 
signaling in MDA-MB-231 cells.  
A) Treatment with OSM, IL-6, and LIF (25 ng/mL) for 24 hours promotes 
expression of HIF1α in MDA-MB-231 TNBC cells. Addition of a siRNA targeting 
HIF1α (siHIF1α) ablates the effect of adding cytokines. B) T47D cells treated with IL-6 
family cytokines for 72 hours express greater levels of HIF1α relative to non-treated 
control. Treatment with siHIF1α reduces this effect, as assessed by immunoblot analysis. 
Immunoblots are representative of at least 3 experiments. Induction of VEGF secretion is 
observed following treatment with IL-6 family cytokines (25 ng/mL) for 24 hours in C) 
MDA-MB-231 cells (n=5) and for 72 hours in D) T47D cells (n=3), as determined by 
ELISA. Treatment with siHIF1α does not affect VEGF secretion in OSM-treated MDA-
MB-231 cells; however, VEGF secretion is modestly reduced in T47D cells treated with 
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OSM and siHIF1α. Data expressed as mean +/- SEM. One-way ANOVA, Tukey’s post-
test, **p<0.01, ***p<0.001. 
 
Figure 2.4. OSM strongly induces phosphorylation of STAT3 
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Figure 2.4. OSM strongly induces phosphorylation of STAT3.  
A) mRNA expression by RT-PCR of OSMRβ, LIFRβ, IL-6Rα, and gp130 in 
MDA-MB-231 and T47D cells. B) Treatment with OSM (25 ng/mL) for 15 minutes, 30 
minutes, and 1 hour strongly induces phosphorylation of STAT3 (Tyr 705) in MDA-MB-
231 cells and moderately induces JNK phosphorylation (T183/Y185). Treatment with 
either IL-6 or LIF (25 ng/mL) does not induce pSTAT3 or pJNK. C) Treatment with 
OSM induces phosphorylation of STAT3 and JNK in T47D cells. IL-6 induces moderate 
phosphorylation of STAT3 and JNK at early time points. Phosphorylation of STAT3 and 
JNK was compared to control β-actin, as assessed by immunoblot analysis. Blots are 
representative of three experiments. Time course experiment for STAT3 phosphorylation 
upon treatment with OSM or IL-6 (25 ng/mL) for 0.25-72 hours in D) MDA-MB-231 
cells, and in E) T47D cells. Treatment with IL-6 does not induce pSTAT3 expression in 
MDA-MB-231 cells, while inducing moderate pSTAT3 expression in T47D cells. ELISA 
was performed in quadruplicate; with each data point expressed as mean +/- SEM. Two-
way ANOVA with Bonferroni post-test, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 2.5. OSM induces VEGF via STAT3 signaling 
Figure 2.5. OSM induces VEGF via STAT3 signaling.  
A) Treatment with OSM (25 ng/mL) and siSTAT3 suppresses VEGF secretion by 
3-fold in MDA-MB-231 cells. B) Treatment with OSM and siSTAT3 moderately reduces 
VEGF secretion by T47D cells. VEGF secretion was not reduced by the addition of 
siRNAs targeting both JNK1 and JNK2 in either C) MDA-MB-231 or D) T47D cells. 
Experiments were performed in triplicate, and data expressed as mean +/- SEM. Two-
way ANOVA with Bonferroni post-test,  *p<0.05, ***p<0.001. 
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Figure 2.6. Mechanistically distinct regulation of VEGF secretion in MDA-MB-
231 TNBC and T47D (ER+/PR+/HER2-) cells 
Figure 2.6. Mechanistically distinct regulation of VEGF secretion in MDA-MB-231 
TNBC and T47D (ER+/PR+/HER2-) cells.  
A) The VEGF promoter can be activated by various transcription factors. B) In 
MDA-MB-231 cells, OSM mediates VEGF secretion by activating the STAT3 signaling 
pathway downstream of the OSMR (OSMRβ + gp130). In T47D cells, OSM regulates 
VEGF secretion via both HIF1α and the STAT3 signaling pathway. 
75 
 
 
Supplemental Materials and Methods 
Endothelial Cell Tube and Branch Point Formation Assay 
For the in vitro Angiogenesis Assay (Chemicon), Matrigel (50 µL) was allowed to 
solidify in 96-well plates at 37°C for 90 minutes prior to the addition of HUVECs (7.5 x 
103 cells). Cells were allowed to adhere for one hour in serum-free M199 medium. 
Medium was then removed and the HUVECs were treated with 1) conditioned media 
(CM) from untreated MDA-MB-231 cells, 2) CM from OSM-treated MDA-MB-231 
cells, 3) control medium with 25 ng/mL rhOSM, or 4) control medium with 50 ng/mL 
rhVEGF. Additionally, HUVECs were treated with OSM in combination with either 0.6 
µg/mL anti-OSM neutralizing antibody or 0.6 µg/mL anti-VEGF neutralizing antibody 
(Genentech). Tube formation was imaged every hour for an eight-hour period using 600 x 
800 pixel digital images. To quantify tube formation, branch points were counted as 
angle formed by an extending cellular process. 
In vivo Matrigel Plug Assay 
The Matrigel plug assay was performed as described previously (70) with the 
following modifications. Briefly, 8-week old female athymic NCr-nu/nu nude mice were 
injected subcutaneously and bilaterally in dorsal groin area with 0.3 mL of Matrigel (BD 
Biosciences) containing 20 units heparin and one of the following: 1) PBS, 2) 200 ng 
VEGF in PBS, 3) control MDA-MB-231 CM (concentrated 3x), 4) OSM-treated MDA-
MB-231 conditioned medium (concentrated 3x), 5) CM plus 0.6 g/mL anti-OSM 
neutralizing antibody or 6) CM plus anti-VEGF neutralizing antibody. After 10 days, the 
Matrigel plugs were removed, trimmed of mouse tissue, photographed, and weighed. 
Hemoglobin was measured using the Drabkin method (Sigma-Aldrich) following 
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homogenization in 0.5 mL distilled water. Concentrations of hemoglobin were calculated 
from known hemoglobin concentrations based on a standard curve run in parallel. 
Athymic NCR-nu/nu mice were housed in environmentally controlled rooms in the 
Veteran’s Administration Medical Center animal facility in Boise, ID. All procedures 
were approved by the International Animal Care and Use Committee. 
JNK Inhibitor Assay 
MDA-MB-231 cells were grown to 70-80% confluency on a 24-well plate with 
RPMI-1640 media. Cells were treated with 100 nM JNK Inhibitor II (CAS 129-56-6, Cal 
Biochem). After four hours, 25 ng/mL OSM was added for 30 minutes, after which cell 
lysates were collected and examined by immunoblot analysis. 
Chapter Two: Supplemental Figures 
 
 
Figure 2.S1.  Mechanistically distinct regulation of VEGF secretion in MDA-MB-
231 TNBC and T47D (ER+/PR+/HER2-) cells 
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Figure 2.S1. Increased co-expression of OSM or OSMRβ and VEGF correlates with 
decreased survival of IDC patients.  
Kaplan-Meier survival curves of invasive ductal breast carcinoma for A) OSM 
and VEGF (n=318) and B) OSMRβ and VEGF expression (n=389), as separated by 
quartiles. As co-expression of OSM and VEGF increases, overall survival trends 
decrease, with patients expressing high OSM high VEGF (upper quartiles, respectively) 
exhibiting significantly worse survival (p=0.0192) than individuals expressing low OSM 
low VEGF (lower quartiles, respectively). A comparable trend is observed with co-
expression of OSMR and VEGF (p=0.0012). Analysis obtained from Oncomine™ 
dataset entitled Curtis Breast. Log-rank test *p<0.05, **p<0.01. 
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Figure 2.S2. Expression of cytokines or their receptors and VEGF appears to 
affect survival in HER2- but not HER2+ subtypes 
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Figure 2.S2. Expression of cytokines or their receptors and VEGF appears to affect 
survival in HER2- but not HER2+ subtypes. 
 Kaplan-Meier survival curves of invasive ductal breast carcinoma for A) HER2- 
and HER2+ patients by IL-6 and VEGF expression. In HER2- patients, high IL-6 and 
high VEGF expression (upper quartiles, respectively) is strongly correlated with 
decreased survival when compared to patients with low IL-6 and low VEGF expression 
(lower quartiles, respectively). However, this trend is not evident in HER2+ individuals. 
Similar trends are observed in Kaplan-Meier survival curves between HER2- and HER2+ 
patients by B) IL-6Rα and VEGF expression and C) LIF and VEGF expression. D) Co-
expression of LIFRβ and VEGF does not significantly affect survival in either HER2- or 
HER2+ patients. Analysis obtained from Oncomine™ dataset entitled Curtis Breast. Log-
rank test *p<0.05, **p<0.01, ***p<0.001.  
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Figure 2.S3. Co-expression of OSM or OSMRβ and VEGF differentially affects 
survival based on estrogen receptor status 
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Figure 2.S3. Co-expression of OSM or OSMRβ and VEGF differentially affects survival 
based on estrogen receptor status.  
Kaplan-Meier survival curves of invasive ductal breast carcinoma for A) HER2-
/ER- and HER2+/ER- patients and B) HER2-/ER+ and HER2+/ER+ patients by OSM 
and VEGF expression. In patients with either HER2+/- and ER- expression, OSM/VEGF 
expression levels do not significantly affect survival. However, in HER2-/ER+ patients, 
high OSM and high VEGF expression (upper quartiles, respectively) is strongly 
correlated with decreased survival when compared to patients with similar receptor status 
expressing low OSM and low VEGF expression (lower quartiles, respectively). Similar 
trends respective of receptor status are observed in Kaplan-Meier survival curves for C) 
HER2-/ER- and HER2+/ER- patients and D) HER2-/ER+ and HER2+/ER+ patients by 
OSMRβ and VEGF expression. While no correlation between OSM/VEGF expression 
and survival is observed in HER2+/ER+ patients, the low number of samples in these 
populations distorts our ability to make a robust assessment of this patient subset. 
Analysis obtained from Oncomine™ dataset entitled Curtis Breast. Log-rank test 
*p<0.05, **p<0.01. 
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Figure 2.S4. OSM induces endothelial cell tube formation and branch points in 
vitro 
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Figure 2.S4. OSM induces endothelial cell tube formation and branch points in vitro.   
Tube formation of human umbilical vein endothelial cells (HUVEC) cells treated 
for 4 hours with conditioned media from A) MDA-MB-231 treated with OSM (25 
ng/mL) with or without anti-VEGF neutralizing antibody (0.6 µg/mL); light microscopy, 
200X. Increased tube formation is observed in HUVECs incubated with conditioned 
media (CM) of OSM-treated breast cancer cells, as compared to HUVECs incubated with 
control CM. B) Quantification of branch points was obtained by counting the number of 
tube-like protrusions originating from each cell node. A two-fold increase in branch 
points is observed in HUVECs treated with CM of OSM-treated MDA-MB-231 cells 
compared to non-treated control CM. The addition of anti-VEGF neutralizing antibody 
reduces branch point numbers to control levels, while anti-OSM neutralizing antibody 
shows a partial effect. Addition of recombinant VEGF or OSM to untreated cell CM are 
included as controls. Data expressed as mean +/- SEM. One-way ANOVA with Tukey’s 
post-test, ***p<0.001, n=5. 
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Figure 2.S5. OSM-treatment of human breast cancer cells stimulates angiogenesis 
in vivo 
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Figure 2.S5. OSM-treatment of human breast cancer cells stimulates angiogenesis in vivo.  
Six- to eight-week old female athymic nude mice were injected with 0.3 mL of 
Matrigel containing heparin (20 units) and 100 L of one of the following: 1) PBS; 2) 
untreated MDA-MB-231 cell conditioned medium, concentrated 3-fold (3X); 3) OSM-
treated (25 ng/mL) MDA-MB-231 cell conditioned medium (3X); 4) OSM-treated 
medium (3X) + anti-OSM neutralizing antibody (0.6 g/mL); 5) OSM-treated medium 
(3X) + anti-VEGF neutralizing antibody (0.6 g/mL); or 6) untreated control cell 
medium + rhVEGF (50 ng/mL). After 10 days the mice were euthanized and the Matrigel 
plugs were removed. A) Representative plugs containing various treatments were 
photographed. B) Quantification of new infiltrating vessel formation was determined by 
the measurement of the amount of hemoglobin in each Matrigel plug using the Drabkin’s 
assay. Hemoglobin levels increases 12-fold for OSM-treated conditioned medium over 
untreated conditioned medium. Data was analyzed from at least 6 replicates per 
condition. Data expressed as mean +/- SEM. One-way ANOVA with Tukey’s post-test, 
***p<0.001. 
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Figure 2.S6. JNK Inhibitor 2 suppresses VEGF secretion and phosphorylation of 
STAT3 
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Figure 2.S6. JNK Inhibitor 2 suppresses VEGF secretion and phosphorylation of STAT3.  
A) MDA-MB-231 cells were treated with JNK Inhibitor 2 or control DMSO for 2 
hours prior to treatment with OSM (25 ng/mL). VEGF levels were assessed following 
treatment with OSM for 48 hours by ELISA. JNK Inhibitor 2 suppresses overall VEGF 
levels by roughly 50%. JNK ELISA was performed in triplicate. B) Phosphorylation of 
STAT3 is suppressed in cell lysates collected from cells treated with JNK Inhibitor 2 and 
OSM, as assessed by immunoblot analysis, indicating non-specific effects of the JNK 
Inhibitor. For the VEGF ELISA, the data was expressed as mean +/- SEM, and assessed 
by two-way ANOVA with Bonferroni post-test was run; **p<0.01, ***p<0.001. 
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Abstract 
 
Systemic and chronic inflammatory conditions reduce patient survival and have 
been associated with increased breast cancer aggressiveness. This paper characterizes the 
role of an inflammatory cytokine oncostatin M (OSM) and its role in the pre-
intravasation aspects of breast cancer metastasis. First, we established the expression 
pattern of OSM in human breast cancer tissue using tissue microarray analysis and found 
that OSM was expressed at highest levels in ductal carcinoma in situ (DCIS) when 
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compared to invasive ductal carcinoma (IDC), lymph node metastasis, or adjacent normal 
tissue. This finding suggests that OSM may be operant during earlier steps of breast 
cancer metastasis. To investigate this further, both xenograft and syngeneic orthotopic 
mouse models of breast cancer were utilized. In mice bearing MDA-MB-231-Luc2 
tumors, injection of rhOSM not only increased metastases to the lung and decreased 
survival, but also increased circulating tumor cell (CTC) numbers. This is the first time 
that a gp130 family inflammatory cytokine has been shown to directly affect the amount 
of tumor cells found in circulation. These findings are corroborated using a 4T1.2 
syngeneic mouse model of breast cancer. Mice bearing 4T1.2-shOSM tumors with KD 
tumor expression of OSM had reduced CTCs, lowered lung metastatic burden, and 
increased survival compared to mice bearing control tumors. CTC numbers were further 
reduced in OSM knockout mice bearing the same tumors, demonstrating the importance 
of both paracrine- and autocrine-produced OSM in this process. On the other hand, after 
bypassing initial steps of metastases by injecting the 4T1.2 cancer cells directly into the 
circulatory system, OSM did not affect survival. During in vitro studies, OSM induced 
both 4T1.2 tumor cell detachment and migration. Collectively, we suggest that OSM 
affects the early steps of metastatic breast cancer progression and that suppression of 
OSM may help prevent breast cancer metastasis. 
Introduction 
The inflammatory gp130 family of cytokines has been shown to modulate 
immune function (1) with important implications in tumor immunology (2). 
Inflammation and inflammatory cytokines have been associated with increased breast 
cancer metastasis and poor survival rates (3-6). Interleukin-6 (IL-6), as a well-known 
97 
 
 
inflammatory cytokine in the gp130 family, promotes breast cancer metastasis but 
therapies targeted against it have failed in clinical trials (7, 8). Other cytokines in the 
gp130 family such as oncostatin M (OSM) also modulate inflammation, and OSM has 
been associated with a wide variety of disease states such as in inflammatory bowel 
disease, arthritis, gingivitis, and lupus nephritis (9-12). In the context of cancer, OSM has 
been shown to induce in vitro metrics associated with cancer invasiveness and promote 
breast cancer metastasis to bone (13-17). In the breast tumor microenvironment (TME), 
OSM is produced by breast tumor cells (13), as well as stromal cells such as tumor-
associated macrophages and neutrophils and adipose tissues (18-20). After OSM is 
secreted, it binds to and accumulates in the extracellular matrix (ECM) in an active form, 
which may lead to chronic local inflammation and increased tumor metastasis (21). 
Specifically, it has been shown that human breast tumor cells signal neutrophils to secrete 
OSM, which subsequently induces tumor cell vascular endothelial growth factor (VEGF) 
production, cell detachment, and invasive capacity (18). Collectively, these studies 
suggest that OSM functions in breast cancer progression both in an autocrine and 
paracrine fashion. 
OSM signaling utilizes two receptors. OSM binds with high affinity to the OSM 
receptor (OSMR) (gp130 subunit + OSMRβ) and with lower affinity to the leukemia 
inhibitory factor receptor (LIFR) (gp130 + LIFR (22). While OSM binding to the  
OSMR has been shown to promote cancer cell malignancy and reduce long-term survival 
in breast cancer patients (23), activation of the LIFR appears to suppress tumor growth 
and metastasis (24). OSMR signaling initiates the JAK/STAT, MAPK, and PI3K/AKT 
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pathways (25-27), as well as the stress-activated mitogen-activated protein kinases p38 
and JNK pathways (28). 
As a pleiotropic cytokine, OSM seems to play an important role in promoting 
breast cancer metastatic potential in vitro while inhibiting breast tumor cell proliferation 
(10, 29, 30). OSM has been shown to function on breast and various other cancer cells in 
culture to: i) promote an epithelial-mesenchymal transition (EMT) and a stem cell-like 
phenotype (27, 31, 32), ii) upregulate expression of proteases such as matrix 
metalloproteinases (MMPs) (10, 15), iii) promote tumor cell detachment and subsequent 
invasion (15, 16, 33), iv) induce the expression of  VEGF, hypoxia inducible factor 1 
alpha (HIF1α), and other proangiogenic factors (33-36), and v) suppress estrogen 
receptor alpha (ERα) expression, (23). Despite increasing evidence in vitro, limited 
studies have addressed the role of OSM in breast cancer metastasis in vivo.  
Our lab’s previous studies were the first to show the importance of OSM in breast 
cancer metastasis to bone. Specifically, reduced tumor cell-produced OSM expression led 
to a decrease in osteolytic bone metastasis in an orthotopic 4T1.2 mouse model (17). 
Along with earlier studies demonstrating OSM’s function in normal bone homeostasis 
(37, 38), this work suggests an important role for OSM during post-intravasation breast 
cancer metastasis to bone and subsequent bone destruction. While in vitro studies suggest 
that OSM promotes the early steps of the metastatic cascade, no extant work 
differentiates between OSM’s impact on pre- versus post-intravasation aspects of the 
breast cancer metastatic cascade. 
This paper demonstrates that OSM initiates pre-intravasation steps of the 
metastasis cascade, increasing CTC numbers and lung metastases and decreasing 
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survival. Conversely, we also show that OSM had no effect on mouse survival in the 
post-intravasation model that bypassed the early steps of metastasis by injecting tumor 
cells directly into circulation. Therefore, our work suggests that therapeutic suppression 
of OSM in the tumor microenvironment might not only be an effective treatment strategy 
for bone metastasis; it could also be used as a preventative therapeutic to mitigate overall 
breast cancer metastasis. 
Materials and Methods 
Tissue microarrays 
Breast tissue from 72 patients was obtained from paraffin block archives at the 
Department of Pathology, Mercy Medical Center, Nampa Idaho. Three tissue microarrays 
(TMA) of 1 mm thickness were assessed. The TMAs were stained for OSM using the 
Histostain Kit (Cat #95-9843; Invitrogen, Carlsbad, CA) per manufacturer’s instructions. 
The TMAs were deparaffinized and stained overnight with 1:400 dilution of rabbit anti-
human OSM primary antibody (Cat #sc-129; Santa Cruz Biotechnology, Santa Cruz, CA) 
and 1 hour with 1:1000 goat-anti rabbit IgG-AP 2o antibody. TMAs stained with 
secondary antibody alone served as the negative control, and spleen and salivary gland 
served as positive controls for OSM staining. 
The TMAs were analyzed in multiple sets of random orders for OSM expression 
intensity by a pathologist graded as follows: 0=No staining; 1=Light staining; 2=Medium 
staining; 3=Dark staining. Gradings for each patient were averaged for each cell tissue 
type (ductal epithelial, vessel, stroma). Additional methods are detailed in the 
Supplemental Materials and Methods. 
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Cell lines and culture conditions 
MDA-MB-231 D3H2LN luc2 cells (Caliper Life Sciences); and MDA-MB-231 
(ATCC) human breast cancer cells were cultured in RMPI media supplemented with 10% 
FBS and 100 units/mL of penicillin and streptomycin. Cells were maintained at 37 oC, 
5% carbon dioxide, and 95% humidity. 4T1.2 mouse mammary cancer cells were 
cultured in alpha-MEM media supplemented with 10% fetal bovine serum (FBS), 1 mM 
sodium pyruvate, and 100 units/mL each of penicillin and streptomycin, and passaged for 
no more than 6 months. All media and supplements were obtained from Hyclone (Logan, 
UT). 
Plasmid construct design and cell transfections 
To transduce MDA-MB-231-Luc2 D3H2LN cells with a tetracycline (TET)- 
inducible vector, the full-length OSM cDNA was cloned into the pLenti 6.3/TO/V5-
DEST vector. Lentiviral transduction of the pLenti 6.3/TO/V5-DEST+hOSM vector and 
pLenti3.3/TR vector was performed using the ViraPower™ II Lentiviral Gateway® 
Expression System (Life technologies, K367-20) in accordance with manufacturer’s 
instructions. Stably transduced cell lines were tested for TET induction of hOSM 
expression by ELISA and Western Blot. 
To create OSM knockdown 4T1.2 cells, OSM shRNA and a LacZ shRNA 
sequences were cloned into the pSilencer 4.1 plasmid and stably transfected into 4T1.2 
cells as previously described (17). 
ELISA 
OSM produced by tetracycline (TET)-inducible MDA-MB-231 (MDATO/OSM) 
cells were tested for in vitro activity. MDATO/OSM cells were treated with 0.1 mg/mL 
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tetracycline for 48 hours to generate conditioned media (CM) containing OSM. The CM 
was then applied to parental MDA-MB-231, MDA-MB-231-Luc2, or T47D cells for 30 
minutes. Respective cell lysates were then collected from treated cells using the 
PathScan® Sandwich ELISA Lysis Buffer (Cell Signaling, Cat# 7018). The lysates were 
then run on a PathScan® Phospho-Stat3 (Tyr705) Sandwich ELISA in accordance with 
the manufacturer’s instructions (Cell Signaling, Cat# 7146). 
To assess OSM concentration in animal serum, whole blood was collected from 
(MDATO/OSM) tumor xenograft animals at the experimental endpoint and allowed to 
coagulate for 30 minutes. The coagulated blood was centrifuged at 2,500 RPM for 10 
minutes and the upper layer collected as serum. The serum was then diluted 1:3 in PBS 
and used in the hOSM ELISA (R&D systems, DY295), which was performed in 
accordance with manufacturer’s instructions. 
Western blot analysis 
OSM was induced in MDATO/OSM cells for 48 hours with 0.1 mg/mLtetracycline 
in 10% FBS RPMI 1640 media. The CM was collected, run on a gel, and blotted onto 
0.22 µM PVDF membranes (Millipore). Membranes were blocked using 5% nonfat dry 
milk (NFDM) diluted in PBS at pH 7.4 with 0.05% Tween-20. Anti-human OSM 
antibody (Santa Cruz Biotechnology, Cat# sc-129) was used at 1:1000 dilution in 5% 
NFDM-PBS-T, and a secondary anti-rabbit-HRP (Jackson Immunologicals, Cat# 711-
035-152) was used at 1:5000 dilution in 5% NFDM- PBS-T. 
Animals and tumor cell injections 
Six-week-old female athymic nude mice were used for the xenograft experiments, 
and six-week-old female Balb/c mice were used for the syngeneic studies. All mice were 
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obtained from the National Cancer Institute’s Animal Production Facility (Frederick, 
MD). OSM knockout Balb/c mice were backcrossed from OSM knockout C57BL/6 mice 
that were a kind gift from Dr. Peter Donovan, indirectly, through Dr. James Ihle (St. 
Jude’s Children’s Hospital, Memphis, TN). Animals were backcrossed for at least 10 
generations and genotyping was done at each generation to ensure the presence of the 
knockout allele. Non-surgical orthotopic injections were performed as described 
previously with 2.0 x 106 cells diluted in 50 µL of PBS containing 10% medium for the 
xenograft model, and 1 x 105 cells for the syngeneic models. (17). For all animals, 
starting at 2 weeks post-injection, tumor length and width were measured by mechanical 
calipers 3 times a week and tumor volume was extrapolated using the following equation 
(tumor volume = (length x width^2) /2). “Survival endpoint” was defined by the IACUC 
as tumor size greater than 20 mm in diameter, 10% or more weight loss, and/or 
appearance of cachexia. At the experimental endpoint animals were sacrificed, their 
organs harvested and examined for any abnormalities. Further analysis specific to each 
model is described below. 
For peri-tumoral OSM injections, either 50 µL PBS or 1 µg recombinant full-
length human OSM (Peprotech) diluted in 50 µL PBS was injected into the area 
surrounding the tumor three times per week until the end point of the experiment. When 
the tumors became palpable, mice were randomized into groups and began receiving per-
tumoral injections. 
For the TET-OSM-inducible MDA-MB-231 (MDATO/OSM) experiments, the 
OSM-induced group was given 2% sucrose water containing 0.1 mg/mL tetracycline, 
while the control mice were given just 2% sucrose water until the endpoint of the 
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experiment. To assess blood platelet numbers, blood was collected at endpoint into 
EDTA-coated blood sample tubes (Cat# BD Biosciences, Franklin Lakes, NJ) and 
complete blood count (CBC) analysis was performed by WestVet Veterinary Clinic 
(5024 W Chinden Blvd, Garden City, ID). 
In vivo bioluminescence imaging and tumor progression 
Bioluminescence imaging (BLI) of live animals was initiated at 13 days after cell 
injection and performed weekly. Three to five mice were imaged at one time. Ex vivo 
organs were also imaged using BLI. Both procedures follow our previously described 
protocols (39). 
Detection of circulating tumor cells (Alu qPCR) 
The detection of human circulating tumor cells in mouse blood was performed as 
described previously (40). A human DNA standard curve was prepared by adding a 
specified number of human MDA-MB-231 cells into mouse blood, and then the DNA 
was isolated for use in the qPCR reactions. Genomic DNA was isolated from 100 uL of 
whole blood collected from mice at the end of the experiment. DNA was isolated using 
the DNeasy Blood & Tissue kit (Qiagen Cat# 69581) using the manufacturer’s standard 
instructions. DNA concentrations were normalized between each sample and 4.5 ng of 
DNA was added to each 25 µL qPCR reaction. The qPCR reaction mixture was obtained 
from the SYBR GoTaq qPCR Master Mix (Promega, Cat# TM318, Madison WI), and 
reaction mixtures were prepared in accordance with manufacturer recommendations. To 
each reaction, 0.125 µL of 100 µM human Alu and GAPDH primers were added. The 
primer sequences used for Alu were (s:CACCTGTAATCCCAGCACTTT  
a:CCCAGGCTRGGAGTCGCAGT), and for GAPDH the sequence used was (s: 
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ATGACATCAAGAAGGTGGTG; a: CATACCAGGAAATGAGCTTG). Reaction 
conditions were: 50 oC for 2 minutes, 95 oC for 3 minutes and 40 cycles of: (95 oC 00:15, 
60 oC 00:30, 72 oC 00:30) and fluorescence measurements were taken during the 
annealing temperature stage (60 oC). Ct values were determined and the final results were 
normalized to GAPDH signal levels. 
Quantitative PCR (qPCR) 
For quantitative analysis of lung metastases, lungs dissected from mice bearing 
mammary tumors were snap-frozen in liquid nitrogen and pulverized into a fine powder. 
DNA was extracted using an STE buffer (100 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM 
EDTA) containing 20 μg/mL of proteinase K and purified by two phenol/chloroform (1:1 
v/v) extractions followed by ethanol precipitation. The ratio of cancer cells to normal 
cells was quantified by measuring the neomycin resistance gene (neor) DNA levels versus 
the vimentin DNA loading control, as described previously (41). Taqman PCR was 
performed on an Applied Biosystems 7500 real-time thermocycler. Probe and primer 
sequences are listed in Supplemental Table 1. The cycling conditions were run as 
follows: 50 oC for 5 minutes, 95 oC for 2 minutes, then 40 cycles of 95 oC for 1 minutes 
and 60 oC for 45 seconds. Fluorescence was measured every cycle after the annealing step 
and threshold cycle number (Ct) values were calculated. The data was analyzed using the 
comparative DCt method (42). 
In-vivo magnetic resonance imaging 
Respiratory-gated, spin-echo magnetic resonance (MR) images of mice were 
collected in an Oxford Instruments (Oxford, UK) 4.7 tesla, 40-cm bore magnet. The 
magnet was equipped with Agilent/Magnex (Yarnton, UK) actively shielded, (21-cm 
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inner diameter, ~30 G/cm, ~200 ms rise time) gradient coils and International Electric 
Company (Helsinki, Finland) gradient power amplifiers and interfaced with an Agilent/ 
Varian NMR Systems (Santa Clara, CA) DirectDriveTM console. Data was collected 
using a Stark Contrast (Erlangen, Germany) 2.5 cm birdcage RF coil. Prior to the 
imaging experiments, mice were anesthetized with isoflurane and were maintained on 
isoflurane/O2 (1-1.5% v/v) throughout data collection. Animal core body temperature was 
maintained at 37 ±1 oC by circulation of warm air through the bore of the magnet. During 
the imaging experiments, the respiration rates for all mice were regular and ~2 sec-1. 
Synchronization of MR data collection with animal respiration was achieved with a 
home-built respiratory-gating unit (43) and all images were collected during post-
expiratory periods. Imaging parameters are TR=3 s, TE=20 ms, FOV=2.5 cm2, Data 
matrix = 128 x 128; slice thickness = 0.5 mm; number of averages (NEX) = 4. Lung 
tumors were manually segmented with ImageJ (rsbweb.nih.gov/ij), and the number and 
volume of all metastatic tumors were measured and recorded, on an animal-by-animal 
basis, as described previously (43). 
Detection of circulating tumor cells (clonogenic assay) 
 Colony forming assays were performed to detect circulating tumor cells in mouse 
blood. At the end point of the animal experiment, whole blood was collected via 
intracardiac puncture into EDTA-coated tubes. Red blood cells (RBCs) were lysed with 
RBC lysis solution (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA diluted in ddH2O) 
for 4 minutes. The remaining cell mixture, containing white blood cells and circulating 
tumor cells, was spun down and washed 2X with PBS. The cell pellet was then 
resuspended in MEM-alpha with 10% FBS, and plated and incubated at 37 oC for 7-10 
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days until colonies formed. The colonies were then fixed with 10% formalin in PBS for 
15 minutes, stained with coomassie blue and counted. 
Epithelial-mesenchymal transition assay 
4T1.2 mouse mammary cancer cells were plated on a 6-well plate to a confluence 
of 30% in alpha-MEM with 10% FBS and 1% penicillin - streptomycin. Following a 
period of 24 hours to allow for cells to adhere, 25 ng/mL recombinant mouse OSM 
(rmOSM) was added to appropriate wells. Photomicrographs were taken at a power of 
100x at times of 24 hours and 48 hours to observe phenotypic EMT changes over the 2-
day period. 
Cell migration assay 
4T1.2 cells were plated on 6-well plates to a confluency of 80% in alpha-MEM 
with 10% FBS. After the cells attached overnight, a straight scratch on the cell monolayer 
was made with a sterile 1000 L polypropylene pipette tip, and loose cells and debris 
were washed away with three sterile PBS washes. The cells were then treated with or 
without 25 ng/mL rmOSM, and imaged every day for 3 days on the same part of the 
scratch using negative phase contrast microscopy. The images were then imported into 
ImageJ (NIH), and raw unmigrated area was measured by calculating the number of 
pixels in the area with no migration. Relative migration intensity was calculated using 
this formula: Migration intensity = (Day 0 unmigrated area / Day n unmigrated area) -1 
Cell detachment assay 
4T1.2 mouse mammary cancer cells were plated on 24-well tissue culture dishes 
to a confluency of 80% in alpha-MEM with 10% FBS. The cells were allowed to attach 
overnight, and rmOSM (25 ng/mL, R&D systems) suspended in alpha-MEM, 10% FBS 
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media was added to the cells. For up to 8 days, cells that were detached were collected 
and counted by hemocytometer and viable cells were detected by lack of trypan blue 
(CAT# SV30084.01, Hyclone) staining. 
Statistical analysis 
Statistical comparisons between multiple groups were assessed by one or two-way 
ANOVA using Tukey’s post-test analysis. Comparisons between two groups were 
analyzed by student’s t-test (two-tailed, unpaired). The statistical analyses were 
performed by using Prism GraphPad 5.0b software (GraphPad Software Inc., San Diego, 
CA). Survival data was analyzed using the Log-rank (Mantel-Cox) test. Asterisks denote 
*p<0.05, **p<0.01, or ***p<0.001. 
Results 
High OSM expression in breast ductal carcinoma in situ (DCIS) and IDC suggests 
autocrine signaling 
To assess breast epithelial cell expression and location of OSM in human breast 
tumors, tissue microarrays (TMAs) containing samples from 72 patients were analyzed 
by immunohistochemistry. Interestingly, staining intensity was highest in the DCIS group 
compared to normal tissue, while 2o antibody alone showed little staining (Fig 1A). The 
mean staining intensity for normal adjacent tissue (1.33) was significantly lower than that 
of DCIS (2.00) and IDC (1.66) tissues, while metastatic tissue (1.24) was statistically 
similar to normal tissue (Fig. 1B and Table 1). These results suggest that OSM protein 
levels are higher in the earlier stages of breast cancer and that tumor cell-produced OSM 
may be important in autocrine signaling for the promotion of tumor progression.  
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OSM generated from TET-inducible MDA-MB-231 (MDATO/OSM) cells increases 
metastases to the lung and decreases survival  
In order assess the effect of cancer cell-produced OSM in a tumor 
microenvironment, we developed a stably-transduced triple negative breast cancer 
(TNBC) MDA-MB-231-Luc2 D3H2LN cell line that secretes OSM in response to 
tetracycline treatment (+TET; MDATO/OSM). To compare the OSM produced by the 
MDATO/OSM cells to recombinant human OSM (hOSM), conditioned media (CM) from 
MDATO/OSM cells treated with TET (0.1 µg/mL) was collected. MDA-MB-231, MDA-
MB-231-Luc, and T47D breast cancer cells were treated with either CM from 
MDATO/OSM cells or with rhOSM (25 ng/mL) for 30 minutes. OSM signaling was 
assessed by measuring STAT3 activation using a pSTAT3 ELISA. For each cell line 
investigated, there were no significant difference in the level of pSTAT3 induced by 
OSM produced from TET-induced MDATO/OSM cells compared to rhOSM (Fig 2A). 
Furthermore, the CM from MDATO/OSM cells treated with TET was assessed on a hOSM 
immunoblot and an expected size band (26 kDa) was detected (Fig, 2A, inset). 
To assess the activity of MDATO/OSM cells in vivo, 1 x 106 cells were injected into 
the 4th mammary fat pad of female athymic nude mice. The mice were given drinking 
water with tetracycline (+TET) or without tetracycline (–TET) (0.1 mg/mL in 2% sucrose 
water) to induce OSM expression in the cancer cells. At the experimental endpoint, their 
serum was then separated from whole blood, and serum OSM levels were assessed by 
ELISA. Tumor bearing mice +TET had a 67-fold higher level of OSM levels present in 
their serum than –TET mice (Fig 2B, left). Each animal’s physical condition was 
assessed, and animals with MDATO/OSM tumors +TET had significantly increased blood 
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platelet counts (Fig. 2B, center). TET-treated mice also experienced a significant 
decrease in body weight compared –TET mice (Fig. 2B, right; sFig. 1A), displaying a 
prominent spinal column and reduced apparent body fat indicative of cachexia (sFig. 1B). 
In the literature, it has been reported that cachexia, elevated inflammatory factors, and 
kidney disease may be correlated with each other (44, 45), and in this study, the cachexic 
animals had kidney abnormalities with hypoperfusion and damage to the gross 
morphological kidney structures (sFig. 1C). This correlated with +TET treatment and 
high levels of serum OSM in the animals (sFig.1D and E), which suggest that high OSM 
levels may contribute to the development of cachexia and kidney organ dysfunction.  
Additionally, in a separate experiment, animals were given TET drinking water 
for only 1 week to assess early effects of OSM on metastasis. Animals on 1 week of 
+TET had higher levels of metastases to the lung as assessed by ex vivo imaging 
compared to –TET mice (Fig. 2C). This result suggests that even short-term elevation in 
the level of OSM can promote the development of metastases. To measure animal 
survival, mice with MDATO/OSM tumors were treated with or without TET and allowed to 
progress to end point. +TET mice had a mean decreased survival of 11 days compared to 
–TET mice (Fig. 2D). Collectively, these results demonstrated that elevated levels of 
tumor cell-produced OSM lead to increased lung metastases, decreased survival, and 
deterioration in body condition indicative of cachexia. 
OSM increases metastasis to lung and circulating tumor cell numbers in an orthotopic 
MDA-MB-231 model of breast cancer 
To assess the paracrine effects of OSM, exogenous OSM was injected peri-
tumorally in an orthotopic MDA-MB-231 xenograft model. In this model, 2 x 106 MDA-
110 
 
 
MB-231-Luc2 D3H2LN cells were injected into the fourth mammary fat pads of female 
nude mice. After the tumors were palpable (~3 mm), OSM (1 µg in 50 L PBS) or PBS 
alone was injected peri-tumorally 3 times per week, and mice were monitored until the 
end-point criteria was met. Unexpectedly, tumor volume did not differ between the 
groups (Fig. 3A), even though OSM has been shown to reduce MDA-MB-231 cell 
proliferation in vitro (46). The BLI intensities of the tumors from both groups were 
similar (Fig. 3B), although a few mice in each group had lower BLI intensities due to 
tumor necrosis. 
Mice receiving peri-tumoral OSM showed larger metastatic volumes in both lung 
and spine compared to mice receiving PBS, as assessed by ex vivo imaging (Fig. 3C, 
left). Additionally, lungs extracted from the OSM-injected group had luminescence 
signals that were two orders of magnitude (102) higher than the PBS-injected group (Fig. 
3C, right). Similarly, spine BLI intensity from OSM-treated mice averaged 2 x 107 
photons/s, while control mice had a mean signal of 3 x 105 photons/s. 
In patients with advanced and/or inflammatory breast cancer, high numbers of 
circulating tumor cells (CTCs) have been detected, suggesting a correlation between 
inflammatory factors and the number of CTCs (47). In our xenograft model, both human 
MDA-MB-231-Luc2 tumor cells as well as potential CTCs contain multiple copies of 
human Alu DNA repeat sequences. To assess CTC numbers, DNA was isolated from 
mouse blood, and the levels of human Alu DNA repeat sequences were determined in the 
blood by qPCR. In animals that received rhOSM injections, there was a 4-fold increase in 
the number of CTCs per 100 µL of mouse blood compared to animals that did not receive 
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OSM (Fig. 3D). Collectively, this suggests that increased paracrine OSM in the tumor 
microenvironment, increases metastasis to lung and spine while also increasing CTCs. 
Suppression of OSM in syngeneic mouse model reduced lung metastases 
To utilize an immunocompetent mouse model, we utilized two highly metastatic 
4T1.2 mouse mammary tumor cell lines exhibiting knockdown expression of OSM in a 
syngeneic, orthotopic model of breast cancer (17). These two independent cell lines 
(4T1.2-shOSM1 and 4T1.2-shOSM2) were shown by ELISA to secrete a 3- to 12-fold 
reduction in OSM, respectively, as compared to control 4T1.2-LacZ cells (17). To test the 
effects of OSM on mammary tumor metastasis in vivo, 1 x 105 control 4T1.2-LacZ, 
4T1.2-shOSM1, and 4T1.2-shOSM2 cells were injected orthotopically into the mammary 
fat pads of female Balb/c mice. 
The mean number of relative lung metastases was shown to be 10-fold lower in 
mice that received 4T1.2-shOSM1 cells and 5-fold lower in mice injected with 4T1.2-
shOSM2 cells, compared to 4T1.2-LacZ control cells (Fig. 4DA). Histology performed 
on tissues from mice injected with parental 4T1.2 cells using an anti-mouse OSM 
antibody showed strong OSM expression in the primary mammary tumor as well as some 
background expression in the normal breast connective tissue (sFig. 2). Specifically, very 
high OSM expression is shown at the leading edge of the primary tumor metastasis, in 
closest proximity to the breast stroma. 
Magnetic resonance imaging (MRI) was used to track lung metastases progression 
in vivo after injection of parental 4T1.2, control 4T1.2-shLacZ, and 4T1.2-shOSM2 cells. 
Mice were imaged post-injection at days 20-21, days 25-26, and just before sacrifice of 
animals at days 29-30 (Fig. 4B). For all three cell lines, MRI images showed essentially 
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no detectable metastasis at days 20-21. At 25-26 days and 29-30 days; however, readily 
identifiable metastases were observed in lung images. The number of metastases was 
reduced by more than 50% in mice injected with 4T1.2-shOSM2 cells compared to 
control 4T1.2-shLacZ control cells at 25-26 days and 29-30 days (Fig. 4B and C). The 
average metastasis volume was also significantly decreased by 50 to 80% in 4T1.2-
shOSM2 cells compared to 4T1.2-shLacZ control or parental 4T1.2 cells, respectively 
(Fig. 4D). Thus, the in vivo MRI imaging confirmed that OSM is a potent inducer of the 
metastatic cascade that ultimately results in lung metastases originating from a primary 
mammary tumor. In total, these results suggest that OSM is necessary for spontaneous 
mammary tumor metastasis to lung in a syngeneic mouse model. 
Suppression of OSM by shRNA increases survival from spontaneous metastasis via 
orthotopic injection but not via intracardiac injection in vivo 
We utilized a tumor-resection survival model to mimic surgical removal of the 
primary tumor in patients and to determine if suppression of tumor-produced OSM limits 
early metastases. Orthotopic mammary fat pad injections were performed using control 
4T1.2-shLacZ cells, 4T1.2-shOSM1, and 4T1.2-shOSM2 cells. Primary tumors were 
resected when they became palpable at day 14 (Fig. 5A), and mice were monitored until 
endpoint criteria were met (see Materials and Methods). The mean survival time of the 
mice that received 4T1.2-shOSM1 and 4T1.2-shOSM2 cell injections significantly 
increased by 5 and 10 days compared to animals with 4T1.2-shLacZ tumors (Fig. 5A). 
These results suggest that following primary mammary tumor resection, decreased OSM 
expression in primary tumor cells leads to increased survival. 
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In order to determine if OSM affects post-intravasation aspects of metastasis, we 
injected the mammary tumor cells directly into the circulatory system via the left 
ventricle of the heart. There was no statistical difference in the survival time between 
mice injected intracardially with 4T1.2-shLacZ versus 4T1.2-shOSM2 cells (Fig. 5B). 
Similarly, there was no statistical difference in lung metastatic burden in the two different 
tumor types as assessed by qPCR (sFig 3). These results suggest that tumor cell OSM 
expression has little effect on post-intravasation aspects of metastasis to lung, such as 
extravasation and metastatic site implantation. 
CTC number and metastatic burden is reduced in OSM knockout mice compared to wild 
type mice 
To determine if knocking out OSM in the whole organism affects CTC numbers 
in the 4T1.2 mouse model, wild type and OSM knockout (KO) Balb/c mice were 
orthotopically injected with either 4T1.2-shLacZ or 4T1.2-shOSM2 cells. Whole blood 
was collected at endpoint, red blood cells were lysed, and the remaining white blood cells 
containing the epithelial CTCs were examined using a Clonogenic assay (Fig. 5C). Blood 
from OSM KO mice injected with 4T1.2-shOSM2 cells had 15-fold less CTCs and 2.5-
fold less lung metastases compared to wild type mice injected with control 4T1.2-shLacZ 
cells (Fig. 5D, left). Additionally, OSM KO mice bearing 4T1.2-shLacZ tumors had 10-
fold less CTCs and 2.5-fold less lung metastases compared to wild type mice with the 
same tumor type (Fig 5D, right). These results suggest that microenvironment OSM, 
independent from the tumor cell secreted OSM, has a large effect on tumor cell 
dissemination into circulation. Furthermore, this highlights the importance of paracrine 
OSM in breast cancer progression and metastasis. 
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OSM increases pre-intravasation metrics of metastatic capacity in 4T1.2 cells 
In order for tumor cells to enter the blood stream as CTCs and subsequently 
metastasize, it is thought that they must first undergo an EMT, followed by detachment, 
migration, and intravasation into the circulatory system (48, 49). To assess OSM’s effect 
on EMT, detachment, and migration, mesenchymal-like triple negative (ER-, PR-, HER2-
) 4T1.2 mouse mammary cancer cells were treated with OSM (25 ng/mL) for 24 to 48 
hours. As 4T1.2 cells are an aggressive mesenchymal mammary cancer cell type, OSM 
did not affect their cell morphology nor produce an EMT, (Fig. 6A). On the other hand, 
OSM significantly increased 4T1.2 mammary tumor cell migration 7-fold by day 3 in a 
cell migration assay (Fig. 6B) and tumor cell detachment 100-fold by day 8 (Fig. 6C). 
Our previous studies also demonstrated that OSM increases overall invasive potential in 
4T1.2 cells (17). Together, these results suggest that OSM may promote tumor cell 
dissemination into circulation by increasing cell migration and detachment, which may 
subsequently increase the number of CTCs. 
Discussion 
In this study, we show that OSM, whether acting in a paracrine fashion or 
produced by breast tumor cells and acting in an autocrine manner, can potentiate pre-
intravasation metastatic events such as migration, detachment, and increased CTCs (Fig. 
7). Recent studies suggest that cells from breast ductal carcinoma in situ (DCIS) can 
actually metastasize prior to their development into malignant invasive ductal carcinoma 
(IDC), though what triggers this early event has not been well characterized (50, 51). Our 
breast cancer immunohistochemistry studies using tissue microarrays resulted in an 
intriguing finding; OSM expression is highest in the epithelium of DCIS, as compared to 
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IDC, metastatic, or adjacent normal tissue. However, García-Tuñón saw higher levels of 
breast tissue OSM and OSMR in IDC than in DCIS or normal tissue (13). While there is 
disagreement in the literature compared to our study in relation to the stage in which the 
highest level of OSM was seen, there is agreement in so far as higher OSM levels were 
detected in cancerous tissue versus normal tissue. 
In this study, three different TNBC mouse models were utilized, one 
immunocompetent Balb/c model using syngeneic 4T1.2 cells, and two 
immunosuppressed athymic xenograft mouse models using either MDA-MB-231-Luc2 or 
MDATO/OSM cells. Despite the differences between the systems used in our study, our 
results were consistent in that suppression of OSM reduced metastasis in Balb/c mice and 
injection of recombinant hOSM or TET-induced hOSM expression in MDATO/OSM cells 
increased human breast tumor metastasis in athymic mice. Although, adaptive immunity 
is stunted in athymic mice due to nonfunctional T-cells, innate immune function is still 
intact (52). Recent studies indicate that innate immunity plays a primary role in 
controlling progression of tumor growth and metastatic disease (53, 54), and innate 
immune cells such as macrophages home to hypoxic tumors and promote angiogenesis 
(19). OSM has recently been shown to increase lung metastatic burden in melanoma by 
increasing M2 macrophage infiltration (55). Thus, OSM may be promoting inflammatory 
responses mediated by innate immunity in the tumor microenvironment of both athymic 
and Balb/c mouse models to promote metastases. 
While the traditional cause of mortality in advanced cancer patients is metastasis 
to vital organs, cachexia has been shown to contribute in up to 50% of cancer patient 
deaths (56, 57). Significant weight loss as a consequence of fat loss and muscle wasting, 
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indicative of cachexia, was seen in our TET-induced OSM in MDATO/OSM xenograft 
mouse model. Other studies have shown that high levels of various inflammatory 
cytokines such as IL-6, and tumor necrosis factor alpha (TNFα) potentiate loss of adipose 
tissue and muscle wasting (58, 59). This suggests that OSM may be yet another cytokine 
that could exacerbate cachexia in breast cancer patients. Furthermore, since cytokines 
modulate the immune system, it’s very probable that cancer cachexia could be related to 
maladaptive immune responses (60). 
Platelets, as an adjunct to their classical role in thrombosis, are also operant in 
mediating inflammation and immune response (61, 62). Interestingly, we found in the 
MDATO/OSM mouse model that higher OSM levels were correlated with increased platelet 
counts and reduced animal survival. Previous studies in breast cancer patients have 
shown that elevated platelet counts were associated with poor prognosis and reduced 
disease-free survival (63). Platelets have also been implicated in the promotion of 
metastasis by acting as a reservoir for factors that induce invasion and function to protect 
CTCs from the immune system (64, 65). In our study, increased viable CTCs were 
detected in our mouse models when higher levels of OSM were present, which may have 
been due, in part, to the elevated levels of platelets in circulation. 
The ability of tumor cells to intravasate into the circulation directly correlates 
with CTC numbers from the corresponding tumor (66). Increased CTC numbers have 
been linked clinically to enhanced metastatic burden in patients and a reduced 5-year 
survival rate (67). As tumors may shed early during cancer development (50), the 
detection of CTCs would be an important tool in the clinic to assess the metastatic 
capacity of a tumor, even as early as in precancerous DCIS. Typically, CTCs are detected 
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using cancer epithelial markers such as cytokeratin (CK) 18/19 (68). However, highly 
aggressive tumor cells that have already undergone an EMT, and thus lost their epithelial 
markers, may evade detection (69, 70). Other possibly viable markers for CTC detection 
include, epithelial cell adhesion molecule (EpCAM) or human mammoglobin A (hMAM) 
(68). For our studies, the highly aggressive mesenchymal-like MDA-MB-231 cells show 
negative or low expression for each of these markers, making conventional CTC 
detection unfeasible (69, 71). Thus, we employed multiple techniques that are marker-
independent, such as the Colony forming assay or a PCR assay targeting human Alu 
sequences in human breast tumor cells growing in a mouse. In our studies, suppression of 
tumor-produced OSM or the absence of OSM in OSM KO mice resulted in reduced 
numbers of CTCs, while injection of recombinant OSM increased CTCs. Interestingly, 
there was no significant difference in the number of CTCs +/-TET in the MDATO/OSM 
mouse metastasis model (data not shown). This suggests that paracrine OSM may be 
more important than autocrine-produced OSM for CTC development. Indeed, in our 
OSM KO mouse model, where there is less paracrine OSM, total CTC numbers and lung 
metastatic burden were significantly reduced compared to WT mice. 
To assess some of the early aspects of metastases that could lead to generation of 
CTCs in vitro, tumor cell EMT, migration, and detachment were studied in the highly 
aggressive 4T1.2 tumor model. The 4T1.2 mammary tumor cells, which are considered 
analogues of high-grade human TNBC, have already undergone EMT and OSM did not 
cause additional EMT-like effects (72). However, our results show that OSM does 
increase cell migration, detachment, and invasion in the 4T1.2 cells (17), supporting the 
idea that OSM operates in the pre-intravasation steps of metastasis. Other OSM-related 
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factors such as transforming growth factor beta (TGF), IL-6, and interleukin-8 (IL-8) 
may promote CTCs by increasing tumor cell invasion, detachment, and epithelial to 
mesenchymal transition (EMT) (73, 74). Furthermore, these effects may be amplified in 
vivo, as OSM possesses a proclivity to accumulate in the acidic ECM of the tumor 
microenvironment (21). 
Based on our findings, OSM may potentiate the pre-intravasation aspects of the 
metastatic cascade to increase metastasis to the lung, and bone (17). This is evidenced by 
the fact that intracardiac injection of 4T1.2 cells with reduced OSM (4T1.2-shOSM2) 
into mice, which bypasses intravasation step of the metastatic cascade, did not result in 
increased survival compared to control cells (4T1.2-shLacZ). Therefore, it is highly 
probable that OSM functions before intravasation during cancer progression, but does not 
appear to affect CTC survival, tumor cell extravasation, and secondary tumor growth.  
Conclusions 
The results from this study suggest that OSM increases lung metastases and CTC 
numbers by acting on the early stages of metastasis. This provides a rationale for the 
administration of anti-OSM therapeutics before tumor resection at the earlier steps of the 
disease with the potential to improve overall breast cancer patient survival. 
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Chapter Three: Figures 
 
Figure 3.1. OSM is highly expressed in DCIS and IDC 
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Figure 3.1. OSM is highly expressed in DCIS and IDC.  
A, To detect the presence of OSM in breast cancer tissue, histological microarrays 
from 72 breast cancer patients were stained with human OSM antibody by 
immunohistochemistry. Twelve patients had ductal carcinoma in situ (DCIS), 54 patients 
had non-metastatic invasive ductal carcinoma (IDC), and 16 patients had IDC with 
metastasis to lymph nodes (Table 1). Results show that normal adjacent tissue does not 
express much OSM, but OSM is highly expressed in DCIS and IDC. Secondary antibody 
alone does not produce any background signals. B, Intensity quantification of OSM 
stained tissues. Mean staining intensity for DCIS (2.00) and IDC (1.66) tissues are 
significantly higher than normal adjacent tissue (1.33) and metastatic tissue (1.24). There 
is no statistical difference between normal and metastatic tissue. Data expressed as mean 
+/- SEM *p<0.05, two-tailed t-test. 
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Figure 3.2. MDATO/OSM tumors increase metastasis and decrease survival 
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Figure 3.2: MDATO/OSM tumors increase metastasis and decrease survival.  
A, MDATO/OSM human breast cancer cells were treated with or without TET and 
the resultant CM from the treated cells were applied to parental MDA-MB-231, MDA-
MB-231-LUC, and T47D cells. The activity of OSM accumulated in the CM was 
compared to commercially obtained rhOSM (25 ng/mL). There is no significant 
difference between OSM produced by MDATO/OSM versus rhOSM in relation to its ability 
to induce pSTAT3. Inset, Western blot analysis depicting that CM produced by 
MDATO/OSM cells stimulated with TET contains OSM. B, Left, Animals with MDATO/OSM 
tumors were given drinking water with or without TET and the whole blood was 
collected at experimental endpoint. After allowing the blood to clot and serum separated 
by centrifugation, the resultant serum OSM levels were measured by ELISA, and animals 
with MDATO/OSM tumors with drinking water containing TET have 67-fold higher OSM 
levels. B Center, Platelet counts are higher in MDATO/OSM tumor bearing mice +TET 
compared to –TET mice. B Right, MDATO/OSM tumor bearing mice +TET have lower 
bodyweight compared to mice –TET. C, Animals with MDATO/OSM tumors were given 
drinking water containing TET for 1 week and their lung metastatic levels were assessed 
by ex vivo bioluminescent imaging. C Left, Representative image of ex vivo 
bioluminescent image. C Right, Average radiance analysis of the ex vivo bioluminescent 
imaging in photons per second per cm2 per square radian (p/s/cm2/sr). Animals with 
MDATO/OSM tumor +TET have a 5-fold higher bioluminescent radiance compared to –
TET mice. (–TET n=3, +TET n=6) Data expressed as mean ± SEM. D, Kaplan-Meier 
survival curve for mice with MDATO/OSM tumors +/- TET. Mice that did not receive TET 
have on average, 11 days longer survival (-TET n=9, +TET n=10) *** p<0.001 log-rank 
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test. Data expressed as mean +/- SEM *p<0.05, **p<0.01, ***p<0.001, two-tailed t-test 
or one-way ANOVA with Tukey’s post-test where appropriate.  
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Figure 3.3. Peri-tumoral OSM injections into mice with MDA-MB-231-D3H2LN 
tumors promotes the development of metastases and CTCs 
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Figure 3.3. Peri-tumoral OSM injections into mice with MDA-MB-231 D3H2LN tumors 
promote the development of metastases and CTCs. A, The timeline shows orthotopic 
MDA-MB-231 D3H2LN human breast tumor cell injection at day 0, peri-tumoral OSM 
or PBS injections beginning 3X per week at day 13, and final day of sacrifice of both 
groups at day 61. Average tumor volume (mm3) does not differ between the peri-
tumorally injected OSM and PBS control groups. B, Representative images of PBS and 
OSM injected tumor-bearing mice imaged ventrally by BLI. There is no statistical 
difference between the groups and recapitulates results seen in A. C left, Representative 
ex vivo BLI of lungs and spine from mice bearing MDA-MB-231 D3H2LN luc2 tumors, 
which were treated with peri-tumoral injections of PBS or OSM. C right, Ex vivo BLI 
intensities were quantified in the lung and spine. Lungs from mice receiving peri-tumoral 
OSM injections show a 37.9-fold higher BLI intensity as compared to PBS injections, 
and spines from mice injected with OSM also show an approximately 25.9-fold increase 
over mice with PBS injections. Data expressed as photon/s (mean ± SEM; n=5-6). D, 
Human CTCs containing human Alu DNA were detected from mouse blood by qPCR. In 
animals that received OSM injections, there is a 4-fold increase in the number of CTCs 
compared to controls. Data expressed as mean +/- SEM *p<0.05, two-tailed t-test. 
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Figure 3.4. Reduced OSM expression results in fewer spontaneous lung 
metastases and lower total volume of lung metastases by MRI 
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Figure 3.4. Reduced OSM expression results in fewer spontaneous lung metastases and 
lower total volume of lung metastases by MRI. 
A, Lung metastatic burden was quantified by qPCR. Mice bearing mouse 
mammary 4T1.2-shOSM1 or 4T1.2-shOSM2 tumors have less metastasis to lung 
compared to mice with 4T1.2-shLacZ tumors. B, Mice bearing 4T1.2-shOSM2 tumors 
have less metastatic lesions in the lung as detected by MRI at the endpoint of the 
experiment compared to mice bearing parental 4T1.2 or control 4T1.2-shLacZ tumors. C, 
MRI quantification of lung metastatic volume, and D, total number of lung metastases, 
shows significantly higher volume and number of lung metastases in the 4T1.2 or 4T1.2-
shLacZ injected mice as compared to the 4T1.2-shOSM2 injected mice. (4T1.2, n=6; 
4T1.2-shLacZ, n=7; 4T1.2-shOSM2, n=7). Data expressed as mean ± SEM, *p < 0.05, 
**p<0.01, one-way ANOVA with Tukey’s post-test. 
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Figure 3.5. Reduced tumor cell OSM expression increases survival in a 4T1.2-
shOSM mouse model of tumor resection 
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Figure 3.5. Reduced tumor cell OSM expression increases survival in a 4T1.2-shOSM 
mouse model of tumor resection. 
A. The timeline shows orthotopic mouse mammary tumor cell injection at day 0, 
resection at day 14, and final day of sacrifice per group (ranging from 35 to 72 days). 
Kaplan-Meier survival analysis following tumor resection shows that mice bearing 
4T1.2-shOSM1 or 4T1.2-shOSM2 tumors have significantly increased survival compared 
to mice with control 4T1.2-shLacZ tumors. *p<0.05, log-rank test B, Timeline shows 
intracardiac mammary tumor cell injection at day 0 and final day of sacrifice (day 21 to 
22). Kaplan-Meier survival analysis shows no difference in survival between mice 
injected with control 4T1.2-shLacZ versus 4T1.2-shOSM2 cells. C, Blood was collected 
from wild type and OSM KO animals with 4T1.2-shOSM2 or control tumors and CTC 
counts were assessed via a Colony forming assay. Representative image depicts higher 
numbers of colonies that formed from the blood collected from wild type mice with 
control tumors. D Left, Quantification of the colony formation assay show that wild type 
animals bearing 4T1.2-shOSM2 tumors have 15-fold lower number of CTCs compared to 
the animals bearing control 4T1.2-shLacZ tumors. Furthermore, OSM KO mice with 
4T1.2-shLacZ tumors have 10-fold less CTCs compared to wild type mice bearing the 
same cells. D Right, Wild type mice bearing 4T1.2-shOSM2 tumors have 2.5-fold lower 
number of lung metastases compared to mice with control 4T1.2-shLacZ tumors. OSM 
KO mice bearing 4T1.2-shLacZ or 4T1.2-shOSM2 tumors have 2- to 2.5-fold less lung 
metastases compared to wild type mice. (4T1.2-shLacZ, n=8-9; 4T1.2-shOSM1, n=7; 
4T1.2-shOSM2, n=9-12) Data expressed as mean ± SEM. *P<0.05, ***P<0.001, one-
way ANOVA with Tukey’s post-test. 
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Figure 3.6. OSM promotes 4T1.2 cell detachment and migration 
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Figure 3.6. OSM promotes 4T1.2 cell detachment and migration.  
A, 4T1.2 mouse mammary cancer cells were plated and treated with rmOSM (25 
ng/mL) for 24 and 48 hours, and no morphological changes indicative of EMT are 
detected. B, 4T1.2 cells were grown to 80% confluency and a scratch was made. Cells 
treated with OSM have higher levels of migration compared to untreated controls (7-fold 
by day 3). C, A detachment assay was performed on 4T1.2 cells, and the number of 
detached cells was quantified. Cells treated with OSM have significantly higher numbers 
of detached cells (100-fold at day 8). Data expressed as mean ± SEM. *p<0.05, 
***p<0.001 two-tailed student’s t-test. 
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Figure 3.7. Model of OSM-mediated metastasis 
Figure 3.7. Model of OSM-mediated metastasis.  
OSM is produced in an autocrine fashion by tumor cells A, and by tumor-
associated macrophages and neutrophils for paracrine signaling B. OSM promotes pre-
intravasation effects such as tumor cell detachment and migration that can drive tumor 
cell intravasation into circulation to develop CTCs and eventual metastasis. C, When 
tumor cells are injected directly into the circulatory system, they bypass the multi-step 
pre-intravasation aspects of metastases, and our data suggest that OSM has little effect on 
their extravasation and colonization at a secondary site.  
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Table 3.1 Comparison of OSM expression in the ductal epithelial cells of 
different stages of ductal carcinoma of the breast (DCIS, IDC, and 
metastatic tissues) and adjacent normal breast tissues. 
 
Mean expression levels are statistically significantly different among the four stages. 
Stage  No. of 
patients 
(Total no. of 
cores)  
Mean 
OSM 
staining  
95% Confidence 
Limits  
Pairwise comparison 
of stage means1 
Adjacent 
Normal DCIS  
IDC  
Metastatic  
50 (83)  
12 (18)  
72 (188)  
16 (29)  
1.33  
2.00  
1.66  
1.24  
(1.15,1.50) 
(1.71,2.30) 
(1.55,1.77) 
(1.02,1.46)  
A 
B 
B 
A 
1Stages with the same letter are not statistically different; those with different letters are 
significantly different at p<0.05. 
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CHAPTER THREE: SUPPLEMENTAL FIGURES 
 
Figure 3.S1. Deterioration of body condition in MDATO/OSM tumor bearing mice 
with TET 
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Figure 3.S1. Deterioration of body condition in MDATO/OSM tumor bearing mice 
treated with TET.  
A, MDATO/OSM tumor bearing mice treated with tetracycline (+TET) lost on 
average 11.4 % of their body weight during TET treatment, compared to –TET mice, 
which gained on average of 5.5% of their body weight over the same time period. B, 
Representative image of mice with MDATO/OSM tumors +TET shows prominent spinal 
column, muscle wasting, and lack of visible adipose tissue. C, Gross morphology of 
normal (left) and abnormal kidneys (right). Normal kidneys have a distinct border 
between the medulla and the cortex, with the cortex shown as a darker pink/red color, and 
the medulla shown as a lighter pink color. This indicates that normal blood perfusion was 
taking place. Abnormal kidneys were both pale and hypoperfused (middle), or damaged 
(right) with no clear distinction between the cortex and the medulla. D, One hundred 
percent of mice in the +TET group have abnormal kidney morphologies, while only 25% 
of the mice in the –TET group have abnormal kidneys. ** p<0.01 fisher’s exact test E, 
Serum from mice with abnormal kidneys have a statistically higher level of OSM 
compared to serum from mice with normal kidneys. Data expressed as mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001 two-tailed student’s t-test.  
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Figure 3.S2. OSM is highly expressed in orthotopic 4T1.2 primary mammary 
tumors in female Balb/c mice 
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Figure 3.S2. OSM is highly expressed in orthotopic 4T1.2 primary mammary tumors in 
female Balb/c mice. 
Histology using H&E confirms the presence of a large, primary mammary tumor 
(T) 32 days after 4T1.2 mouse mammary tumor cell injection into the 4th mammary fat 
pad of female Balb/c mice. High OSM expression is seen in the tumor, as is background 
expression in the normal breast connective tissue (CT). OSM expression is shown to be 
highest in the invasive edge of the tumor (T) closest to the normal breast connective 
tissue (CT). Control slides with no primary OSM antibody show low background 
staining. 
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Figure 3.S3. qPCR analysis of lung metastases after intracardiac injections 
Figure 3.S3. qPCR analysis of lung metastases after intracardiac injections.  
4T1.2-shLacZ cells and 4T1.2-shOSM2 cells were injected through intracardiac 
injection, and qPCR analysis of the lung metastases indicate that the difference between 
the groups was not significant.  
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Supplemental Materials and Methods 
Complete details for tissue microarrays.  
Breast tissue was obtained from paraffin block archives at the Department of 
Pathology, Mercy Medical Center, Nampa, ID and removed of patient identity as per IRB 
guidelines. Three tissue microarrays (TMA) of 1 mm thickness and totaling 72 patients 
were made using a Quick-Ray, an instrument used for boring tissue from a paraffin block 
(Woo-Ri Medic, Kent, WA). The TMAs were built in Dr. William Fyffe’s lab at 
Northwest Nazarene University, Nampa, ID. Two blocks consisted of tissues from 54 
breast cancer patients (32 adjacent normal, 9 DCIS patients, 54 IDC) without metastasis 
and included three primary tumor cores and one adjacent normal core for each case. The 
third block included samples from a total of 18 breast cancer patients (18 adjacent 
normal, 3 DCIS, 18 IDC and 16 metastatic) with lymph node metastasis and contained 
three primary tumor cores, two metastatic cores and one adjacent normal tissue core per 
case. The TMAs included a row of control tissues including spleen, lung, placenta, 
salivary gland, liver and brain. Spleen and salivary gland served as positive controls for 
OSM staining. 
Immunohistochemistry: The TMAs were stained for oncostatin M using the 
Histostain Kit (Cat #95-9843; Invitrogen, Carlsbad, CA) per manufacturer’s instructions. 
The TMAs were deparafinized using Histosol (National Diagnostics, Atlanta, GA) and 
stained overnight with 1:400 dilution of rabbit anti-human OSM primary antibody (Cat 
#sc-129; Santa Cruz Biotechnology, Santa Cruz, CA) and 1 hour with 1:1000 goat-anti 
rabbit IgG-AP secondary antibody. TMAs stained with secondary antibody alone served 
as the negative control, and spleen and salivary gland served as positive controls for 
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OSM staining. The specificity of the ɑ-OSM antibody was tested by treating tissue 
sections with 10 times the amount of OSM blocking peptide (Santa Cruz 
Biotechnologies, Santa Cruz, CA) and incubating overnight at 40C. The mixture was then 
diluted to the required concentration and immunohistochemistry was performed as above. 
The TMAs were analyzed for OSM expression by an experienced pathologist, Dr. 
Joseph Kronz, at Mercy Medical Center, Nampa, ID. The intensity of OSM staining in 
the ductal epithelium was graded as follows:  0=No staining; 1=Light staining; 
2=Medium staining; 3=Dark staining. In order to confirm reproducibility of the results, 
the pathologist, Dr. Joseph Kronz, reread 10 TMA cores that were chosen at random, and 
his observations were consistent with the previous results. In cases where a single core 
had both cancerous and normal tissue, the OSM expression data in the cancerous part was 
combined with other cancerous tissues. Similarly, the expression in the normal part was 
combined with other adjacent normal tissues for statistical analysis. 
Statistical analysis: Assessments from multiple cores for each patient were 
averaged for epithelial cells and stage of malignancy (normal, DCIS, IDC, metastatic) 
that was present in the core. These four stages were statistically compared among ductal 
tissues. The OSM staining intensity was analyzed as a mixed model to accommodate 
repeated observations on each patient. These repeated observations were assumed to have 
non-negligible correlation and were modeled under standard repeated measures variance-
covariance assumptions. Stage was treated as a fixed effect. Additionally, statistical 
models considering patient prognostic markers were evaluated. These models included 
the stage and the prognostic marker, with or without an interaction; the model with the 
lowest AICc was selected to determine whether the prognostic factor was associated with 
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OSM staining. These prognostic factors considered were age, tumor size, lymph node 
status, angiolymphatic invasion, tumor grade, tumor type, histologic grade, nuclear 
atypia, margin status, mitotic rate, Her2/neu expression, progesterone, and estrogen 
receptor. Initial assessments indicated that OSM staining intensity did not differ 
significantly between the two groups of patients (patients with and without lymph node 
metastasis) so patient group was not included as an analysis factor in the study. All 
models were assessed for adequacy by residual analysis, a concern here because of the 
bounds on OSM staining intensity (0-3) and our specific interest in changes in mean 
staining intensities. No predicted values exceeded the possible observational boundaries 
and residual patterns were acceptable despite the categorical nature of the data collection. 
All analyses were conducted using SAS version 9.1.3 (SAS 2004). 
Animal Histology 
To verify lung metastasis, lungs from each experimental group (4T1.2-LacZ, n=2; 
4T1.2-shOSM2, n=2; and 4T1.2-shOSM1, n=1) were placed in ultralight fixative 
(Ultralight Histology, Nampa, ID) paraffin embedded, and sectioned (Bi-Biomics, 
Nampa, ID). For each spine, four 1 m sections were collected 10 m apart in the lumbar 
region and H&E stained. The sections were then stained overnight with 1:400 dilution of 
goat anti-mouse OSM primary antibody (Cat # AF-495-NA; R&D systems) and 1 hour 
with 1:1000 donkey-anti goat IgG-AP secondary antibody. The sections were then 
stained and imaged. 
 
 
 
 
 
143 
 
 
References 
1. C. Lange, E. Storkebaum, C. R. de Almodovar, M. Dewerchin, P. Carmeliet, 
Vascular endothelial growth factor: a neurovascular target in neurological 
diseases. Nat Rev Neurol 12, 439-454 (2016). 
2. N. R. West, S. McCuaig, F. Franchini, F. Powrie, Emerging cytokine networks in 
colorectal cancer. Nat Rev Immunol 15, 615-629 (2015). 
3. J. I. Murray, N. R. West, L. C. Murphy, P. H. Watson, Intratumoural 
inflammation and endocrine resistance in breast cancer. Endocr Relat Cancer 22, 
R51-67 (2015). 
4. T. Deng, C. J. Lyon, S. Bergin, M. A. Caligiuri, W. A. Hsueh, Obesity, 
Inflammation, and Cancer. Annu Rev Pathol 11, 421-449 (2016). 
5. H. Zahid, E. R. Simpson, K. A. Brown, Inflammation, dysregulated metabolism 
and aromatase in obesity and breast cancer. Curr Opin Pharmacol 31, 90-96 
(2016). 
6. H. R. Harris, W. C. Willett, R. L. Vaidya, K. B. Michels, An Adolescent and 
Early Adulthood Dietary Pattern Associated with Inflammation and the Incidence 
of Breast Cancer. Cancer Res 77, 1179-1187 (2017). 
7. Q. Chang et al., The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and 
metastasis. Neoplasia 15, 848-862 (2013). 
8. E. Angevin et al., A phase I/II, multiple-dose, dose-escalation study of siltuximab, 
an anti-interleukin-6 monoclonal antibody, in patients with advanced solid 
tumors. Clin Cancer Res 20, 2192-2204 (2014). 
9. N. R. West et al., Oncostatin M drives intestinal inflammation and predicts 
response to tumor necrosis factor-neutralizing therapy in patients with 
inflammatory bowel disease. Nat Med 23, 579-589 (2017). 
10. W. Hui, A. D. Rowan, C. D. Richards, T. E. Cawston, Oncostatin M in 
combination with tumor necrosis factor alpha induces cartilage damage and 
matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 48, 
3404-3418 (2003). 
11. Q. Liu et al., Anti-OSM Antibody Inhibits Tubulointerstitial Lesion in a Murine 
Model of Lupus Nephritis. Mediators Inflamm 2017, 3038514 (2017). 
12. A. R. Pradeep, T. M. S, G. Garima, A. Raju, Serum levels of oncostatin M (a gp 
130 cytokine): an inflammatory biomarker in periodontal disease. Biomarkers 15, 
277-282 (2010). 
13. I. García-Tuñón et al., OSM, LIF, its receptors, and its relationship with the 
malignance in human breast carcinoma (in situ and in infiltrative). Cancer Invest 
26, 222-229 (2008). 
14. M. Esquivel-Velázquez et al., The role of cytokines in breast cancer development 
and progression. J Interferon Cytokine Res 35, 1-16 (2015). 
15. C. L. Jorcyk, R. G. Holzer, R. E. Ryan, Oncostatin M induces cell detachment and 
enhances the metastatic capacity of T-47D human breast carcinoma cells. 
Cytokine 33, 323-336 (2006). 
16. R. G. Holzer, R. E. Ryan, M. Tommack, E. Schlekeway, C. L. Jorcyk, Oncostatin 
M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: 
role of cyclooxygenase-2. Clin Exp Metastasis 21, 167-176 (2004). 
144 
 
 
17. C. Bolin et al., Oncostatin m promotes mammary tumor metastasis to bone and 
osteolytic bone degradation. Genes Cancer 3, 117-130 (2012). 
18. M. M. Queen, R. E. Ryan, R. G. Holzer, C. R. Keller-Peck, C. L. Jorcyk, Breast 
cancer cells stimulate neutrophils to produce oncostatin M: Potential implications 
for tumor progression. Cancer Research 65, 8896-8904 (2005). 
19. C. Tripathi et al., Macrophages are recruited to hypoxic tumor areas and acquire a 
Pro-Angiogenic M2-Polarized phenotype via hypoxic cancer cell derived 
cytokines Oncostatin M and Eotaxin. Oncotarget,  (2014). 
20. L. Lapeire et al., Cancer-associated adipose tissue promotes breast cancer 
progression by paracrine oncostatin M and Jak/STAT3 signaling. Cancer Res 74, 
6806-6819 (2014). 
21. R. E. Ryan et al., Oncostatin M binds to extracellular matrix in a bioactive 
conformation: implications for inflammation and metastasis. Cytokine 72, 71-85 
(2015). 
22. E. C. Walker et al., Murine Oncostatin M Acts via Leukemia Inhibitory Factor 
Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 
(STAT3) but Not STAT1, an Effect That Protects Bone Mass. J Biol Chem 291, 
21703-21716 (2016). 
23. N. R. West, L. C. Murphy, P. H. Watson, Oncostatin M suppresses oestrogen 
receptor-α expression and is associated with poor outcome in human breast 
cancer. Endocr Relat Cancer 19, 181-195 (2012). 
24. L. Humbert, M. Ghozlan, L. Canaff, J. Tian, J. J. Lebrun, The leukemia inhibitory 
factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human 
cutaneous melanoma. BMC Cancer 15, 200 (2015). 
25. M. Murakami et al., IL-6-induced homodimerization of gp130 and associated 
activation of a tyrosine kinase. Science 260, 1808-1810 (1993). 
26. D. A. Smith, A. Kiba, Y. Zong, O. N. Witte, Interleukin-6 and oncostatin-M 
synergize with the PI3K/AKT pathway to promote aggressive prostate 
malignancy in mouse and human tissues. Mol Cancer Res 11, 1159-1165 (2013). 
27. D. J. Junk et al., Oncostatin M promotes cancer cell plasticity through cooperative 
STAT3-SMAD3 signaling. Oncogene,  (2017). 
28. P. C. Heinrich et al., Principles of interleukin (IL)-6-type cytokine signalling and 
its regulation. Biochem J 374, 1-20 (2003). 
29. M. Kortylewski et al., Interleukin-6 and oncostatin M-induced growth inhibition 
of human A375 melanoma cells is STAT-dependent and involves upregulation of 
the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene 18, 3742-3753 (1999). 
30. C. Li, T. E. Ahlborn, F. B. Kraemer, J. Liu, Oncostatin M-induced growth 
inhibition and morphological changes of MDA-MB231 breast cancer cells are 
abolished by blocking the MEK/ERK signaling pathway. Breast Cancer Res 
Treat 66, 111-121 (2001). 
31. N. R. West, J. I. Murray, P. H. Watson, Oncostatin-M promotes phenotypic 
changes associated with mesenchymal and stem cell-like differentiation in breast 
cancer. Oncogene 33, 1485-1494 (2014). 
32. J. M. Smigiel, N. Parameswaran, M. W. Jackson, Potent EMT and CSC 
Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer. Mol Cancer Res 
15, 478-488 (2017). 
145 
 
 
33. S. L. Fossey, M. D. Bear, W. C. Kisseberth, M. Pennell, C. A. London, 
Oncostatin M promotes STAT3 activation, VEGF production, and invasion in 
osteosarcoma cell lines. BMC Cancer 11, 125 (2011). 
34. R. Soldi et al., Oncostatin M activates phosphatidylinositol-3-kinase in Kaposi's 
sarcoma cells. Oncogene 9, 2253-2260 (1994). 
35. S. Vollmer et al., Hypoxia-inducible factor 1alpha is up-regulated by oncostatin 
M and participates in oncostatin M signaling. Hepatology 50, 253-260 (2009). 
36. M. Zhu et al., Oncostatin M activates STAT3 to promote endometrial cancer 
invasion and angiogenesis. Oncol Rep 34, 129-138 (2015). 
37. P. R. Jay, M. Centrella, J. Lorenzo, A. G. Bruce, M. C. Horowitz, Oncostatin-M: 
a new bone active cytokine that activates osteoblasts and inhibits bone resorption. 
Endocrinology 137, 1151-1158 (1996). 
38. P. Guihard et al., Oncostatin M, an Inflammatory Cytokine Produced by 
Macrophages, Supports Intramembranous Bone Healing in a Mouse Model of 
Tibia Injury. The American journal of pathology,  (2015). 
39. C. Bolin, C. Sutherland, K. Tawara, J. Moselhy, C. L. Jorcyk, Novel mouse 
mammary cell lines for in vivo bioluminescence imaging (BLI) of bone 
metastasis. Biol Proced Online 14, 6 (2012). 
40. I. Martin-Padura et al., Spontaneous cell fusion of acute leukemia cells and 
macrophages observed in cells with leukemic potential. Neoplasia 14, 1057-1066 
(2012). 
41. B. L. Eckhardt et al., Genomic analysis of a spontaneous model of breast cancer 
metastasis to bone reveals a role for the extracellular matrix. Molecular Cancer 
Research 3, 1-13 (2005). 
42. K. J. Livak, T. D. Schmittgen, Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 
402-408 (2001). 
43. J. R. Garbow, J. P. Dugas, S.-K. Song, M. S. Conradi, A simple, robust hardware 
device for passive or active respiratory gating in MRI and MRS experiments. 
Concepts in Magnetic Resonance Part B: Magnetic Resonance Engineering 21B, 
40-48 (2004). 
44. R. H. Mak et al., Wasting in chronic kidney disease. J Cachexia Sarcopenia 
Muscle 2, 9-25 (2011). 
45. Y. Imai et al., Injurious mechanical ventilation and end-organ epithelial cell 
apoptosis and organ dysfunction in an experimental model of acute respiratory 
distress syndrome. JAMA 289, 2104-2112 (2003). 
46. J. Liu et al., Oncostatin M-specific receptor expression and function in regulating 
cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10, 
295-302 (1998). 
47. G. Somlo et al., Multiple biomarker expression on circulating tumor cells in 
comparison to tumor tissues from primary and metastatic sites in patients with 
locally advanced/inflammatory, and stage IV breast cancer, using a novel 
detection technology. Breast Cancer Res Treat 128, 155-163 (2011). 
48. H. Liu et al., The biological and clinical importance of epithelial-mesenchymal 
transition in circulating tumor cells. J Cancer Res Clin Oncol 141, 189-201 
(2015). 
146 
 
 
49. F. van Zijl, G. Krupitza, W. Mikulits, Initial steps of metastasis: cell invasion and 
endothelial transmigration. Mutat Res 728, 23-34 (2011). 
50. Y. Husemann et al., Systemic spread is an early step in breast cancer. Cancer Cell 
13, 58-68 (2008). 
51. H. Hosseini et al., Early dissemination seeds metastasis in breast cancer. Nature,  
(2016). 
52. L. D. Hazlett, R. S. Berk, Heightened resistance of athymic, nude (nu/nu) mice to 
experimental Pseudomonas aeruginosa ocular infection. Infection and immunity 
22, 926-933 (1978). 
53. J. Koch et al., Immune cells from SR/CR mice induce the regression of 
established tumors in BALB/c and C57BL/6 mice. PloS one 8, e59995 (2013). 
54. A. M. Hicks et al., Transferable anticancer innate immunity in spontaneous 
regression/complete resistance mice. Proceedings of the National Academy of 
Sciences of the United States of America 103, 7753-7758 (2006). 
55. S. Lauber et al., Novel function of Oncostatin M as a potent tumour-promoting 
agent in lung. International journal of cancer. Journal international du cancer 
136, 831-843 (2015). 
56. M. J. Tisdale, Mechanisms of cancer cachexia. Physiol Rev 89, 381-410 (2009). 
57. K. B. Harvey, L. L. Moldawer, B. R. Bistrian, G. L. Blackburn, Biological 
measures for the formulation of a hospital prognostic index. Am J Clin Nutr 34, 
2013-2022 (1981). 
58. H. J. Patel, B. M. Patel, TNF-α and cancer cachexia: Molecular insights and 
clinical implications. Life Sci 170, 56-63 (2017). 
59. A. Miller et al., Blockade of the IL-6 trans-signalling/STAT3 axis suppresses 
cachexia in Kras-induced lung adenocarcinoma. Oncogene 36, 3059-3066 (2017). 
60. J. K. Onesti, D. C. Guttridge, Inflammation based regulation of cancer cachexia. 
Biomed Res Int 2014, 168407 (2014). 
61. C. Li et al., Crosstalk between Platelets and the Immune System: Old Systems 
with New Discoveries. Adv Hematol 2012, 384685 (2012). 
62. R. A. Ali, L. M. Wuescher, R. G. Worth, Platelets: essential components of the 
immune system. Curr Trends Immunol 16, 65-78 (2015). 
63. S. Taucher et al., Impact of pretreatment thrombocytosis on survival in primary 
breast cancer. Thromb Haemost 89, 1098-1106 (2003). 
64. C. K. Meikle et al., Cancer and Thrombosis: The Platelet Perspective. Front Cell 
Dev Biol 4, 147 (2016). 
65. L. Yuan, X. Liu, Platelets are associated with xenograft tumor growth and the 
clinical malignancy of ovarian cancer through an angiogenesis-dependent 
mechanism. Mol Med Rep 11, 2449-2458 (2015). 
66. B. Gligorijevic et al., N-WASP-mediated invadopodium formation is involved in 
intravasation and lung metastasis of mammary tumors. J Cell Sci 125, 724-734 
(2012). 
67. N. Bednarz-Knoll, C. Alix-Panabieres, K. Pantel, Clinical relevance and biology 
of circulating tumor cells. Breast Cancer Res 13, 228 (2011). 
68. S. Zhao et al., Circulating tumor cells (CTCs) detected by triple-marker EpCAM, 
CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic 
breast cancer patients. Cell biochemistry and biophysics 65, 263-273 (2013). 
147 
 
 
69. T. M. Gorges et al., Circulating tumour cells escape from EpCAM-based 
detection due to epithelial-to-mesenchymal transition. BMC Cancer 12, 178 
(2012). 
70. A. Gradilone et al., Circulating tumour cells lacking cytokeratin in breast cancer: 
the importance of being mesenchymal. Journal of cellular and molecular 
medicine 15, 1066-1070 (2011). 
71. M. Zafrakas et al., Expression analysis of mammaglobin A (SCGB2A2) and 
lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal 
tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 6, 
88 (2006). 
72. A. M. Tester, N. Ruangpanit, R. L. Anderson, E. W. Thompson, MMP-9 secretion 
and MMP-2 activation distinguish invasive and metastatic sublines of a mouse 
mammary carcinoma system showing epithelial-mesenchymal transition traits. 
Clin Exp Metastasis 18, 553-560 (2000). 
73. M. Y. Kim et al., Tumor self-seeding by circulating cancer cells. Cell 139, 1315-
1326 (2009). 
74. R. S. Muraoka et al., Increased malignancy of Neu-induced mammary tumors 
overexpressing active transforming growth factor beta1. Mol Cell Biol 23, 8691-
8703 (2003). 
148 
 
 
CHAPTER FOUR: HIGH EXPRESSION OF OSM AND IL-6 IS ASSOCIATED WITH 
DECREASED BREAST CANCER SURVIVAL: SYNERGISTIC INDUCTION OF IL-6 
SECRETION BY OSM AND IL-1β   
 
 
Authors 
Ken Tawara, Hannah Scott, Jacqueline Emathinger, Cody Wolf, Celeste Bolin, Danielle 
Hedeen, Laura Bond, Cheryl Jorcyk 
 
Boise State University, Boise, Idaho 83725 
 
 
Abstract 
Inflammation is driven by various immunomodulatory cytokines such as 
interleukin-6 (IL-6), oncostatin M (OSM), and interleukin-1 beta (IL-1β). Independently, 
each of these cytokines can promote in vitro metrics of cancer metastasis such as tumor 
cell detachment, epithelial-mesenchymal transition (EMT), and invasive potential. 
Furthermore, these cytokines promote breast cancer metastases to distant organs in in 
vivo mouse models. However, anti-IL-6 and anti-IL-1β therapeutics have not yielded 
significant results against solid tumors in clinical trials. Only anti-OSM therapies remain 
untested against human cancer progression. Here we show that these three cytokines are 
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interrelated in function, which may explain why single anti-cytokine therapies have been 
ineffective. Using Oncomine™ data, we have determined that there is a correlation 
between high co-expression levels of OSM, IL-6, and IL-1β and reduced breast cancer 
patient survival. Furthermore, we confirm that OSM induces the expression of IL-6 in 
breast cancer in a manner that is dependent on both an estrogen receptor-negative (ER-) 
status, as well as STAT3 signaling. In addition, OSM and IL-1β synergistically induce 
IL-6 secretion using independent signaling pathways in MDA-MB-231 and MCF7 human 
breast cancer cells. Specifically, OSM signals through STAT3 and ERK, while IL-1β 
signals through p65 and ERK. This study demonstrates that OSM, IL-6, and IL-1β 
expression levels in breast cancer patient data are correlated, suggesting a complex 
interplay between these cytokines in tumor progression. Importantly, we provide a 
rationale for a breast cancer treatment regime that simultaneously targets these three 
proteins, as these cytokines appear to independently possess many overlapping functions 
that increase metastasis and worsen patient survival. 
Introduction 
Breast cancer-related morbidity and mortality remains one of the top concerns for 
women worldwide with 252,710 new cases of breast cancer predicted for 2017 (1). 
Despite new treatments and extensive preventative screening initiatives, the breast cancer 
incidence rate has remained flat, and there has been little improvement in the survival 
rate for stage 4 metastatic breast cancer (2). Major breast cancer risk factors include 
metabolic abnormalities and central obesity where there is extensive adipose tissue 
accumulation in the midsection (3). Obesity incidence rates have been increasing in the 
developed world and there are strong associations between obesity, cancer, and 
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inflammation, suggesting increased rates of breast cancer with increasing obesity (4-7). 
Inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha, 
(TNF), and interleukin-1 beta (IL-1β) have been linked to tumor invasion and 
metastasis (8). IL-6, in particular, has been associated with increased breast tumor cell 
proliferation, metastatic capacity, and decreased patient survival rates (9). Although 
recent research has shown the importance of IL-6 in cancer disease progression, anti-IL-6 
therapies have not produced clinically beneficial results for the treatment of solid tumors 
(10, 11). This suggests a redundancy where other pro-inflammatory mediators further 
contribute. 
The IL-6 cytokine is a part of the gp130 family of cytokines which include IL-6, 
oncostatin M (OSM), leukemia inhibitory factor (LIF), IL-31, IL-11, IL-27, 
cardiotrophin-1, ciliary neurotrophic factor, and cardiotrophin like cytokine (12). These 
cytokines have a shared gp130 receptor subunit and have a wide range of functions in 
cancer and inflammation (12-14). OSM, in particular, has been shown to induce tumor 
cell detachment, invasion, EMT, induction of cancer stem cells, immune evasion, and 
osteolytic bone metastases, (15-21). OSM is thought to exert much of its function through 
binding to the OSM receptor (OSMR), a gp130/ OSMRβ complex, to induce downstream 
signaling pathways such as signal transducer and activator of transcription 3 (STAT3), 
mitogen-activated protein kinase (MAPK), and AKT (22-24). 
OSM has been known to synergize with interleukin-1 (IL-1α) and IL-1β in the 
context of cartilage breakdown in the joint, showing an amplified induction of matrix 
metalloproteinases (MMPs), IL-8, as well as IL-6 (25-27). Additionally, OSM and IL-1β 
have been shown to synergistically induce vascular endothelial growth factor (VEGF) in 
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astroglioma cells (28). Both IL-1α and IL-1β activate the same IL-1 receptor, (a dimer of 
IL-1R1 and IL-1RAcP), while IL-1α is a membrane bound protein and IL-1β is a soluble 
protein (29). IL-1β increases tumor invasiveness, immunosuppression, and progression of 
metastatic disease (29, 30). IL-1β is able to promote these effects through the activation 
of p65 and ERK and induce the production of nitric oxide and proteinases (31-33). 
Similar to our studies with OSM and breast cancer metastasis to bone (18), IL-1β also 
stimulates the development of bone metastases (34). Unfortunately, anti-IL-1β therapies 
such as anakinra (Kineret™) have not demonstrated significant effects against solid 
tumors, although additional clinical trials are in progress to investigate its effectiveness 
further (35-37). Together, these studies suggest that there are many overlapping functions 
between IL-6, OSM, and IL-1β that expose possible weaknesses in the use of singular 
anti-cytokine therapies. 
Gene expression studies on breast cancer subtypes and immunological factors 
such as TLR9, and signaling factors such as STAT3, MAPK, and AKT suggest that there 
may be sub-type specific differences in the level of expression and activation of 
downstream pathways (38, 39). This may inform that there are possible breast cancer 
subtype specific differences in cytokine signaling, which would further complicate 
possible therapeutic interventions using anti-cytokine biologics. Subtyping breast cancer 
relies on the positive or negative detection of estrogen receptor (ER) and progesterone 
receptor (PR), as well as the expression level of human epidermal growth factor receptor 
2 (HER2) and Ki67 (40). Specifically, breast cancer cells that are classified as luminal A 
(ER+/PR+/Her2low) are the less aggressive and have good prognosis overall, while triple 
negative (ER-/PR-/Her2low) are much more aggressive (41). OSM have been shown to 
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suppress ER expression in luminal A cells, and drive them into a more metastatic 
phenotype (42, 43). In particular high expression of OSMR has been correlated with low 
survival rates, which suggest that OSM signaling in general may promote breast cancer 
progression (42). Other studies suggest that OSM may be higher in triple negative 
compared to luminal A or B breast cancer phenotypes (44). Collectively, these studies 
suggest that OSM expression and signaling may be correlated with breast cancer 
subtypes, and that subtype specific breast cancer response to cytokines may drive breast 
cancer disease progression. 
In this study, we investigate the effect of OSM, IL-6, and IL-1β on breast cancer 
patient survival as well as how these cytokines are interrelated in terms of cell signaling. 
Using Oncomine™ data, we assessed the correlation between OSM and IL-6 with regards 
to patient survival. Specifically, we found that high expression of OSM or IL-6 was 
correlated to significantly decreased breast cancer patient survival. Furthermore, we 
found distinct signaling differences between breast cancer subtypes in terms of OSM 
induction of IL-6 in vitro with ER- MDA-MB-231 (ER-/PR-/Her2low), ER+ T47D 
(ER+/PR+/Her2low), and ER+ MCF7 (ER+/PR+/Her2low) cells. Interestingly, OSM 
induction of IL-6 only occurred in the ER- MDA-MB-231 cells through the STAT3 
signaling pathway and not in the two ER+ cells lines tested. We also reveal that co-
treatment of breast cancer cells with both OSM and IL-1β led to a synergistic increase in 
IL-6 secretion. These results highlight that OSM and IL-1β synergistically increase IL-6 
in breast cancer, promote a more metastatic phenotype, and reduce breast cancer patient 
survival. 
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Materials and Methods 
Oncomine analysis 
The Curtis human breast cancer mRNA microarray dataset (45) and the Finak 
breast cancer stromal gene expression mRNA dataset (46) were obtained from 
OncomineTM (Compendia Bioscience, Ann Arbor, MI). For survival analysis, the Curtis 
dataset was filtered for “Invasive Ductal Carcinoma” and valid “Alive” or “Dead of 
Disease” status. From the filtered dataset, upper (>75th percentile), and lower (<25th 
percentile) quartiles of gene expression for OSM, IL-6, and IL-1β were selected for 
comparison. For multi-gene co-expression analysis, we calculated for patients high in 
both OSM and IL-6, or OSM and IL-1β. Survival statistical analysis was performed using 
a log-rank test in Graphpad Prism 5 software. 
To analyze gene correlations, the Curtis dataset was subjected to a correlation 
analysis using Graphpad Prism 5 software and the RealStatistics package on Microsoft 
Excel. To assess gene expression levels of OSM and IL-1β in stromal tissue, patients in 
the Finak dataset were separated into normal and breast cancer categories, as well as into 
ER+ and ER- breast cancer categories. Additionally, the Curtis dataset was also separated 
into ER+ and ER- breast cancer categories to assess gene expression levels in the tumor 
cells. Statistical analysis was performed using the 2-tailed student’s T-test in Graphpad 
Prism 5 software. 
Enzyme linked immunosorbent assay 
Serum was collected from breast cancer patients of various stages at St. Luke’s 
Mountain States Tumor Institute (MSTI) in accordance with the institutional review 
board or purchased from Proteogenix (Schiltigheim, France) and Bioreclamations 
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(Baltimore, Maryland). The serum was diluted 1:3 in PBS and used in the DuoSet ELISA 
for IL-6 (DY206, R&D system) or for OSM (DY295, R&D systems) on Immulon HBX4 
ELISA plates (3855, ThermoFisher) in accordance with the manufacturer’s instructions. 
Data was analyzed using Graphpad prism 5.0 to determine correlations between OSM—
IL-6 serum concentrations. 
Cells were incubated with OSM or IL-1β treatments (10 ng/mL) ranging from 48-
72 hours and the resultant cytokine levels were assessed. To measure human IL-6 and 
OSM in conditioned media, the same R&D ELISA kits were utilized according to the 
manufacturer’s instructions. Conditioned media from MDA-MB-231 cells were diluted 
1:10 to 1:20 in order to accurately detect the amount of IL-6 within the range of the 
standard. Conditioned media was collected from 24-well plates containing 1x 105 cells at 
the time of cell plating. 
Cell lines 
MDA-MB-231, T47D, MCF7, and MDA-MB-468 human breast cancer cells, 
PC3 and DU145 human prostate cancer cells, and HeLa human cervical cancer cells were 
obtained from the American Type Culture Collection (Rockville, MD). All human cell 
lines were maintained in RPMI 1640 media supplemented with 10% fetal bovine serum 
and to 100 units/mL of streptomycin and penicillin (Hyclone, Logan UT). 4T1.2 mouse 
mammary carcinoma cells were maintained in MEM-alpha media supplemented with 
10% fetal bovine serum and to 100 units/mL of streptomycin and penicillin. All cells, and 
experimental incubations were maintained at 37oC, 5% carbon dioxide, and 100% 
humidity in a water-jacketed cell culture incubator. 
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Stable and transient transfections 
To generate stably transduced MDA-MB-231 Luc2 D3H2LN cells (Caliper Life 
Sciences) with inducible expression of OSM, the OSM cDNA (862 bp) (A generous gift 
from Dr. Atsushi Miyajima, The University of Tokyo) was cloned into the pLenti 
6.3/TO/V5-DEST vector (A11144 ThermoFisher). The vector+hOSM was then co-
transduced with pLenti3.3/TR (A11144, ThermoFisher) into MDA-MB-231 Luc2 
D3H2LN cells using the ViraPower™ II Lentiviral Gateway® Expression System 
(K367-20, Life technologies) using the manufacturer’s instructions. Stably transduced 
cells were injected into mice and resultant tumors and animal sera tested for TET 
induction by western blot and ELISA. The stable TET inducible OSM expressing MDA-
MB-231 Luc2 D3H2LN clone has been designated as MDATO/OSM. 
To generate stable expression of estrogen receptor alpha (ERα) in ER- MDA-MB-
231 cells, an ERα expressing plasmid (Cat# 28230, AddGene) was stably transfected into 
MDA-MB-231 cells using Lipofectamine LTX (Cat# 15338100, Life Technologies). For 
control cells, an empty pEGFP-C1 (Cat#6084-1, Clontech) vector was stably transfected 
into these cells. Cells were transfected at 80% confluency in 96-well plates containing 
RPMI 1640+10% FBS with 6 µg DNA per well and a lipofectamine:DNA ratio of 1.35:1. 
Transfected cells were selected for using G418 at a concentration of 500 μg/mL. 
Surviving colonies were expanded under antibiotic pressure and their expression of ERα 
was verified by western blot analysis. 
To transiently suppress STAT3, a siRNA pool targeting STAT3 was purchased 
from Dharmacon (Cat #L-003544-00-0005). 100,000 cells per well were seeded in a 24-
well plate, and the siRNA was transfected in accordance to the Fast-Forward protocol as 
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per the technical manual included with the Hyperfect siRNA transfection reagent (Cat# 
301705, Qiagen). STAT3 siRNA was used at 25 nM and the cells were transfected for 72 
hours before being treated with OSM or IL-1β. Knockdown of STAT3 was assessed by 
western blot. 
Animal tumor xenograft model 
Six-week old female athymic nude mice were purchased from the NCI Animal 
Production Facility (Fredrick, MD). The MDATO/OSM cells were grown to 90% 
confluency and the cells were concentrated to 4.0 x 107 cells/mL in PBS containing 10% 
RPMI 1640, and 50 uL of the cell suspension was injected into the 4th mammary fat pad. 
When the tumors became palpable, the animals were given drinking water containing 
tetracycline in 2% sucrose water for one week with doses ranging from 0 mg/mL, 0.1 
mg/mL and 1 mg/mL. Animals were sacrificed and their serum and tumors collected for 
analysis. 
Immunoblot assay 
Cells were plated on 24-well plates at 70-80% confluency and allowed to adhere 
overnight at 37 oC. Cells were treated with cytokines, OSM (CAT#300-10T) and/or IL1-
Beta (CAT# 200-01B) (Peprotech), and with inhibitors, the ERK inhibitor PD98059 
(CAT# 9900, Cell Signaling) or the p65 inhibitor caffeic acid phenyl ester (CAPE) 
(CAT# 2743, Tocris). Cells were treated for 30 minutes or 72 hours. Conditioned media 
was collected from the cells treated for a 72 hours, and cell lysates were collected from 
both time points using 1x RIPA buffer containing a protease inhibitor cocktail (Sigma 
Aldrich, CAT# P8340). Lysates were run on an SDS-PAGE gel and transferred to 
nitrocellulose immunoblot membranes via semi-dry transfer. Blots were rinsed in ddH2O 
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and allowed to completely dry before being blocked with PBS-T (PBS, pH 7.4; Tween-
20,0.05%; 5% non-fat dry milk) for 1 hour. After 3 x 5 min PBS-T washes, primary 
antibodies (1:1000) suspended in PBS-T complemented with 1% BSA were then applied 
to the membrane and incubated overnight at 4oC. After another 3 x 5 min PBS-T washes, 
horse radish peroxidase conjugated secondary antibodies suspended in PBS-T were then 
applied to the membrane. Then with a final 5 x 5 min PBS-T wash, the membrane was 
developed with enhanced chemiluminescence and imaged using Syngene G:BOX imager. 
All antibodies used for the immunoblots were acquired from Cell Signaling 
Technologies. STAT3 (CAT#9132), phospho-STAT3 (Y705) (CAT# 9145), Beta-Actin 
(CAT#3700), NFκB p65 (CAT#8242), phospho-NFκB p65 (CAT#3033), phospho-ERK 
(CAT# 4370), Anti-rabbit IgG-HRP (CAT# 7076). 
Immunoprecipitation 
MCF7 and T47D cells were incubated with 10 ng/mL of OSM and/or IL-1β for 
48 hours at a density of 100,000 cells per well in a 24-well plate. Cells were lysed with 
Cell Signaling PathScan® Lysis buffer (Cat# 7018) using the manufacturer’s 
instructions. The lysates were then used on a Dynabeads® Protein A 
Immunoprecipitation Kit (Cat# 10006D, Life Technologies) using ERα IP antibody at 
1:50 dilution from Cell Signaling (Cat# D8H8) in accordance with the kit instructions 
with the following modification. In order to reduce co-elution of the antibody, the 
antibody was cross-linked using 20 mM dimethyl pimelimidate dihydrochloride (Cat# 
21666, Pierce) in 0.2 M triethanolamine at a pH of 8.2. The antibody-bead complex was 
cross-linked for 30 minutes, and the reaction was stopped by resuspending the beads for 
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15 minutes in 50 mM pH7.5 Tris. The beads were then used in the rest of the 
immunoprecipitation protocol following a 3x PBS-0.05% Tween-20 wash. 
Statistical analysis 
All the statistical analyses were performed using GraphPad Prism version 5 
software or with the RealStatistics™ package for Microsoft Excel. To compare multiple 
groups, one- or two-way ANOVA was performed using Tukey’s post-test where 
appropriate. Comparisons between two groups were assessed by unpaired two-tailed 
student’s t-test. Correlations were assessed using the Spearman nonparametric correlation 
analysis. Survival data was assessed using the Log-rank test. Statistical significance was 
assigned to experimental p values that were less than 0.05. Error bars represent the 
standard error of the mean unless otherwise specified, and all experiments were 
performed at least three times. 
Results 
OSM and IL-6 expression are correlated with each other and associated with decreased 
invasive breast cancer survival 
Both OSM and IL-6 have previously been shown to increase breast cancer 
metastatic potential in vitro as well as promote metastasis in vivo (9, 18, 22, 42, 47-51), 
which suggests that these cytokines may negatively affect patient survival. In particular, 
serum IL-6 levels have been correlated with reduced breast cancer patient survival (52). 
To assess the relevance of tumor tissue expression of OSM and IL-6 in the context of 
invasive breast cancer patient survival, we used the Curtis Breast dataset obtained from 
Oncomine ™ (45). The upper quartile was delineated as the top 25% of patient 
expression levels (high expression), while the lower quartile represents the bottom 25% 
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expression (low expression). High tumor tissue expression of OSM (p<0.001, Fig. 1A) 
and IL-6 (p<0.001, Fig. 1B) both correlated with a significant decrease in survival. As 
this data demonstrates that OSM and IL-6 independently correlates with decreased 
survival in invasive breast cancer patients, we next assessed whether co-expression of 
high levels of OSM and IL-6 is also correlated with decreased survival. Indeed, high co-
expression of both OSM and IL-6 were significantly correlated with decreased survival 
compared to low co-expression of both OSM and IL-6 (p=0.0091, Fig. 1C). Further 
assessment revealed that expression of OSM correlates with IL-6 with a Spearman 
coefficient of 0.576 (p<0.0001, Fig. 1D). Collectively, this suggests that elevated breast 
cancer tissue levels of OSM and IL-6 leads to decreased survival and that their expression 
is correlated with each other. This kind of co-expression is indicative of potential co-
regulation and suggests that these cytokines may induce the expression of each other. 
High OSM serum levels in breast cancer patients are correlated high IL-6 levels 
Previous studies suggest that aberrant expression of growth factors and cytokines 
in the tumor microenvironment (TME) can result in these proteins leaking into the 
circulation and become detectable in patient serum (53, 54). To assess whether serum 
concentrations of OSM and IL-6 also show a correlation, as seen with the Curtis Breast 
dataset in Figure 1D, we assessed serum samples collected from breast cancer patients 
and healthy individuals by ELISA. Breast cancer patient serum had significantly higher 
levels of OSM and IL-6 compared to serum from individuals without malignancies (Fig. 
2A, B). Next, we analyzed the serum sample data to test whether OSM serum 
concentrations are correlated to IL-6 concentrations. In samples with no OSM, there was 
very little IL-6 in the serum, while any serum sample with >0 pg/mL concentration of 
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OSM had a significantly higher level of IL-6 (Fig. 2C). Furthermore, a serum OSM and 
IL-6 concentration correlation analysis reveal that there is a Spearman coefficient of 
0.3774 (p<0.0001, Fig. 2D). These results suggest that patients with breast cancer have 
elevated serum OSM and IL-6 levels compared to normal patients and that the serum 
concentrations of these cytokines correlate with each other similarly to the tumor 
expression levels of OSM and IL-6 seen with the Curtis dataset. 
OSM promotes IL-6 expression in a mouse model of human breast cancer 
 In order to recapitulate potential OSM-induced IL-6 expression in breast cancer, 
we utilized an MDA-MB-231 orthotopic mouse model of human breast cancer. MDA-
MB-231-Luc2 cells were stably transfected with a TET-inducible OSM expression 
vector, and these MDATO/OSM cells were orthotopically injected into athymic nude mice 
into the 4th mammary fat pad. Once the tumors were palpable ~3-5 mm, the animals were 
given drinking water with 2% sucrose containing 0.1 mg/mL tetracycline (+TET) or 2% 
sucrose water alone (-TET). MDATO/OSM tumor bearing animals +TET had a 32-fold 
higher expression of OSM in their tumors compared to –TET tumors (Fig 3A) and 10.8-
fold higher IL-6 expression level (Fig 3B) as measured by western blot analysis. After 
collecting blood, OSM and IL-6 serum levels were assessed by ELISA. TET- treated 
mice had higher levels of OSM (9.8-fold, Fig 3C Left) and IL-6 (96-fold, Fig 3C Right) 
in their serum, and the concentrations correlated with each other with an r2 coefficient of 
0.9058 (p=0.0034, sFig 1). Collectively, TET induction in these mice led to increased 
levels of OSM and IL-6 in both the tumors and serum, which concurs with the breast 
cancer patient serum data and the Curtis breast cancer tumor expression data from 
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Oncomine. This also suggests that elevated cytokine serum levels may be indicative of 
high cytokine expression levels in the tumor microenvironment (TME). 
OSM induces human IL-6 secretion in the absence of ER from various cancer cells in 
vitro  
Our results indicate that there is strong inter-correlation between OSM and IL-6 
expression and secretion levels in breast cancer. To assess the nature of cytokine 
production in breast cancer cells, various cell lines including two human ER+ cell lines, 
T47D and MCF7, and three ER- cell lines MDA-MB-468, MDA-MB-231, and 4T1.2 
mouse mammary cancer cells were treated with OSM, and their IL-6 secretion was 
assessed. In addition, PC3 and Du145 human prostate cancer cells as well as HeLa 
human cervical carcinoma cells were tested for OSM-induced IL-6 secretion. 
Recombinant hOSM (25 ng/mL) was used to treat the human cell lines, while 
recombinant mouse OSM (rmOSM; 25 ng/mL) was used for the 4T1.2. The cells were 
treated with OSM for 48 hours, and IL-6 levels in the conditioned media (CM) were 
assessed by ELISA. Interestingly, OSM did not induce IL-6 secretion in the ER+ MCF7 
or T47D cells but did in the ER- cells (Fig. 4A). OSM promoted IL-6 secretion 
approximately 5-fold in MDA-MB-468 cells, ~4-fold in MDA-MB-231 cells, and ~4-fold 
in 4T1.2 mouse mammary carcinoma cells (Fig 4A). Androgen receptor-negative (AR-) 
PC3 cells express high levels of IL-6 with or without OSM, while OSM induced IL-6 
approximately 6.5-fold in the AR- Du145 cells (Fig 4B). Also in the ER- HeLa cells, IL-
6 levels were undetectable in the absence of OSM treatment, but the cells produced 1245 
pg/mL of IL-6 with OSM treatment (Fig 4B). On the other hand, IL-6 had no effect on 
OSM secretion in MDA, T47D, or MCF7 cells (sFig 2), which suggest that there is no 
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reciprocal induction of cytokine secretion. These results show that OSM increased IL-6 
expression in cells that are more aggressive and may correlate to estrogen receptor status. 
To assess whether the presence of ER is essential for OSM induction of IL-6, ER- 
MDA-MB-231 cells were stably transfected with an ER expression vector (pEGFP-C1). 
Two independent colonies, MDAER+/C7, and MDAER+/H6, were shown to express ER by 
western blot analysis (Fig 4C). Parental MDA-MB-231 cells, MDAER+/C7, and 
MDAER+/H6 were treated with rhOSM (25 ng/mL) for 48 hours to assess their IL-6 
secretion. The CM was then collected and their IL-6 concentrations were analyzed by 
ELISA. MDAER+/C7 cells exhibited a 7.8-fold decrease and MDAER+/H6 cells demonstrated 
a 12.1-fold decrease in the levels of IL-6 produced in response to OSM, as compared to 
the parental MDA-MB-231 cells (Fig 4D). This result indicates that the ER+ MDA-MB-
231 cells have limited OSM-induced IL-6 expression and suggests that ER may play a 
negative regulatory role in OSM signaling that leads to IL-6 expression. 
STAT3 is phosphorylated by OSM signaling in both ER- and ER+ cells 
Previous studies show that IL-6 induction is dependent on the activation of NFκB 
and STAT3 signaling pathways (55). MDA-MB-231, T47D, and MCF7 were treated with 
25 ng/mL OSM for 5 and 30 minutes to assess which signaling pathways are activated in 
response to OSM in these cells. STAT3, AKT, ERK, and JNK pathways were activated 
by OSM in all three cell lines, however only MDA-MB-231 cells produced IL-6 in 
response to OSM (Fig 5A). This suggests that despite the nearly uniform activation of 
OSM-induced pathways in both ER+ and ER- cells, there must be something else 
occurring that is suppressing IL-6 production in the ER+ cells. Further investigation 
using siRNA (20 nM) against STAT3 completely abrogated OSM-induced IL-6 secretion 
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in MDA-MB-231 cells as detected by immunoblot (Fig 5B) and ELISA (Fig 5C), thereby 
implicating STAT3 as the primary signaling pathway responsible for OSM induction of 
IL-6 secretion. This also demonstrates that STAT3 is not able to induce IL-6 expression 
in ER+ T47D or MCF7 cells despite the apparent phosphorylation of STAT3 by OSM. 
Invasive breast cancer patient stroma expresses high levels of OSM and IL-1 
IL-1β has been known to synergize with OSM in the context of inflammatory 
conditions such as arthritis and progressive joint deterioration (25, 56) and has been 
shown to induce the expression of IL-6 in vitro (57). As inflammation appears to have 
negative effects on breast cancer patient survival, we assessed patient data related to these 
cytokines. In particular, stromal cytokines in the breast cancer microenvironment appear 
to play a major role in the progression of metastatic disease (58). We assessed OSM and 
IL-1β stromal expression in both normal and invasive breast cancer patient data using the 
Finak Breast Stromal dataset (46) obtained from Oncomine™. Stromal OSM expression 
was 5.9-fold higher in invasive breast cancer compared to normal samples (Fig 6A), and 
stromal IL-1β was 5.4-fold higher in invasive breast cancer compared to normal samples 
(Fig 6B). There was also a significant increase in stromal OSM (sFig 3A) and IL-1β 
expression (sFig 3B) in ER- samples compared to ER+ samples. Using the Curtis dataset, 
a significant increase in tumor OSM expression (sFig 3C) as well as tumor IL-1β (sFig 
3D) expression was seen in ER- samples compared to ER+ samples. These data suggest 
that in breast cancer patients both paracrine and autocrine production of OSM and IL-1β 
may work in an ER-dependent manner to affect patient survival. 
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OSM and IL-1β promote increased lymph node metastases and decreased survival: a 
three-way correlation for OSM-IL-1β-IL-6 expression  
The correlation between tumor OSM and IL-1β expression and metastatic 
capacity was assessed in the Curtis patient dataset. A 2.1-fold increase in lymph node 
metastasis seen with high OSM versus low OSM expression for invasive breast cancer 
(Fig 6C Left). Similarly, lymph node metastasis was higher in patients with high IL-1β 
expression (Fig 6C Center). Furthermore, when both OSM and IL-1β co-expression was 
high, there was also a significantly higher number of lymph node metastases compared to 
the low OSM and IL-1β co-expression group (Fig 6C Right). High expression of OSM 
and IL-1β also led to decreased patient survival (Fig 6D). In addition, OSM expression 
levels correlated with IL-1β expression level (sFig 4A) and IL-1β expression levels 
correlated with IL-6 expression level (sFig 4B). To determine whether all three cytokines 
were correlated with each other, OSM, IL-6, and IL-1β expression levels were assessed 
using a least squares multiple correlation analysis (Fig 6E). The three-way correlation 
coefficient of OSM, IL-6, and IL-1β was 0.6001, with a p-value of 2.2 x 10-23, indicating 
significant correlation between the three cytokines in this analysis. Collectively, these 
results suggest that OSM, IL-6, and IL-1β are interrelated in breast cancer patient 
metastasis and survival. These results demonstrate that not only does each one of these 
cytokines increase metastasis and decrease survival in breast cancer patients but also 
induce the expression of other cytokines as well. This may provide at least in part, an 
explanation as to why clinical trials using single anti-cytokine therapies thus far have 
failed. 
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 OSM works synergistically with IL-1 to promote IL-6 secretion 
We have shown that high OSM, IL-6, and IL-1β levels all correlate with 
decreased breast cancer patient survival, and that high expression levels of these three 
cytokines correlate with each other in patient samples. Therefore, it is possible that OSM 
and IL-1β may work synergistically to promote IL-6 expression and secretion. To better 
assess the relationship between the two cytokines, we decreased the amount of OSM and 
IL-1β used in the experiments from 25 ng/mL to 10 ng/mL, thus reducing the probability 
of saturating the cell’s capacity to produce IL-6. Treating ER- MDA-MB-231 cells with a 
combination of OSM and IL-1β  for 72 hours resulted in a 44.8-fold increase in IL-6 
secretion by ELISA, while OSM alone lead to a 6.4-fold increase and IL-1 alone lead to 
a 17.3-fold increase compared to not-treated cells (Fig 7A). This suggests that OSM and 
IL-1β induce IL-6 production in a synergistic manner in ER- cells. No induction of IL-6 
secretion by OSM was seen in either ER+ T47D or MCF7 cells. After adjusting the scale 
for IL-6 secretion levels, an increase in IL-6 secretion by IL-1 was seen in ER+ MCF7 
cells, as compared to untreated controls (Fig 7B). MCF7 cells also exhibited a synergistic 
24.8-fold increase in IL-6 secretion by treatment with both OSM and IL-1β compared to 
IL-1β alone (Fig 7B). Although the level of IL-6 production is much lower in the ER+ 
MCF7 cells compared to the ER- MDA-MB-231 cells, there is a clear indication of a 
synergistic relationship between OSM and IL-1β in this cell line as well. T47D cells, on 
the other hand, were unable to produce any IL-6 in response to OSM or IL-1β, even 
though their activity was confirmed by an increased EMT-like morphology and 
invadopodia formation (sFig 5). This indicates that even if a breast cancer cell line like 
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T47D is unable to produce IL-6 in response to OSM or IL-1β, it can still promote 
invasive characteristics independently of IL-6 (20). 
OSM and IL-1β activate separate signaling pathways to promote IL-6 production 
The synergistic upregulation of IL-6 secretion in response to OSM and IL-1β 
suggests that these cytokines may be using separate pathways to promote IL-6 in breast 
cancer cells. Our data here and previously published work demonstrate that IL-1β utilizes 
the NFκB pathway and OSM uses the STAT3 pathway to induce IL-6 production (55). 
Interestingly, a past study indicated that there is crosstalk between STAT3 and NFκB to 
promote downstream effects (59). To assess gross signaling pathway differences between 
OSM and IL-1β on MDA-MB-231, T47D, and MCF7 cells, the cells were treated with 
both cytokines (10 ng/mL) for 20 minutes (Fig 7C) or 72 hours (Fig 7D). In all breast 
cancer cell lines tested, OSM specifically induced STAT3 phosphorylation, while IL-1β 
induced p65 phosphorylation. This suggests that OSM may primarily induce IL-6 
expression through STAT3 activation, while IL-1β induces IL-6 expression through the 
activation of the NFκB pathway. Additionally, ERK phosphorylation was unaffected in 
ER- MDA-MB-231 cells, but both OSM and IL-1β increased phospho-ERK in both 
T47D and to a lesser extent, in MCF7 cells. This data hints that there may be some ERK 
signaling related aspects to IL-6 secretion as both OSM and IL-1β affected ERK 
phosphorylation. To investigate the involvement of the ERK pathway, a small molecule 
inhibitor against ERK (PD98059) was used (sFig 6A). While MDA-MB-231 cells were 
unaffected by ERK inhibition (sFig 6B), IL-1β and OSM+IL-1β induced IL-6 secretion 
in MCF7 cells was significantly reduced (sFig 6C). Therefore, IL-1β-mediated induction 
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of IL-6 in MCF7 cells may utilize the ERK signaling pathway in addition to the NFB 
pathway, while only the NFκB pathway is used in MDA-MB-231 cells, 
Another signaling difference between the cell lines was that OSM-induced 
STAT3 phosphorylation was much weaker in MCF7 cells compared to T47D or MDA-
MB-231 cells (Fig 7C and D). This could suggest that IL-6 induction by OSM and IL-1β 
might not be dependent on STAT3 activation in MCF7 cells unlike with MDA-MB-231 
cells. To confirm that IL-1β does not signal through STAT3 to induce IL-6, STAT3 
siRNA was used in the OSM+ IL-1β co-treatment experiment. In the MCF7 cells, STAT3 
siRNA did not affect IL-1β-induced IL-6 levels (sFig 7). However, OSM-induced IL-6 
was suppressed by STAT3 siRNA in MDA-MB-231 cells, and with the OSM+IL-1β co-
treatment, IL-6 levels were lower compared to control siRNA levels. Additionally, 
caffeic acid phenyl ester (CAPE), a p65 inhibitor, suppressed OSM induction of IL-6 in 
MDA-MB-231 cells despite OSM’s inability to activate p65 phosphorylation (sFig 8). 
This may suggest some type of crosstalk occurring between STAT3 and NFκB signaling 
pathways in MDA-MB-231 cells (59). Overall, these results indicate that there are minor 
differences between cell lines in terms of intracellular signaling activation in response to 
OSM and IL-1β, and suggest that there may be a mechanism of IL-6 suppression that is 
independent of phosphorylation in the ER+ cells. 
ER interaction with STAT3 is suppressed by OSM and IL-1β in MCF7 cells 
In other studies, ER has been known to directly interact with various signaling 
molecules including p65 to suppress downstream signaling despite its apparent activation 
by protein phosphorylation (60). To assess whether ER may be binding to intracellular 
signaling pathway proteins, an immunoprecipitation with ER pull-down was performed 
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on ER+ MCF7 and T47D cell lysates treated with OSM and/or IL-1β for 48 hours. While 
no interaction between ER and p65, AKT, or ERK was observed (data not shown), a 50% 
reduction in interaction between ER and STAT3 in response to OSM or IL-1β in MCF7 
cells was seen using a STAT3 immumoblot of ERα-imunoprecipitation eluates (Fig 7E). 
With T47D cells, no interaction between ER and any of the signaling proteins was 
detected (data not shown). This suggests that the interaction of ER with STAT3 may 
suppress OSM induction of IL-6 in MCF7 cells, and that in the ER+ T47D cells an 
alternate mechanism may be operant. Collectively, OSM and IL-1β appear to induce IL-6 
in a synergistic manner with OSM signaling through STAT3 and IL-1β operating through 
p65 and ERK. 
Discussion 
Previous therapeutic interventions against inflammatory cytokines such as IL-6 
have failed in clinical trials despite their well-known role in tumor and metastasis 
promotion (9, 10, 12). Nevertheless, there has been renewed interest in mitigating 
inflammation in the tumor microenvironment, as a growing recognition that chronic 
tumor inflammation leads to angiogenesis, immunosuppression, proliferation, and 
metastasis exists (61). Inflammatory cytokines such as OSM, IL-6 and IL-1β have 
individually been shown to promote effects associated with metastatic cancer (9, 29, 62, 
63). Here we show for the first time the interplay between the three cytokines in breast 
cancer. We demonstrate that not only were the levels of tumor and stromal expression of 
these cytokines correlated with metastatic disease and decreased patient survival, but that 
there was an ER subtype-specific response in terms of OSM- and or IL-1β-mediated 
induction of IL-6. Specifically, ER+ MCF7 and T47D human breast cancer cells failed to 
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produce IL-6 in response to OSM, while high levels of IL-6 was produced with OSM 
treatment in the ER- MDA-MB-231 cells. Other studies have shown that there are 
subtype-specific differences in breast cancer’s response to IL-6 cytokines where the 
magnitude of STAT3 pathway activation in response to IL-6 correlated to ER expression 
(64, 65). Additionally, our results indicated that, OSM and IL-1β synergistically 
increased IL-6 production by activating two separate pathways, STAT3 and NFκB, in 
ER- MDA-MB-231 cells. This was also seen in the ER+ MCF7 cells, albeit at a much 
lower level. Studies on arthritis and joint physiology have also demonstrated a synergistic 
relationship between OSM and IL-1β in terms of joint damage and synovial fibroblast-
mediated inflammation (25, 56). We further showed that OSM induces IL-6 secretion in 
the MDA-MB-231 cells through the STAT3 pathway, and that ER appears to inhibit 
downstream STAT3 signaling (Fig. 8). Unlike in the ER+ MCF7 cells, which produced 
IL-6 in response to IL-1β and OSM co-treatment, T47D cells did not produce IL-6 under 
any conditions tested. This suggests that despite these two cell lines being the same 
luminal A breast cancer cell subtype, there are major differences in their intracellular 
signaling mechanisms. Additional studies are required to elucidate this difference as there 
may be mechanisms independent of pathway activation via phosphorylation. Taken 
together, this study highlights the complex interplay of various inflammatory cytokines in 
a manner that is subtype specific. 
Of the three cytokines studied in the paper, only therapeutic interventions 
targeting IL-6 have received a lot of attention (9, 47, 66-68). Recent clinical trials using 
an anti-IL-6 biologic, siltuximab, have failed to produce any clinically positive results in 
the treatment of solid tumors (10, 11). Our results suggest that inflammation in the tumor 
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microenvironment may be instigated by multiple cytokines and that IL-6 may only be a 
part of the whole picture. Here, we have shown that OSM and IL-6 are correlated with 
each other in patient serum data and in an in vivo mouse model of breast cancer 
(manuscript in preparation). Additionally, we show that OSM, IL-6, and IL-1β levels are 
correlated with each other in patient data, and that high levels of these cytokines lead to 
reduced patient survival. To date, there are no anti-OSM therapeutics available, nor are 
there any clinical trials in progress or planned to investigate anti-OSM therapies against 
solid tumors. On the other hand, there are several anti-IL-1β (Anakinra) therapeutics 
available that were developed for Castleman’s disease, where abnormally high levels of 
inflammatory cytokines are produced by various immune cells (69, 70). While this anti-
IL-1β therapeutics appeared promising for the treatment metastatic disease (35), it failed 
to produce significantly positive results in a colorectal cancer model (36). Additional 
studies and clinical trials for anti- IL-1β therapeutics are underway to assess their anti-
tumor capacity in other types of metastatic disease (37, 71, 72). 
An interesting aspect of this study is that we demonstrated a breast cancer 
subtype-specific difference in the production of IL-6 in response to OSM and/or IL-1β, 
thus suggesting that subtype-specific markers like ER may play a role in this difference. 
Previous studies have shown that induction of IL-6 expression is dependent on the NFκB 
pathway and that ER suppresses this signaling through inhibition of p65 (60, 73). 
However, our immunoprecipitation results suggest that ER may interact with STAT3 to 
suppress OSM induced-IL-6 secretion. Furthermore, suppression of the STAT3 pathway 
by siRNA also reduced OSM-induced IL-6 production to untreated control levels in 
MDA-MB-231 cells. On the other hand, induction of IL-6 by IL-1β alone or by both 
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OSM and IL-1β was not affected by STAT3 siRNA. Instead, IL-1β has been previously 
shown to induce IL-6 expression through p65 and PI3K dependent pathways (57). Here, 
we show that IL-1β induction of IL-6 is partially dependent on ERK signaling in MCF7 
cells, as the usage of the ERK inhibitor suppressed IL-1β and IL-1β+OSM induction of 
IL-6. 
Our immunoprecipitation result in MCF7 cells also suggested that treatment of 
the cells with OSM, IL-1β, or with both cytokines reduced the association of ER with 
STAT3. Initially this seems to be an unusual result as IL-1β does not utilize the STAT3 
pathway to induce downstream signaling. However there appears to be some measure of 
cross talk between the STAT3 pathway and the p65 pathway, where in some cases the 
function of the pathway may be interdependent on one another (74). We also saw 
reduction in OSM induced IL-6 secretion from MDA-MB-231 cells with the use of the 
NFκB inhibitor caffeic acid phenyl ester (CAPE) (75), despite OSM’s inability to activate 
p65 phosphorylation. This suggests that there may be crosstalk between STAT3 and 
NFκB for the induction of IL-6, and may explain the synergistic relationship between 
OSM and IL-1β. While the exact nature of the crosstalk mechanism is not well known, it 
appears that NFκB and STAT3 signaling proteins must be activated and directly bind to 
each other during signaling (59, 74) (Fig. 8). However, if this is the case, STAT3 siRNA 
should have inhibited IL-1β-mediated IL-6 secretion in MDA-MB-231 and MCF7 cells. 
A possible alternative explanation is that ER forms an inhibitory complex with STAT3 to 
suppress IL-6 expression, similar to the ER/p65 complex which is known to have a 
regulatory role in gene expression (76). This would make suppression of total STAT3 
ineffective for reduction of IL-6 expression, as doing so would also render the ER-
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STAT3 inhibitory complex less effective at regulating IL-6 gene expression. While we 
have not been able to elucidate the exact mechanism of STAT3/ER interaction and the 
crosstalk with NFκB, these results necessitate investigation into pathways that are not 
necessarily canonically known to be activated by the specific cytokine. Therefore, further 
investigation into the mechanistic nature of how these signaling pathways interact with 
each other in the context of breast cancer is needed. 
Conclusions 
Collectively, our study demonstrates that OSM, IL-6, and IL-1β levels are 
correlated with each other and that cytokine signaling differs in an ER subtype-specific 
manner. This highlights the possible implications of multi-cytokine effects in the tumor 
microenvironment and that singular anti-cytokine therapies may not be sufficient for the 
successful treatment of metastatic breast cancer. This may be due to the fact that OSM, 
IL-6, and IL-1β each work independently to impair breast cancer patient survival and 
increase metrics of metastases. Thus, suppression of one cytokine may be countered by 
an increase in a different but related cytokine to maintain the cancer metastatic potential. 
Therefore, this study substantiates the rationale for a therapeutic design that 
simultaneously targets multiple cytokines, such as OSM, IL-6, and IL-1β, as these 
cytokines are strongly intercorrelated in breast cancer. In conclusion, we suggest that 
further studies need to be done to unravel the complex interplay between these cytokines 
and that future clinical trials should include the inhibition of multiple cytokines. 
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Chapter Four: Figures 
 
Figure 4.1. OSM and IL-6 are associated with decreased invasive breast cancer 
survival 
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Figure 4.1. OSM and IL-6 are associated with decreased invasive breast cancer survival.  
A, Kaplan-Meier curves of invasive breast cancer patient samples with high OSM 
expression levels show significant reduction in survival compared to curves of patients 
with low OSM expression levels. Log-rank test (p<0.0001) B, This trend is repeated with 
IL-6. Survival curves of breast cancer patients with high IL-6 expression have reduction 
in survival compared to patients with low IL-6 expression level Log-rank test (p<0.0001). 
C, Survival curves of breast cancer patients with high co-expression of OSM and IL-6 
also demonstrate a reduction in survival compared to patients with low co-expression of 
both OSM and IL-6 Log-rank test (p=0.0091). D, Two-way correlation analysis depicts a 
statistically significant correlation between OSM and IL-6 expression levels in breast 
cancer patients with a Spearman coefficient of 0.576. (p<0.0001).  
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Figure 4.2. OSM breast cancer patient serum levels correlate with IL-6 levels 
Figure 4. 2. OSM breast cancer patient serum levels correlate with IL-6 levels.  
Sera from breast cancer patients were procured from various sources, and OSM 
levels (A) and IL-6 levels (B) were measured by ELISA. When OSM and IL-6 were 
assessed between normal patients versus patients with non-metastatic or metastatic breast 
cancer, there was a significant increase in serum OSM and IL-6 levels in both patients 
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with non-metastatic or metastatic breast cancer versus normal patients. C, Patient sera 
with undetectable OSM levels also have low IL-6 levels (8.5 pg/ml), while patient sera 
with detectable levels of OSM have high levels of IL-6 (89 pg/ml). D, The serum 
cytokines concentration data was then assessed for correlation and suggests that higher 
levels of serum OSM correlates with higher levels of serum IL-6 (Spearman Correlation 
coefficient = 0.923 (95% CI 0.825, 1.0) P<0.0001). Data expressed as mean +/- SEM. 
and assessed by one-way ANOVA with Tukey’s post-test*p<0.05, **p<0.01, 
***p<0.001.  
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Figure 4.3. OSM induces IL-6 in an animal model of human breast cancer 
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Figure 4.3. OSM induces IL-6 in an animal model of human breast cancer.  
A,.MDATO/OSM cells were injected orthotopically in vivo in athymic nude mice. 
After the tumors became palpable, the animals were given tetracycline, and after one 
week, the animals were sacrificed and tumors harvested. Western blot analysis of the 
tumors indicates that OSM levels increase in response to tetracycline administration 
(top). Densitometry of western blots indicate a 40-fold increase in tumor OSM in animals 
given tetracycline compared to animals given control water (bottom). B, IL-6 levels in 
the tumor, as assessed by western blot, also show similarly elevated levels in the 
tetracycline-treated animals. C, Sera collected from the animals were assessed for hOSM 
and hIL-6 levels by ELISA. Animals given tetracycline have an ~10-fold increase in 
mean serum hOSM levels and an ~100-fold increase in mean serum hIL-6 levels. Data 
expressed as mean +/- SEM, and significance assessed by two-tailed student’s t-test. 
*p<0.05. 
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Figure 4.4. OSM induces IL-6 secretion in an ER-dependent manner 
 
 
 
 
 
181 
 
 
Figure 4.4. OSM induces IL-6 secretion in an ER-dependent manner.  
 A, IL-6 secretion levels were measured by ELISA on CM collected from various 
OSM-treated cells. ER- MDA-MB-231, MDA-MB-468, and 4T1.2 cells display high 
(over 4-fold) levels of OSM-induced IL-6 secretion, while ER+ MCF7, and T47D cells 
do not. B, OSM also induces IL-6 secretion in PC3 and DU145 (prostate) and HeLa 
(ovarian) ER- non-breast cancer cell types. C, MDA-MB-231 cells were transfected with 
an ERα expression vector, and the presence of ERα in transfected colonies was 
determined by western blot. The two ER expressing cell lines are designated as 
MDAER+/C7 and MDA ER+/H6. D, MDAER+/C7 cells secrete 9-fold less IL-6 and MDAER+/H6 
cells secrete 12-fold less IL-6 in response to OSM compared to the parental MDA-MB-
231 cells. Data expressed as mean ± SEM and significance assessed by one-way ANOVA 
with Tukey’s post-test. *p<0.05, **p<0.01, ***p<0.001.  
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Figure 4.5. OSM signals through STAT3 in ER- MDA-MB-231 cells to induce IL-
6 
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Figure 4.5. OSM signals through STAT3 in ER- MDA-MB-231 cells to induce IL-6. 
 A, OSM induces the phosphorylation of multiple signaling pathways including 
ERK, JNK, AKT, and STAT3 as assessed by western blot. Overall, phosphorylation of 
STAT3 and ERK occurs faster than other signaling pathway proteins. B, With STAT3 
suppression by STAT3 siRNA, there is little induction of Y705 phosphorylation of 
STAT3 by OSM. Additionally, OSM-induced IL-6, as detected by western blot, is also 
suppressed. C, STAT3 siRNA suppressed OSM induction of IL-6 production as assessed 
by ELISA in MDA-MB-231 cells. Data expressed as mean ± SEM, and significance 
assessed by one-way ANOVA with Tukey’s post-test. *p<0.05. 
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Figure 4.6. OSM and IL-1β expression is higher in invasive breast cancer 
compared to normal tissue and correlates with higher lymph node metastasis, 
decreased survival, and IL-6 levels 
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Figure 4.6. OSM and IL-1β expression is higher in invasive breast cancer compared to 
normal tissue and correlates with higher lymph node metastasis, decreased survival, and 
IL-6 levels.  
A, Using the FINAK dataset obtained from Oncomine™ we assessed stromal 
tissue expression of OSM and IL-1β. Stromal tissue expression of OSM is 5.9-fold higher 
in invasive breast cancer patients compared to normal patients. B, Similarly, expression 
of IL-1β is 5.4-fold higher in the stromal tissue of invasive breast cancer patients 
compared to normal patients. C, Using the Curtis dataset obtained from Oncomine™, we 
correlated OSM and IL-1β tissue expression levels to the number of lymph node 
metastases. Patients with high OSM (Left), high IL-1β (Center), and high co-expression 
of both OSM and IL-1β (Right) have significantly higher number of lymph node 
metastatic nodules compared to the respective low expression group. D, High co-
expression of both OSM and IL-1β leads to a decreased overall patient survival. Log-rank 
test (p=0.0401). E, Expression of OSM, IL-1β, and IL-6 were analyzed in a three-way 
correlation analysis with OSM on the x-axis, IL-6 on the y-axis, and IL-1β on the z-axis. 
There is significant correlation with a coefficient of 0.6001, with a p-value of 2.2 x 10-23. 
Bar and scatter plot data expressed as mean ± SEM, and significance assessed by two-
tailed student’s t-test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.7. OSM and IL-1β activate separate signaling pathways and 
synergistically induce IL-6 secretion 
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Figure 4.7. OSM and IL-1β activate separate signaling pathways and synergistically 
induce IL-6 secretion.  
A, IL-1β alone promotes IL-6 production in MDA-MB-231 and MCF7 cells, 
while a combination of OSM and IL-1β causes a synergistic response in IL-6 secretion. 
T47D cells do not produce IL-6 in any of these conditions. B, Reduced IL-6 scale to 
allow visualization of MCF7 cell-IL-6 induction. C, With a 20-minute cytokine treatment 
with OSM, phosphorylation of STAT3 but not p65 is upregulated, while ERK is 
moderately phosphorylated. MCF7 cells have a weak STAT3 induction in response to 
OSM. A 20-minute cytokine treatment with IL-1β on the other hand induces the 
phosphorylation of p65 but not STAT3. D, The above phosphorylation of STAT3 and 
p65 are sustained at 72 hours with the same cytokine treatments. E, MCF7 cells were 
treated with OSM and/or IL-1β for 48 hours, and the cell lysates were run through an 
immunoprecipitation with an ER pulldown. The eluate was then immunoblotted with the 
input for STAT3. Lysates collected from MCF7 cells treated with OSM or with both 
cytokines have significantly reduced ER-STAT3 interaction. Data expressed as mean ± 
SEM, and significance assessed by one-way ANOVA with Tukey’s post-test. *p<0.05, 
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Figure 4.8. OSM and IL-1β promote IL-6 expression in a breast cancer cell-
subtype specific manner 
 
Figure 4.8. OSM and IL-1β promote IL-6 expression in a breast cancer cell-subtype 
specific manner.  
OSM signals through the STAT3 pathway and leads to IL-6 induction in MDA-
MB-231 cells, while IL-1β induces IL-6 through the p65 pathway. In MCF7 cells, ER 
may be interacting with STAT3 to suppress IL-6 production. There may also be some 
crosstalk-like interaction between STAT3 and p65, however the exact nature of this 
interaction is not known (59, 74). 
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Chapter Four: Supplemental Figures 
 
 
Figure 4.S1.  OSM and IL-6 serum concentration is correlated in vivo 
 
Figure 4.S1. OSM and IL-6 serum concentration is correlated in vivo.  
OSM and IL-6 serum concentrations in the MDATO/OSM mouse model were 
assessed by ELISA, and the resultant numbers were analyzed using a correlation analysis. 
OSM and IL-6 levels correlate with a spearman correlation coefficient of 0.9058 and a p-
value of 0.0034. 
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Figure 4.S2. IL-6 does not promote OSM secretion 
Figure 4.S2. IL-6 does not promote OSM secretion.  
MDA, T47D, and MCF7 cells were treated with IL-6, and secreted OSM levels in 
the conditioned media were assessed by ELISA. IL-6 did not promote OSM secretion in 
any of the cell lines tested. 
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Figure 4.S3.  IL-6 does not promote OSM secretion 
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Figure 4.S3. Stromal and tumor tissue expression of both OSM and IL-1β are higher in 
ER- patients.  
A, Stromal OSM and B, IL-1β expression is significantly higher in patients with 
ER- breast cancer compared to ER+ breast cancer, as assessed using the Finak 
Oncomine™ dataset. Additionally, using the Curtis Oncomine™ dataset, tumor tissue 
expression of OSM (C) and IL-1β (D) is also significantly higher in ER- breast cancer 
patients compared to patients with ER+ breast cancer. Data expressed as log2 median-
centered ratio +/- SD and significance assessed by two-tailed student’s t-test. *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 4.S4.  IL-1β mRNA expression levels correlate with both OSM and IL-6 in 
breast cancer patients 
Figure 4.S4. IL-1β mRNA expression levels correlate with both OSM and IL-6 in breast 
cancer patients.  
The Curtis breast cancer dataset was assessed for OSM, IL-6, and IL-1β tumor 
mRNA expression levels. A, OSM and IL-1β expression levels correlates with each other 
with a spearman coefficient of 0.604 with a p value of less than 0.0001. B, IL-6 and IL-
1β expression levels correlates with each other with a spearman coefficient of 0.526 and a 
p value of less than 0.0001. Correlation coefficients were assessed using the Spearman 
correlation analysis.  
 
194 
 
 
 
Figure 4.S5.  OSM and IL-1β promotes EMT-like morphology in T47D cells 
 
Figure 4.S5. OSM and IL-1β promotes EMT-like morphology in T47D cells.  
T47D cells did not produce any IL-6 under any treatment conditions. To assess 
whether the cytokines were having any effect on T47D cells, they were treated with 10 
ng/mL of OSM and/or IL-1β for 72 hours and the cell morphology assessed by phase 
contrast microscopy. Treatment of the cells with OSM and/or IL-1β promotes an EMT-
like cell morphology with the cells becoming more mesenchymal and spreading apart 
from each other. Red arrows indicate areas with invadopodium formation. These results 
indicate that OSM and IL-1β have an effect on T47D cells but does not produce IL-6 in 
response. 
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Figure 4.S6.  ERK signaling is required for MCF7’s synergistic response to OSM 
and IL-1β 
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Figure 4.S6. ERK signaling is required for MCF7’s synergistic response to OSM and IL-
1β.  
MCF7 and MDA-MB-231 cells were treated with 10 ng/mL of OSM and/or IL-1β 
with or without an ERK inhibitor (50 µM, PD98059) or carrier (DMSO) for 48 hours. A, 
The ERK inhibitor suppresses pERK levels in both MCF7 and MDA-MB-231 cells. B, 
The ERK inhibitor suppresses IL-6 secretion in both IL-1β and OSM+ IL-1β treatment 
groups in MCF7 cells, but not in C, MDA-MB-231 cells.  
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Figure 4.S7.  STAT3 siRNA does not affect IL-1β-induced IL-6 secretion 
Figure 4.S7. STAT3 siRNA does not affect IL-1β-induced IL-6 secretion. 
 MDA-MB-231 and MCF7 cells were treated with 25 nM of STAT3 siRNA with 
or without 10 ng/mL of OSM and/or IL-1β for 72 hours. Although the usage of the 
STAT3 siRNA suppresses OSM-induced IL-6 secretion, it had no effect on IL-1β-
induced IL-6 secretion. 
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Figure 4.S8.  CAPE inhibits OSM-induced IL-6 secretion 
Figure 4.S8. CAPE inhibits OSM-induced IL-6 secretion.  
MDA-MB-231 cells were treated with various concentrations of the p65 inhibitor 
CAPE with or without 25 ng/mL of OSM. By ELISA, CAPE inhibits OSM-induced IL-6 
secretion by approximately 6-fold with 20 µM of the inhibitor. 
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